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 It is well documented that more than 50% of all human cancers have a mutated 
p53 gene status, rendering it inactive. The resulting tumor-derived p53 variants, similar to 
wild-type (wt) p53, retain their ability to oligomerize via the tetramerization domain. 
Upon hetero-oligomerization, mutant p53 enforces a dominant negative effect over active 
wt-p53 in cancer cells. To overcome this barrier, we have designed a chimeric 
superactive p53 (p53-CC) with an alternative oligomerization domain (CC) from 
breakpoint cluster region (Bcr). This approach led to the hypothesis that swapping the 
oligomerization domain of p53 with an alternative oligomerization domain will prevent 
hetero-oligomerization and transdominant inhibition by mutant p53 in cancer cells. 
The tumor suppressor activity of the chimeric p53-CC was evaluated in vitro and 
found to be similar to that of wt-p53 regardless of cancer type or endogenous p53 status. 
However, co-immunoprecipitation and viral transduction of p53-CC and wt-p53 into a 
breast cancer cell line that harbors a tumor derived transdominant mutant p53 validated 
that p53-CC indeed evades sequestration and consequent transdominant inhibition by 
endogenous mutant p53. Following proof-of-concept studies, the superior tumor 
suppressor activity of p53-CC and its ability to cause tumor regression of the MDA-MB-
468 aggressive p53-dominant negative breast cancer tumor model was demonstrated in 
vivo. In addition, the underlying differential mechanisms of activity for p53-CC and wt-
p53 delivered using viral-mediated gene therapy approach in the MDA-MB-468 tumor
  
 model were investigated. Finally, since domain swapping to create p53-CC could result 
in p53-CC interacting with endogenous Bcr, which is ubiquitous in cells, modifications 
on the CC domain were necessary to minimize potential interactions with Bcr. Hence, the 
possible design of mutations that will improve homo-dimerization of CC mutants and 
disfavor hetero-oligomerization with wild-type CC (CCwt) were investigated, with the 
goal of minimizing potential interactions with endogenous Bcr in cells. Indeed, the 
resulting lead candidate p53-CCmutE34K-R55E avoided binding to endogenous Bcr and 
retained p53 tumor suppressor activity. 
Although breast cancer was the main focus of this dissertation, the application of 
this research extends to many other types of cancer, including the deadliest cancers 
(pancreatic, lung, and ovarian), which currently lack effective treatments. 
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INTRODUCTION AND BACKGROUND 
 
1.1 Introduction 
With more than 200 different types of cancer identified to date, the large 
heterogeneity observed among the different types of cancers makes it challenging to 
develop effective therapeutics to treat cancer patients. In fact, it is commonly observed 
that even patients with the same type of cancer respond differently to the same drugs. 
Thus, demand for personalized medicine has increased in the last few years, which has 
proven effective in treatment of cancer patients (1-3). However, personalized medicine 
usually comes with high costs that render it inaccessible to the majority of cancer 
patients. Therefore, there is an urgent need for a therapeutic approach that can benefit a 
large subset of cancer patients. With that in mind, we searched for common molecular 
features and abnormalities in different types of cancers that can be targeted for 
development of effective therapeutics.  
The tumor suppressor p53 is one of the most well-studied and commonly 
abrogated self-defense mechanisms of normal cells prior to malignant transformation. It 
is well documented that more than 50% of all human cancers have a mutated p53 gene 
status, rendering it inactive. In addition, the majority of the remaining cancers, although 
harboring wild-type copies of the gene, have an inactivated p53 pathway via mechanism 
2 
  
other than mutational inactivation. Hence, we pursued a p53-based gene therapeutic 
approach in order to reactivate the p53 pathway in cancer cells. Although breast cancer 
is the main focus of this work, the application of this research extends to many other 
types of cancer, including the deadliest cancers (pancreatic, lung, and ovarian), which 
currently lack effective treatments.  
 
1.2 Rationale of Study 
p53 is a transcription factor that can activate multiple pathways such as DNA 
repair, cell cycle arrest, and apoptosis (4-6). Current targeting of p53 as a therapeutic is 
mainly focused on introducing the wild-type (wt) p53 gene into cancer cells using various 
delivery vehicles (7-9). However, many cancer cells contain endogenous mutant p53 that 
has a squelching effect over wt-p53 upon hetero-oligomerization. The hetero-tetramers 
have a significantly reduced transcriptional activity compared to homo-tetramers of wt-
p53. Such a phenomenon gives rise to a great barrier that limits the utility of p53 for 
cancer therapy (10-12). This work focuses on investigating a chimeric p53 with an 
alternative oligomerization domain, which can offer an improved approach to using wt-
p53 for cancer gene therapy.  
p53 relies on its oligomerization or tetramerization domain (TD) to form 
tetramers, a step that is essential for its transcriptional activity and activation of signaling 
pathways. It is well established that p53 lacking its TD is transcriptionally inactive (13). 
However, the presence of the TD allows for mutant p53 found in most cancer cells to 
oligomerize with exogenous wt-p53, leading to diminished efficacy of p53 gene therapy. 
This is known as the “dominant negative effect” of mutant p53 in cancer cells (9). Thus, 
3 
 
we investigated possible swapping of the native TD with an alternative oligomerization 
domain to prevent hetero-oligomer formation. The oligomerization domain of breakpoint 
cluster region (Bcr) protein, a coiled-coil (CC) that tetramerizes in a similar orientation to 
the TD of wt-p53 (antiparallel dimer of dimers) (14-17), was chosen as the alternative 
oligomerization domain. Thus, replacing the native TD of p53 with CC from Bcr to 
create p53-CC should sustain the transcriptional and tumor suppressor activity of p53, 
while preventing hetero-oligomer formation and transdominant inhibition of our chimeras 
by mutant p53 in cancer cells. 
 
1.3 Summary of Dissertation 
This introductory chapter provides an overview of the dissertation in brief, 
followed by background and rationale for the work presented. In addition, three different 
hypotheses under investigation are presented along with the specific aims for each 
subproject. Chapter 2 (our published book chapter) reviews cancer biology. The different 
theories explaining how cancers originate (cancer stem cell hypothesis vs stochastic 
clonal model) are described in detail. In addition, the genetic and epigenetic pathways 
that lead to cancer are delineated, and the alterations of nutrient and metabolic pathways 
as well as tumor physiology and the cancer microenvironment are examined in this 
chapter.  
While Chapter 3 describes the proof-of-concept studies for the chimeric p53-CC 
conducted in vitro (18), Chapter 4 focuses on validating its activity in a p53-dominant 
negative orthotopic breast tumor model in mice (under review, Gene Therapy). Chapter 5 
describes a set of rationally and computationally designed modifications that can be 
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introduced in the coiled-coil domain of p53-CC chimera to enhance its binding 
specificity, and minimize any possible interactions with endogenous Bcr in the cells 
(submitted, Molecular Pharmaceutics). Finally, Chapter 6 provides conclusions, 




 The oldest identification and description of cancer dates back to 1600 BC in 
Egypt (19). Since then, different theories have been proposed to explain the origins for 
cancer development and survival. While the word cancer itself refers to the blood vessels 
that feed the tumors, cancerous cells develop from normal cells that eventually acquire 
the ability to proliferate aberrantly and grow uncontrollably into malignant tumors that 
can metastasize (20). In addition, cancerous cellular growth can take place in any organ 
or tissue anywhere in the body, with more than 200 different types of cancers identified 
so far. Furthermore, different types of cancers usually have distinct molecular features 
and abrogated pathways that make them respond differently to varying treatment 
regimens. This heterogeneity in the nature of the disease adds to the complexity of the 
diagnosis, treatment, and overcoming drug resistance in cancer (21-23). Furthermore, a 
certain cancer type can vary significantly from one patient to another. Even within the 
same patient, the tumor tissue may contain several heterogeneous types of cancer cells 
(24, 25). Therefore, cancer is commonly viewed as a collection of different diseases, 
often with one treatment approach insufficient for remission. Hence, it is extremely 
challenging to find a single drug that can be effective in more than one type of cancer. In 
5 
 
Chapter 2, a review is presented to offer a better fundamental understanding of cancer 
biology, and to shed the light on some of the causes for the heterogeneity of the disease. 
 
1.4.2 Breast Cancer 
The focus of this work is breast cancer, which remains the most common cancer 
and the second leading cause of cancer death among women, owing to the high and 
increasing incidence rate (26). According to the American Cancer Society, the lifetime 
risk of a woman developing breast cancer is 13% or almost 1 in 8. Even though patients 
with noninvasive cancers have a good treatment prognosis and high survival rates, 
invasive cancer (invading the fat tissue) remains a deadly form of the disease. For 
instance, approximately 80% of all breast cancers are invasive ductal carcinomas in 
which the cancer moves into the lymphatic system and metastasizes to regional lymph 
nodes, which helps it spread to different tissues (27, 28). A breast-conserving surgical 
approach benefits some patients, while others receive neoadjuvant (presurgery) 
chemotherapy or hormone therapy to downstage large tumors, thus potentially allowing 
conservative surgery (26). Moreover, adjuvant therapy (chemotherapy given after 
surgery) is used to eradicate micro-metastases, to improve survival rate, and to delay 
tumor recurrence (29). Anthracycline (doxorubicin or epirubicin) and taxane-based 
agents have been the standard chemotherapy for breast cancer (30, 31). However, most 
chemotherapeutic agents are known to have serious side effects (32-35). In addition, 
certain patients may be eligible for hormonal breast cancer therapy (e.g., tamoxifen, 
which blocks the activity of estrogen in the body), or targeted drugs such as trastuzumab 
(Herceptin™) based on the molecular features of their cancer cells (e.g., HER-2 receptor) 
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(36, 37). Furthermore, there is no one therapy currently that can be used for treatment of 
all breast cancers, and some breast cancers do not even have combination therapies that 
address their particular molecular status. One such indication is triple negative breast 
cancer (TNBC), which lacks molecular targets that can be utilized for therapy. Hence, a 
universal approach such as our chimeric p53-CC that does not depend on the molecular 
features of a cell would be a highly significant approach for TNBC. 
 
1.4.3 Triple Negative Breast Cancer 
Triple negative breast cancer (TNBC) accounts for about 15 to 20% of the 1.5 
million cases of breast cancers diagnosed per year, but is responsible for a 
disproportionate number of deaths (38, 39). The challenge of treating TNBC originates 
from the absence of molecular targets (including estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2)) (40) and disease 
heterogeneity. This heterogeneity stems from the numerous subtypes of TNBC, the 
variable status of other receptors (such as BRCA1, BRCA2, EGFR, c-kit, PARP) and 
other genetic mutations present in TNBC, further complicating targeted treatment 
options. Standard chemotherapy (41) (such as platinum and anti-tubulin agents) and anti-
angiogenic therapy (bevacizumab) are the only currently available FDA-approved 
treatment options for TNBC, but both response to treatment and prognosis are poor (42, 
43). Additionally, TNBC responds 10-100 fold less to platinum agents when the p53 
pathway is damaged (44). TNBC generally occurs in women less than 50 years old, and 
is linked to recurrence and death, particularly in the first 3-5 years of follow up (45). 
Triple negative tumors are also more likely to form lung or brain metastases (46). Up to 
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10,000 women die per year from TNBC in the U.S. alone. While much progress has been 
made against many types of breast cancer, the same cannot be said for TNBC, mainly due 
to the lack of molecular targets for this disease (40, 43, 47-49). Gene expression profiling 
of TNBC has identified 5 main clusters with a remarkable heterogeneity (50). While 
existing chemotherapeutics/dosing regimens may be effective for a minority of patients 
(51), it is thought that development of new targeted therapeutics are an urgent medical 
need for these patients (52). Targeted therapies against EGFR, c-kit, or PARP, multi-
tyrosine kinase inhibitors, and adjuvant anti-angiogenic agents are being currently tested 
(41, 53), but their success will hinge on the clinicians’ ability to discover distinct 
molecular features for stratification of breast cancer subtypes and for identifying triple 
negative breast cancer in patients (54). Clinical trials for some of these agents have been 
somewhat disappointing to date (55), and no single drug can be used for all types of 
TNBC. However, mutation of the tumor suppressor p53 has been reported in 60-88% of 
TNBC (56, 57); likewise, loss of p53 function is known to be associated with metastasis 
(58, 59). Therefore, a universal approach such as our chimeric p53 that does not depend 
on the molecular features of a cell would be a highly significant approach for TNBC 
treatment. 
 
1.4.4 The Tumor Suppressor p53 
The tumor suppressor p53 is encoded by the TP53 gene mapped on the short arm 
of chromosome 17. Its structure and function have been highly preserved over one billion 
years of evolution (60). p53 is a 393 amino acid sequence-specific transcription factor 




Figure 1.1 Schematic structure of wild-type p53. The amino terminus contains the 
MDM-2 binding domain (MBD) and the transactivation domain (TA). The DNA binding 
domain (DBD) spans from amino acids 102-292. The C-terminus consists of three 





region (codons 1-101), a DNA binding domain (DBD, codons 102-292), and a basic C-
terminal region (codons 293-393). The N-terminal region contains a transactivation 
domain (TA, codons 1-42), a MDM2 binding domain (MBD, codons 17-28) and a proline 
rich domain (PRD, codons 67-97). The C-terminus contains three nuclear localization 
signals (NLSs, with the strongest NLS spanning on codons 305-322), a nuclear export 
signal (E, codons 340-351), and a tetramerization domain (TD, codons 323-355).  
p53 is commonly referred to as the “guardian of the genome" (62) due to its 
pivotal role in suppressing malignancy (63, 64). In fact, inactivation of p53 pathway is 
reported in more than half of all human tumors and can be achieved via several 
mechanisms including nuclear exclusion and hyperactivation of MDM2, the main 
regulator of p53 function (65-67). Therefore, disruption of the MDM2-p53 complex has 
been targeted for its potential to restore p53 activity in cancers that harbor a wild type 
copy of the gene. MDM2 targeting by small molecules (such as Nutlin-3a) achieved 
significant success in restoring p53 functionality in cancer cells (68). Although effective, 
the outcomes of preventing p53 degradation by MDM2 remain limited to cancers that 
retain a wild-type p53 status, which includes only a small subset of cancer patients. 
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Acquisition of missense mutations in one or both alleles of the TP53 gene remains 
one the most common mechanisms of p53 inactivation (21, 69). Although there have 
been countless efforts to ‘reactivate’ mutant p53 in cancer cells, the diversity of p53 
mutations precludes finding a single drug that hits all possible variants of the protein (55). 
Hence, recent drug development was aimed to reactivate specific types of p53 mutants, 
such as the small molecule drugs PRIMA and MIRA. While PRIMA reactivates DNA-
contact p53 mutants as well as structural mutants via forming adducts with thiols in 
mutant p53 core domain (70, 71), MIRA relies on its maleimide group to interact with 
thiol and amino groups and restore the native folding state of p53 (71, 72). 
To exert its tumor suppressor function, p53 acts as a transcription factor that 
responds to various cellular stimuli including, and not limited to, DNA damage, hypoxia, 
and oncogenic activation. Upon activation, p53 regulates the expression of several genes 
involved in different cellular signaling events including DNA repair, cell cycle arrest, and 
programmed cell death (apoptosis) (73). While p53 is able to induce apoptosis when 
targeted to the mitochondria (74-76), its tumor suppressor function mainly depends on 
localization to the nucleus and formation of p53 tetramers leading to its function as a 
transcription factor of several target genes. The role of p53 at the nucleus and 
mitochondria is further examined below. 
 
1.4.4.1 Nuclear p53 
The cellular levels of p53 are tightly regulated in normal cells at the protein level 
(77). This regulation is carried out via the MDM2 negative feedback loop. MDM2 is an 
E3 ubiquitin ligase that acts as the main regulator of p53 via nuclear exclusion and 
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proteasomal degradation of the tumor suppressor. Upon activation, the MDM2-p53 
complex is disrupted and the half-life of the p53 protein is rapidly increased from minutes 
to hours (78), which facilitates tetrameric formation and binding to the response elements 
of target genes. At the nucleus, tetrameric p53 regulates the expression of hundreds of 
target genes involved in several signaling pathways (see Table 1.1) (79). The outcome of 
nuclear p53 activation is highly dependent on the type and intensity of cellular stimuli 
detected in the cell. For instance, upon DNA damage caused by UV radiation, p53 forces 
the cells to undergo p21-dependent cell cycle arrest to allow time for repair, and up-
regulates the expression of the GADD45 and p48XPE proteins involved in the DNA 
repair machinery (80, 81). However, if the damage is too extensive and cannot be 
repaired, or if cell cycle arrest lasts for too long, then p53 activates the apoptosis pathway 
(82).  
p53 can activate apoptosis via two distinct pathways: the extrinsic or intrinsic 
apoptosis pathways (Figure 1.2). The extrinsic apoptosis pathway relies on p53 up-
regulation of death receptor genes, including Fas, DR5, and PERP, which upon binding 
to their corresponding ligand can activate the caspase cascade terminating in apoptosis. 
p53 can also mediate apoptosis via the intrinsic apoptosis pathway following the 
induction of several pro-apoptotic proteins that act at the mitochondria. PUMA, Noxa, 
and Bax are some of the key players in inducing the intrinsic apoptosis pathway. Upon 
expression, these pro-apoptotic proteins and others translocate to the mitochondrial and 
induce mitochondrial outer membrane disruption, resulting in the release of cytochrome 




Table 1.1 Some of the p53 target genes involved in different cellular signaling 
pathways (adapted from (83)). 
 
Symbol Description Symbol Description 
APAF1 Apoptotic peptidase 
activating factor 1 
KRAS V-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog 
ATM Ataxia telangiectasia 
mutated 
PIDD P53-induced death domain protein 
TR Ataxia telangiectasia and 
Rad3 related 
MCL1 Myeloid cell leukemia sequence 1 
BAI1 Brain-specific angiogenesis 
inhibitor 1 
MDM2 Mdm2 p53 binding protein homolog  
BAX BCL2-associated X protein MDM4 Mdm4 p53 binding protein homolog  
BCL2 B-cell CLL/lymphoma 2 MYC V-myc myelocytomatosis viral oncogene 
homolog 
BCL2A1 BCL2-related protein A1 MYOD1 Myogenic differentiation 1 
BID BH3 interacting domain 
death agonist 
NFKB1 Nuclear factor of kappa light polypeptide 
gene enhancer in B-cells 1 
BIRC5 Baculoviral IAP repeat 
containing 5 
TP53AIP1 Tumor protein p53 regulated apoptosis 
inducing protein 1 
BRCA1 Breast cancer 1, early onset PCNA Proliferating cell nuclear antigen 
BRCA2 Breast cancer 2, early onset PTEN Phosphatase and tensin homolog 
CASP2 Caspase 2, apoptosis-related 
cysteine peptidase 
PTTG1 Pituitary tumor-transforming 1 
CASP9 Caspase 9, apoptosis-related 
cysteine peptidase 
RB1 Retinoblastoma 1 
CDK1 Cyclin-dependent kinase 1 RPRM Reprimo, TP53 dependent G2 arrest 
mediator candidate 
CDK4 Cyclin-dependent kinase 4 STAT1 Signal transducer and activator of 
transcription 1, 91kDa 
CDKN1A Cyclin-dependent kinase 
inhibitor 1A (p21, Cip1) 
TNF Tumor necrosis factor 
CDKN2A Cyclin-dependent kinase 
inhibitor 2A (melanoma, 
p16, inhibits CDK4) 
TNFRSF10D Tumor necrosis factor receptor 
superfamily, member 10d 
E2F1 E2F transcription factor 1 TP53 Tumor protein p53 
E2F3 E2F transcription factor 3 TP53BP2 Tumor protein p53 binding protein, 2 
EGR1 Early growth response 1 TP73 Tumor protein p73 
EI24 Etoposide induced 2.4 
mRNA 
TP63 Tumor protein p63 
ESR1 Estrogen receptor 1 TRAF2 TNF receptor-associated factor 2 
FADD Fas (TNFRSF6)-associated 
via death domain 
TSC1 Tuberous sclerosis 1 
FASLG Fas ligand (TNF 
superfamily, member 6) 
XRCC5 X-ray repair (double-strand-break 
rejoining) 
GADD45A Growth arrest and DNA-
damage-inducible, alpha 
IGF1R Insulin-like growth factor 1 receptor 









Figure 1.2 p53-dependent induction of apoptosis requires transcriptional activation of 
pro-apoptotic target genes. Tetrameric p53 transactivates genes involved in the extrinsic 
apoptotic pathway (Fas, DR5, and PERP) which in turn activates the caspase cascade via 
cleavage of procaspase-8. In addition, p53 transactivates genes involved in the intrinsic 
apoptotic pathway (PUMA, Noxa, and Bax), which lead to mitochondrial outer 
membrane permeabilization and release of cytochrome-C. Similarly, the intrinsic 








1.4.4.2 Mitochondrial p53 
Although p53 is a transcription factor, and hence, achieves its tumor suppressor 
function at the nucleus, it is known that p53 can directly translocate to the mitochondria 
and cause transcriptionally independent activation of the intrinsic apoptosis pathway (84-
87). Under certain stress conditions (e.g., radiation), p53 is translocated to the 
mitochondria; first, p53 must be mono-ubiquitinated to achieve nuclear export to the 
cytoplasm, followed by shuttling via the herpes virus-associated ubiquitin-specific 
protease (HAUSP) (88, 89). At the mitochondrial outer membrane, p53 can then directly 
either inhibit anti-apoptotic proteins such as Bcl-2 and Bcl-XL, or activate pro-apoptotic 
proteins including Bak and Bax (90-92). Moll et al. were the first to show that due to the 
ability of p53 to mediate apoptosis directly at the mitochondria, mitochondrial targeting 
of p53 has a therapeutic potential for cancer gene therapy (93-95). However, for optimal 
mitochondrial targeting without causing unintentional toxicity to cells, a mitochondrial 
targeting signal (MTS) must be fused to the p53 protein. Furthermore, therapeutic p53 
can be targeted to different mitochondrial subcompartments based on the MTS used, 
which results in different toxicity profiles and has been recently reported by our lab (86, 
87).  
 
1.4.5 Dominant Negative Effect of Mutant p53 
Acquisition of missense mutations in the TP53 gene results in aberrant p53 that is 
transcriptionally inactive (96-98). More than 50% of solid tumors contain mutated p53, 
whereas the majority of the remaining tumors have inactive p53 via other mechanisms. 
Such mutations mainly take place in the DNA binding domain (DBD) and are divided 
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into two main classes: class I contains mutations that can cause p53 to lose DNA binding 
contact sites, and class II contains mutations that lead to significant changes in the 
structural conformation of the protein (Figure 1.3) (10, 99). Consequently, mutated p53 is 
unable to regulate its target genes. Since the negative regulator MDM2 is one of the 
target genes for p53, tumor cells with mutated p53 tend to accumulate relatively high 
concentrations of the dysfunctional protein (100, 101). Such mutant proteins retain their 
tetramerization capabilities since their tetramerization domain (TD) remains intact, and 
can form inactive p53 hetero-tetramers with wild type (wt) p53 in cancer cells (Figure 
1.4). Tetramer inactivity is due to the dominant negative effect of mutant p53 upon 
hetero-oligomerization with wt-p53 (102, 103). This sequestration of wt-p53 into inactive 
tetramers is commonly known as the dominant negative effect of mutant p53, and forms a 
critical barrier to the efficacy of introducing active p53 into tumor cells for cancer 
therapy (10-12, 104). Furthermore, the dominant negative effect of mutant p53 has been 
shown to be operative in vivo using knock-in mice expressing mutant p53 (105). To 
bypass this dominant negative effect, we suggested that a coiled-coil domain could be 
used as an alternative oligomerization due to its dimerization capability.  
 
 











Figure 1.4 Bypassing the dominant negative effect with p53-CC.  Wt-p53 interacts with 
dominant negative p53 in cancer cells, and is inactivated.  On the other hand, p53-CC 
cannot tetramerize with dominant negative p53 in cancer cells.  Instead, p53-CC can only 


















1.4.6 Alternative TD: Coiled-Coil Domain 
In general, coiled-coil domains are characterized by heptad repeats of amino acids 
(denoted by letters for each residue, (abcdefg)n, for n repeats) that control the specificity 
and orientation of the oligomerization motif (106, 107). Furthermore, distinct interaction 
profiles exist between the different residues based on the orientation (parallel or 
antiparallel) of the coiled-coil (106, 108). Residues a and d are usually occupied by 
hydrophobic residues while residues e and g are usually hydrophilic. Surface interactions 
between positions e to e’ (where the prime refers to a residue on the opposite helix) and g 
to g’ are known to be essential in antiparallel coiled-coils, whereas interactions between 
positions g to e’ are the most critical for parallel coiled-coils (106, 108). Hence, coiled-
coils thermodynamically favor association in cells in order to bury the hydrophobic 
residues of each coiled-coil from the hydrophilic environment, forming an amphipathic 
structure. This association is usually very strong and stable, which qualifies coiled-coils 
as extremely efficient oligomerization domains as observed in many transcription factors 
and proteins that require oligomerization to achieve their functions (109, 110).  
The coiled-coil domain from break point cluster region (Bcr) protein is assembled 
as two 36-residues helices antiparallel to each other (see Figure 1.5) (111, 112). This 
antiparallel orientation gives rise to the aforementioned e to e’ and g to g’ interactions 
that can be utilized to potentially create more salt brides within a dimer. The potential 
design of enhanced coiled-coil mutants to achieve higher binding specificity is further 




Figure 1.5 A ribbon diagram with the corresponding helical wheel of the coiled-coil 
domain of Bcr. The side chains of key residues are shown as red (acidic) or blue (basic). 




1.4.7 Break Point Cluster Region (Bcr) 
Since the CC domain was obtained from Bcr, it may be important to minimize 
any possible cross-interaction with Bcr found in most cells. Bcr is a ubiquitous eukaryotic 
phosphotransferase protein that may have a role in general cell metabolism. Bcr-knockout 
mice still survive; the major defect in these mice was reduced intimal proliferation in 
low-flow carotid arteries compared to wt mice (113). Bcr has mostly been studied in the 
context of chronic myeloid leukemia (CML) where a reciprocal chromosomal 
translocation with Abl results in the fusion protein Bcr-Abl, the causative agent of CML 
(114, 115). The activity of Bcr-Abl is largely due to the constitutive activation of the Abl 
portion of the molecule (116). In addition, Bcr plays a role in arterial proliferative 
disease in vivo as well as differentiation and inflammatory responses of vascular smooth 
muscle cells (113, 117). Hence, optimizing the CC domain to prevent possible interaction 
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with Bcr is essential, and is further investigated in Chapter 5. 
 
1.4.8 Gene Therapy 
The main theme for this work is to utilize p53-based therapeutics in cancer gene 
therapy. Gene therapy entails introduction of gene(s) in the forms of therapeutic DNA to 
correct a cellular dysfunction or replace a mutated gene (118-120).  Since proteins 
encoded within the genome carry out all biological events in cells, gene therapy has 
enormous therapeutic potential to cure many diseases. Hence, identifying the molecular 
features or the aberrant proteins within a certain disease is a prerequisite for gene therapy. 
For instance, cancers often develop following acquisition of mutations in tumor 
suppressor genes, which renders their protein products inactive. Once the inactive or 
dysfunctional protein is identified within the context of the cancer cells, either the native 
corresponding gene, or an enhanced version of it, is delivered to cancer cells to restore 
normal function. Recent advances in the Human Genome Project and the Hap Map 
Project have accelerated identification of genes and proteins involved in several diseases 
(121). Although many clinical trials utilize gene therapy approaches for certain diseases 
such as neurodegenerative, cardiovascular, and infectious diseases, cancer remains to be 
the largest target for gene therapy clinical trials (122). As of 2012, there have been over 
1843 clinical trials approved, undergoing, or completed for several diseases worldwide, 
64.4% of which are focused on cancer diseases (123). Cancer gene therapy usually aims 
towards introduction of tumor suppressor genes (such as p53), immunotherapy, and 
oncolytic virotherapy (124-126). In fact, introduction of the tumor suppressor p53 gene 
into cancer cells was the first clinically approved cancer gene therapeutic worldwide. 
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Approved in 2004 by the State Food and Drug Administration in China (SFDA) for head 
and neck squamous cell carcinoma, p53 delivered using an adenovirus was marketed 
under the brand name Gendicine™. One year later (2005), another p53-based gene 
therapeutic was also approved in China under the brand name Oncorine™. However, 
using wt-p53 for cancer gene therapy has moderate success so far for many types of 
cancers due to several barriers that must be overcome, such as the dominant negative 
effect of mutant p53 commonly found in cancer cells. In addition, delivery of wt-p53 and 
any therapeutic DNA genes in general into cells represents one of the major barriers in 
utilizing gene therapy approaches for many diseases. Hence, great research efforts are 
aimed towards designing a carrier system that can successfully deliver its gene loads 
efficiently and specifically to target cells. These carrier systems are commonly referred to 
as vectors, and can range from simple plasmids or natural gene carriers such as viruses to 
very complex nonviral delivery systems.  
 
1.4.8.1 Viral vs. Nonviral Vectors 
Viral gene delivery takes advantage of the evolutionary design and evolvement of 
viruses to efficiently deliver genes of interest into host cells. The concept behind using 
viral vectors is to harness the viral infection pathway and expression of genes without 
subsequent toxicity (127). This is often achieved by reengineering the viral genome to 
eliminate certain coding regions that are responsible for viral toxicity, while preserving 
viral genes responsible for desired functions such as packaging the capsid of the viral 
vector or integration into the host cell genome (128). Table 1.2 summarizes the main 
features of the viral vectors commonly used in clinical trials for gene therapy.  
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Table 1.2 Comparison of mainly used viral vectors for gene therapy (adapted 










Adenovirus dsDNA 30kb No 
Capsid mediates a 
potent inflammatory 
response 
Cancer therapy, angiogensis 





ssDNA 5kb No 
Small packaging 
capacity 
Genetic diseases, cancer, 
neurological, ocular and 
cardiovascular diseases 





Genetic diseases of T cells, 
hematological diseases, 
HIV/AIDS 
Lentivirus RNA 8kb Yes 
Integration may 
cause oncogenesis 






dsDNA 40kb No 
Inflammatory; 
transient expression 






Although initial use of viral vectors for gene therapy was rapidly criticized for 
lack of safety and efficacy, better understanding of how to safely harness the advantages 
of viruses as biological delivery vehicles over the last 15 years has resulted in promising 
clinical successes. In addition, the use of viral vectors is approved for clinical trials, and 
comprises more than 70% of gene therapy clinical trials (131). One of the most common 
viral vectors used in clinical trials is adenoviral Ad5, derived from a serotype 5 
adenovirus. Adenovirus is the most efficient in terms of delivering their genetic cargo to 
the nucleus (131-134). Adenoviral vectors will transduce both dividing and nondividing 
cells and transfer to a target cell nucleus in an epi-chromosomal location with rare 
integration into chromosomes (135).  
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Therefore when the target cell divides, only one daughter cell will receive the 
transferred gene. In addition, the immunogenicity of adenovirus has improved recently 
enhancing its prospects for long-term gene transfer in a wide range of different tissues 
(128). Although not without issues, adenovirus will be used in this proposal as a means to 
validate our model as a high efficiency vector. Alternatively, nonviral delivery systems 
have steadily gained their place as gene delivery vectors due to their safety and ease of 
large-scale production (136-138). However, different concerns must be addressed for the 
design of optimal nonviral delivery vehicles such as optimizing uptake by cells and 
intracellular release of the vector and/or the gene load (139-141). While the actual 
delivery of our candidate gene therapeutics is not the focus of this work, they can be 
delivered virally or nonvirally as DNA encoded products.   
 
1.5 Statement of Objectives 
The long-term objective of this work is to develop and optimize a p53-based 
therapeutic that can be used for cancer gene therapy. This study describes the design of a 
novel chimeric p53 by swapping the TD from p53 with the coiled-coil (CC) 
tetramerization domain from Bcr protein (142) to create p53-CC. These 2 domains are 
structurally analogous in that they both form antiparallel dimer of dimers (tetramers).  
The choice to replace the TD of p53 with the CC from Bcr is entirely novel, and has 
never been attempted before. Hence, extensive proof-of-concept experiments and 
preliminary work was carried out to validate the tumor suppressor function of our 
constructs. Breast cancer was mainly chosen as the disease model to test the efficacy of 
our constructs. In vitro work showed that as hypothesized, p53-CC was able to bypass 
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hetero-oligomerization with endogenous mutant p53 and prevent any consequent 
transdominant inhibition in vitro (Chapter 3). Once the tumor suppressor activity of our 
lead construct was validated, we initiated efficacy studies in a mouse breast cancer model 
to test if the activity of p53-CC translates in vivo (Chapter 4). Indeed, p53-CC 
demonstrated superior tumor suppressor activity compared to wt-p53 and caused tumor 
regression of an aggressive p53-dominant negative orthotopic breast cancer xenograft 
tumor model (using MDA-MB-468 TNBC cells) in vivo. In addition, the underlying 
differential mechanisms of activity for p53-CC and wt-p53 delivered using viral-
mediated gene therapy approach were investigated in the MDA-MB-468 tumor model. 
Finally, the chimeric p53-CC construct was further optimized to increase specificity and 
reduce any potential off-target effects (Chapter 5). Since domain swapping to create p53-
CC could result in p53-CC interacting with endogenous Bcr, modifications on the CC 
domain were necessary to minimize potential interactions with Bcr. These approaches 
lead to the hypothesis that swapping the oligomerization domain of p53 with an 
alternative oligomerization domain will prevent hetero-oligomerization and 
transdominant inhibition by mutant p53 in cancer cells.  In this study, three major 
hypotheses were proposed with their corresponding aims, as follows: 
Hypothesis 1: The chimeric p53-CC can bypass the dominant negative effect of mutant 
p53, while retaining the tumor suppressor function of p53 in cancer cells. 
Aim: To design the chimeric p53-CC by swapping the TD of p53 with the CC 
domain from Bcr, and investigate its transcriptional and tumor suppressor activity 
in vitro. 
Hypothesis 2: The tumor suppressor function of p53-CC is superior to wt-p53 activity, 
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and will demonstrate significant efficacy in a p53-dominant negative breast cancer tumor 
model.  
Aim: To test if the activity of p53-CC translates in vivo in a p53-dominant 
negative orthotopic breast tumors in mice. 
Hypothesis 3: Rationally designed mutations in the coiled-coil domain of p53-CC will 
reduce potential interactions with endogenous Bcr without affecting the tumor suppressor 
function. 
Aim: To introduce the designed mutations on the CC domain and create an 
enhanced version of the p53-CC chimera that has minimal interactions with endogenous 
Bcr.  
These hypotheses and aims have been discussed in detail in Chapters 3, 4, and 5, 
respectively. Chapter 2 reviews topics regarding cancer biology and some causes for the 
complexity of the disease, and has been published as a book chapter by Springer (21). 
The results in the studies described in Chapter 3 have also been peer-reviewed and 
published by Molecular Pharmaceutics. In addition, the work from Chapter 4 and 5 has 
been submitted to Gene Therapy and Molecular Pharmaceutics, respectively.  
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CANCER BIOLOGY: SOME CAUSES FOR A VARIETY  
OF DIFFERENT DISEASES 
 
2.1 Abstract 
Advances and integration of biochemistry, cell biology, molecular biology, and 
genetics have led to a better fundamental understanding of cancer biology and the causes 
for many types of cancer. Cancer is now thought to originate following either the "cancer 
stem cell hypothesis" or the "stochastic clonal model." The pathways that lead to cancer 
have been delineated genetically and epigenetically. In addition, post-translational 
players such as miRNA are now known to have a significant role in cancer diagnosis. To 
meet the high demands of rapidly proliferating cancer cells, alterations of nutrient and 
metabolic pathways are required. Accordingly, tumor physiology and the cancer 
microenvironment have been extensively studied due to their significant role in 
malignancy. This chapter will discuss these topics and provide a detailed investigation of 
cancer biology including identification of many of the genes, proteins, signals, and other
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factors involved in tumorigenesis. 
 
2.2 Introduction 
The oldest identification and description of cancer dates back to 1600 BC in 
Egypt (1). Since then, different theories have been proposed to explain the origins for 
cancer development and survival. While the word cancer itself refers to the blood vessels 
that feed the tumors, cancerous cells develop from normal cells that eventually acquire 
the ability to proliferate aberrantly and grow uncontrollably into tumors that can 
metastasize (2). From the most common initiating events that lead to malignant 
transformation, the diverse modifications in tumor metabolic pathways that give 
cancerous cells a clear proliferative advantage, and terminating in the dynamics of the 
cancer microenvironment, this comprehensive cache of knowledge can be used for 
effective drug delivery of existing and novel cancer therapeutics. 
 
2.3 Origins of Cancer 
2.3.1 Cancer Stem Cells 
Based on data obtained from both in vitro and in vivo studies, only a small 
population of tumor cells are capable of self-renewal, commonly identified as cancer 
stem cells (CSCs) (3, 4). Characterized by their ability to proliferate indefinitely, these 
tumorigenic cells drive malignancy in a similar manner to the way normal stem cells 
construct organs. As with normal organs and tissues, tumors are formed from 
heterogeneous populations of cells with different levels of differentiation and 
proliferation capacities. Therefore, tumors have been viewed as aberrant organs that 
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originate from cancer stem cells that have acquired mutations allowing them to 
proliferate abnormally (4). However, cancer stem cells are only a small subset of cells in 
a given tumor. For instance, 1-4% of leukemic cells were capable of forming spleen 
colonies when introduced in vivo (5, 6), and only 0.0001% to 0.01% of  leukemic mouse 
myeloma cells, separated from normal hematopoietic cells, were able to form colonies in 
vitro (7). Although cancer stem cells are very similar in nature and function to normal 
stem cells, cancer stem cells are not necessarily aberrant counterparts of normal stem 
cells (8). In certain cases, genetic modifications of normal stem cells can lead to their 
transformation into cancer stem cells (Figure 2.1).  
 
 
Figure 2.1 Certain genetic changes or mutations can transform normal stem cells or 
progenitor cells into cancer stem cells. Such an event allows malignant tumors to divide 




For example, it is well accepted that the reciprocal translocation between 
chromosomes 9 and 22 [t(9;22)(q34;q11)] in chronic myelogenous leukemia (CML), 
which leads to the formation of the Bcr-Abl oncogene, can transform normal 
hematopoietic stem cells into cancer stem cells that propagate in the bone marrow (10, 
11). However, it is often difficult to establish a link between normal stem cells and cancer 
stem cells. It is well accepted now that CSCs can also originate from progenitors that 
have acquired the ability to self-renew as well as from normal stem cells (Figure 2.1). 
Therefore, identifying proper markers and techniques to isolate a homogenous population 
of CSCs remains challenging and is considered to be the rate-limiting step in 
understanding the nature and function of CSCs.  
In addition, proper isolation of CSCs could lead to identification of the specific 
molecular characteristics of such cells for cancer targeted therapy (12). Some success has 
been achieved in isolating CSCs often in a heterogeneous mixture with normal stem cells. 





contain a subset of cells that were capable of initiating human acute myeloid leukemia 
(AML) when transplanted into murine models (13). Table 2.1 illustrates some of the 
well-established definitions of CSCs in different cancer types and their origins (8). 
Similar work has led to the identification of cancer stem cells in breast cancer (14), 
gliomas (15, 16), melanoma (17), prostate cancer (18), and osteosarcoma (19). These 
observations have led to an increased interest in the “cancer stem cell hypothesis” (4) due 





Table 2.1 Markers of cancer stem cells in different cancers (adapted from (8)) 
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2.3.2 Cancer Stem Cell vs. Stochastic Model 
While the “cancer stem cell hypothesis” suggests a hierarchical organization in 
which a) tumors originate in cancer stem cells niches or their progeny through 
dysregulation of self-renewal process, and b) tumors contain a subset of cells that have 
stem cell characteristics (26), other models have been suggested to describe tumor 
development. One such model is the stochastic model for cancer origins in which tumors 
are thought to develop as a consequence of random somatic mutations and develop the 
capability to self-renew and differentiate similar to stem cells. According to the stochastic 
model, any cell has the potential to activate carcinogenesis implying that tumor initiation 
is no longer exclusive to a rare subset of cells. In other words, every cell in the tumor 
bulk will have an equal probability to develop cancer stem cell-like characteristics and 
recapitulate the tumor (27, 28). Some of the major arguments supporting the stochastic 
model are the high heterogeneity, genomic instability, and epigenetic alterations observed 
in tumors (29). Nevertheless, it is well-established now that not all cancers follow one 
model or another. Even though in vivo studies suggest that leukemias (15, 30), breast 
cancer (31-33), and squamous cell carcinoma (34) in mice follow the cancer stem cell 
model, it remains dangerous to generalize that cancers in mice follow a hierarchical CSC 
model rather than a stochastic clonal evolution model for tumor development. 
 
2.4 Pathways that Lead to Cancer 
Following vast advances in the field of genetics, the stochastic genetic model for 
cancer development has predominated other models, supported by the discovery of 
dominantly acting oncogenes, recessively acting tumor-suppressor genes, and diverse 
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molecular changes observed in cancer that lead to the highly heterogeneic nature of the 
disease (35). Nevertheless, recent correlations between cancer development and the 
pathological epigenetic changes commonly observed in cancers such as global DNA 
methylation, chromatin alterations, and genomic imprinting suggest that such events can 
serve as surrogates for genetic mutations (35, 36). In this section, an overview of the 
main changes that take place during cellular transformation in cancer cells will be 
discussed. In addition, a summary of the main pathways that lead to cancer cell survival 
will be presented. 
 
2.4.1 Genetic Changes 
First postulated by Carl O. Nordling in 1953, the multiple-hit hypothesis offered a 
clonal approach for explaining cancer development (37). Nordling suggested that 
accumulation of mutations in the DNA of cells leads to malignant development. In 
addition, Nordling emphasized that cancer susceptibility in industrialized nations can be 
correlated to the sixth power of age, implying that for cancer to develop, six mutations in 
the DNA must be acquired. However, Nordling’s explanation for cancer development did 
not agree well with the fact that cells possess several defense mechanisms against 
acquiring mutations via the expression of tumor suppressors. Therefore, it was not until 
1971 that the geneticist Alfred Knudson developed the concept of a “two-hit hypothesis” 
based on several studies of retinoblastoma patients. Between 1944 and 1969, Knudson 
studied 48 patients that had retinoblastoma due to either somatic or germ-line mutations. 
Interestingly, Knudson showed that for patients with somatic mutations, tumors took 
longer to develop in the eye compared to patients who inherited a mutation (38). He 
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concluded that for retinoblastoma to develop, a subject has to acquire a mutation in both 
alleles of a tumor suppressor gene (TSG) that encodes for the retinoblastoma protein 
(pRb). Thus, subjects who inherited a mutation in one of the two copies of the RB1 gene 
were more susceptible to developing tumors, since only one more mutation in the second 
copy of the tumor suppressor needed to be acquired. (39). Knudson’s hypothesis (Figure 
2.2) forms the basis for understanding how mutations in tumor suppressor genes correlate 
to tumor development, where, for a tumor suppressor to become inactivated, both alleles 
need to be mutated or “hit” before a tumor can develop. 
 
 
Figure 2.2 According to the “two-hit hypothesis,” both alleles of a tumor suppressor 
gene must be mutated prior to malignant transformation. In sporadic cancers, two 
mutations must be acquired before a complete inactivation of a tumor suppressor gene. In 
hereditary cancers, an inherited mutation exists and only one more “hit” is required 





2.4.1.1 Tumor Suppressor Genes in Cancer 
Following Knudson’s findings, aberrant function of tumor suppressor genes 
emerged as the leading cause for cancer development. It is well-documented now that 
activation of a proto-oncogene will not lead to cancer unless accompanied by an 
inactivation event of both alleles of a TSG. Therefore, it is important to examine tumor 
suppressor genes and understand the mechanisms by which they prevent uncontrolled 
cellular growth in normal cells. In this section, several key prototypical tumor suppressor 
genes will be discussed. 
 
2.4.1.1.1 pRb 
The retinoblastoma protein (pRb) was one of the first tumor suppressors to be 
identified during extensive studies on cancer-prone families in the 1940s (40). Even 
though pRb is important in all cells, its inactivation usually corresponds in most cases to 
tumor development specifically in the eye. Similar to other tumor suppressors, the pRb 
protein inhibits tumor growth by interfering directly with cell cycle progression, leading 
to arrest in G1 phase. To exert its tumor suppressor function, pRb inhibits the E2F 
transcription factor family known to be essential for transactivating a cohort of genes 
involved in DNA replication in S phase. Consequently, pRb prevents replication of 
damaged DNA commonly found in cancer cells. During pathogenesis and tumor 
progression, pRb function can be impaired via several mechanisms. In retinoblastoma, 
small cell lung carcinoma, and bladder carcinoma, the tumor suppressor gene is mutated 
leading to a loss of function of pRb (41). In cervical carcinomas, the human 
papillomavirus E7 oncoprotein can bind the active pocket of pRb causing the tumor 
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suppressor protein to become incapable of binding E2F transcription factors (42). Finally, 
in esophageal, breast, and squamous cell carcinomas, cyclin D is frequently 
overexpressed which then destabilizes the pRb-E2F complex by phosphorylating pRb 
resulting in the inhibition of the tumor suppressor (43, 44). Figure 2.3 summarizes the 
effects of pRb on the cell cycle.  
 
2.4.1.1.2 p53 
Encoded by the TP53 gene mapped on the short arm of chromosome 17, p53 is 
commonly referred to as the “guardian of the genome" (45). Its tumor suppressor 
function can be divided into two main categories: the first being a sensor for DNA 
damage that activates the DNA repair machinery in the cells, and the second being a 
“policeman” for oncogenic signaling and activation (45).  
 
 
Figure 2.3 Retinoblastoma tumor suppressor function in cell cycle progression (adapted 
from (46).  
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Known to be mutated in more than 50% of human cancers, the tumor suppressor 
p53 is a major player in several signaling pathways that are dependent on the context of 
the stimuli such as DNA repair, cell cycle progression, angiogenesis inhibition, and 
programmed cell death (apoptosis). 
Similar to the tumor suppressor gene RB1, both alleles of TP53 must be 
inactivated for the protein to lose its function. According to Knudson’s “two-hit 
hypothesis,” subjects with an inherited mutation in one of the two copies of TP53 are 
predisposed to develop tumors in early adulthood since only one mutation needs to be 
acquired in the second copy of the gene to completely inactivate the tumor suppressor. 
This condition is rare and is known as Li-Fraumeni syndrome. Once activated in response 
to various cellular stimuli such as DNA damage (via UV, IR, or chemotherapy), hypoxia, 
or oncogene activation, the tumor suppressor, in its tetrameric form, acts as a 
transcription factor that regulates the expression of several genes involved in different 
cellular signaling events. This activity is mainly mediated by nuclear p53 which activates 
both the extrinsic and intrinsic apoptotic pathway. Furthermore, p53 can activate the 
extrinsic apoptotic pathway via the mitochondria as well (47). One of the most important 
signaling pathways controlled by p53 is DNA repair and its ability to induce apoptosis if 
cellular damage is too extensive to be repaired. Two of the main factors that control p53 
activation upon DNA damage are ataxia–telangiectasia mutated (ATM) and ataxia–
telangiectasia and Rad3-related (ATR) protein kinases. ATM and ATR are capable of 
rapidly degrading MDM2 (48), the main negative regulator protein of p53, as well as 
influencing the outcome of the p53 response to DNA damage by inducing various post-
translational modifications on the tumor suppressor (49, 50). This is depicted in Figure 
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2.3, bottom right. In addition, p53 can be activated via the tumor suppressor ARF 
signaling pathway in response to sustained cellular proliferation. Similar to ATM and 
ATR, ARF can act as an inhibitor of MDM2 leading to the accumulation of p53 in the 
nucleus (51). Another major pathway by which p53 can regulate cell growth is via 
transactivation of the CDKN1A gene that leads to the expression of p21/WAF1 protein. 
As a member of the cyclin-dependent kinase inhibitor (CKI) family, p21 can inhibit the 
cyclin-CDK2 complex required for entry into G1 phase, causing an arrest in cell cycle 
progression (52). Therefore, p53 inactivation can be crucial during malignant 
transformation due to its ability to inhibit tumor growth via many different mechanisms. 
Once activated in response to various cellular stimuli such as DNA damage (via 
UV, IR, or chemotherapy), hypoxia, or oncogene activation, the tumor suppressor, in its 
tetrameric form, acts as a transcription factor that regulates the expression of several 
genes involved in different cellular signaling events. This activity is mainly mediated by 
nuclear p53 which activates both the extrinsic and intrinsic apoptotic pathway. 
Furthermore, p53 can activate the extrinsic apoptotic pathway via the mitochondria as 
well (47). One of the most important signaling pathways controlled by p53 is DNA repair 
and its ability to induce apoptosis if cellular damage is too extensive to be repaired. Two 
of the main factors that control p53 activation upon DNA damage are ataxia–
telangiectasia mutated (ATM) and ataxia–telangiectasia and Rad3-related (ATR) protein 
kinases. ATM and ATR are capable of rapidly degrading MDM2 (48), the main negative 
regulator protein of p53, as well as influencing the outcome of the p53 response to DNA 
damage by inducing various post-translational modifications on the tumor suppressor (49, 
50). This is depicted in Figure 2.3, bottom right. In addition, p53 can be activated via the 
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tumor suppressor ARF signaling pathway in response to sustained cellular proliferation. 
Similar to ATM and ATR, ARF can act as an inhibitor of MDM2 leading to the 
accumulation of p53 in the nucleus (51). Another major pathway by which p53 can 
regulate cell growth is via transactivation of the CDKN1A gene that leads to the 
expression of p21/WAF1 protein. As a member of the cyclin-dependent kinase inhibitor 
(CKI) family, p21 can inhibit the cyclin-CDK2 complex required for entry into G1 phase, 
causing an arrest in cell cycle progression (52). Therefore, p53 inactivation can be crucial 
during malignant transformation due to its ability to inhibit tumor growth via many 
different mechanisms.  
 
2.4.1.1.3 PTEN 
PTEN is another tumor suppressor gene that is commonly found to be mutated in 
several human cancers. Although the PTEN gene product helps regulate cell cycle 
progression in a similar fashion to p53, this protein functions as a dual protein/lipid 
phosphatase. One of the major substrates for PTEN is PIP3, a crucial protein involved in 
the AKT/PKB signaling pathway. Upon dephosphorylation by PTEN, PIP3 can no longer 
recruit AKT to the cell plasma membrane, therefore disrupting the AKT/PKB pathway. 
This results in increased proliferation and activation of the growth regulatory factor 
mTOR (53). Similar to other tumor suppressor genes, PTEN can be inactivated by 
inheriting a mutation or by acquiring sporadic mutations that can render the protein 
inactive. Although PTEN knock-out models in vivo showed embryonic lethality, the 





murine models where animals developed tumors in several organs (54, 55). 
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2.4.1.2 Proto-oncogenes and Oncogenes in Cancer 
As part of the malignant transformation process, oncogene activation lies at the 
heart of tumor initiating mechanisms. Proto-oncogenes are normal genes involved in 
controlling cellular growth in normal cells that upon alteration (usually mutation or 
overexpression) can lead to the production of oncogenes, whose protein products induce 
cancer formation (40). Certain alterations of proto-oncogenes during tumorgenesis result 
in oncogene activation that allows cancer cells to exhibit abnormal proliferation. It has 
been suggested that the main mechanisms of proto-oncogene activation are a) point 
mutations that lead to gain-of-function, b) gene amplification resulting in growth 
advantage of cancer cells, and c) chromosomal rearrangement and fusion that can result 
in aberrant expression of growth-regulatory proteins (56). Since tumor suppressor 
proteins such as p53 respond rapidly and efficiently to oncoprotein activity in normal 
cells, it is frequently observed that oncogene activation is accompanied by inactivation of 
tumor suppressor genes. In this section, some examples of oncogenes and their activation 
mechanisms will be examined in the context of malignant progression. 
 
2.4.1.2.1 Ras mutations 
The Ras family of proto-oncogenes (H-ras, K-ras, N-ras and others) is known to 
be mutated in approximately 20% to 30% of human cancers (57). K-ras is mutated in 
about 30% of lung cancers, 50% of colon carcinomas, and 90% of pancreatic carcinomas 
(58). N-ras is known to be mutated in acute myeloid leukemias (59). The full function of 
ras proteins remains elusive. However, ras proteins are known to be monomeric 
membrane G proteins that can be activated in response to several extracellular stimuli 
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that control cellular proliferation and differentiation (60). Upon mutation, ras proteins are 
locked in the GTP-bound active state, resulting in constitutive activity. Consequently, 
oncogenic ras continuously activates downstream effectors such as the MAP-kinase Raf-
1, which further activates the MEK/ERK gene regulation pathway that governs 
proliferation, differentiation and survival of cancer cells (61). 
 
2.4.1.2.2 Myc amplification 
The myc family of proto-oncogenes encodes transcription factors that are 
involved in several cellular pathways that control cell cycle, cell growth, differentiation, 
apoptosis and angiogenesis (62). C-myc is a myc family member that is commonly 
overexpressed in several carcinomas. Studies show that the gene encoding c-myc is 
amplified in about 20% to 30% of breast, ovarian and squamous cell carcinomas (63). N-
myc is another member of the myc family that is amplified in neuroblastomas, where up 
to 300 copies of the gene can be found in a single cell (64, 65). Upon overexpression of 
Myc, several genes involved in cellular proliferation are altered. For example, cyclins 
(which promote cell cycle progression and division) (66) and ribosomal RNA and 
proteins (which increase global protein synthesis needed for cell division) (67) are 
upregulated, and p21 (a key factor in causing cell cycle arrest) is downregulated (68). 
Similarly, the proto-oncogene erbB is another example in which amplification of a 







2.4.1.2.3 Bcr-Abl Chromosomal Translocation 
Chromosomal rearrangements are another mechanism by which proto-oncogenes 
can be activated during pathogenesis. Such events are frequently detected in hematologic 
cancers and to a lesser extent in some solid tumors (70, 71). In chronic myelogenous 
leukemia, a reciprocal translocation between chromosome 9 and 22 results in the 
formation of the Philadelphia chromosome that encodes the Bcr-Abl oncogene. Capable 
of autophosphorylation (i.e., auto-activation), the Bcr-Abl oncogene does not require 
activation by other cellular signals which allows it to retain constitutive activity (72). As 
a result, Bcr-Abl can drive malignant transformation by activating several prosurvival 
signaling pathways such as Ras-Raf-ERK, JAK-STAT and PI(3)K pathways (73). 
 
2.4.2 Epigenetic Alterations 
Epigenetic alterations in cancers are mitotically and meiotically heritable 
phenotypes caused by changes in the gene expression profile of cells and not dependent 
on alteration of the primary DNA sequence in the nucleus. Such alterations during 
carcinogenesis involve events such as DNA methylation, histone modifications, and gene 
silencing. Unlike genetic changes during carcinogenesis, most of the epigenetic 
alterations that take place in cancer cells are clinically reversible by directly targeting the 
moieties  that contribute to carcinogenesis (74).  
It has become clear that epigenetic silencing of certain genes contributes 
significantly to pathogenesis. For instance, an alternative mechanism to gross or 
intragenic deletions and point mutations that lead to inactivation of tumor suppressor 
genes could be epigenetic silencing of the promoters that drive the expression of those 
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genes. Such an event can play a major role during malignant transformations since 
inactivation of one tumor suppressor allele via genetic alterations combined with 
silencing of the second allele can lead to a complete loss of function of the tumor 
suppressor. Although modifications of other parts of the genes can contribute to gene 
silencing, the main cause for epigenetic changes in the expression profiles of genes is 
methylation patterns in the promoter regions of those genes. DNA methylation in 
mammalian cells usually takes place on cytosine bases on cytosine-guanine (CpG) 
dinucleotide pairs. (75). Approximately half of all genes contain CpG rich regions, 
commonly referred to as CpG clusters or islands, in their promoters (74). It is estimated 
that up to 70% of the CpG pairs are methylated in humans. In addition to gene silencing 
in cancer, methylation of DNA can prompt point mutations in DNA and lead to general 
genomic instability in tumors. For instance, the “hot spot” mutations of the tumor 
suppressor gene TP53 at residues 248 and 273 are caused by cytosine to thymine (T) 
transition following the deamination of m
5
C, the methylated form of cytosine (76). 
Parallel to hypermethylation of cytosine residues in the CpG rich regions of many gene 
promoters is the global genomic hypomethylation phenotype observed in cancer cells. 
DNA hypomethylation is responsible for upregulating several genes such as the MDR1 
(multiple drug resistance 1) gene (77). It has been well-established that tumors 
demonstrate large scale loss of DNA methylation (78-80). Furthermore, it has been 
suggested that DNA hypomethylation can reactivate silenced genes in normal cells 
(mostly genes involved in cell proliferation and survival signaling) and the transcription 
of intragenomic parasitic DNA (such as viral DNA) (81). 
Additionally, chromatin methylation and histone modifications are another set of 
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epigenetic alterations that are frequently observed in many cancers. Histones are proteins 
around which the DNA wraps itself, and understanding histone modifications and how 
they alter the gene expression profile in cancer cells remains a major barrier in the field 
of epigenetic characterization of cancer (82). However, since histones represent the core 
building blocks for chromatin structures which can regulate gene expression, the variable 
posttranslational modifications that take place on histones can contribute to gene 
silencing or reactivation by changing chromatin structure depending on which amino 
acids are undergoing modification (83-85). Therefore, studies on epigenetic alterations in 
cancer have focused on validating the significance of the synergy between genetic and 
epigenetic alterations during malignant transformation, rather than attempting to prove 
whether cancer is a genetic or an epigenetic disease (86). 
 
2.5 miRNA in Cancer Diagnosis 
MicroRNAs (miRNAs) are short biological molecules (23 ribonucleotides on 
average) that are involved in interference with messenger RNAs (mRNAs) leading to 
post-translational repression (87). The rapid discovery and identification of new 
microRNAs have led to a better understanding of the complexity of cancers and the 
different biological processes underlying the disease. Indeed, the ability to detect 
miRNAs has required the development of sensitive and high-throughput screening 
methods such as microarrays that can screen hundreds of miRNA expression profiles at 
once. In the last few years, miRNA expression profiles have become one of the most 
powerful tools in cancer diagnosis. For instance, detection of miR-221 is considered to be 
a very specific and accurate diagnosis for human prostate cancer (88). Another example 
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for using miRNA as a signature for cancer diagnosis is the over-expression of miR-155 
and downregulation of miR-141 in 97% of patients with renal malignancy (89). In 
addition, cancer-related miRNAs (known as oncomiRs) can serve not only as biomarkers 
for diagnosing malignant development, but also for progression, metastasis and response 
to therapy (90). In gastric cancer, it is currently established that downregulation of miR-
451 correlates with poor prognosis. In gastric cancer, upregulation of miR-451 leads to 
repression of the oncogene MIF (macrophage migration inhibitory factor), leading to 
inhibition of cell growth and sensitization of cancer cells to radiotherapy (91, 92). 
Furthermore, miRNA expression profiles can serve as biomarkers for anticipating 
survival rates. In pancreatic cancer, patients who demonstrate overexpression of miR-
155, miR-203, miR-210, and miR-222 have a 6-fold higher fatality rate from pancreatic 
malignancy compared to patients with lower levels of the miRNAs (93). Table 2.2 
summarizes some of the well-defined miRNAs in different cancers. Finally, miRNAs 
have also been found to influence malignant transformation due to the fact that they can 
function as tumor suppressors (e.g., miR-15a and miR-16-1) or oncogenes (e.g., miR-17-
92 cluster) (94). However, the utility of miRNAs in cancer diagnosis remains a largely 
underutilized field that requires more research before it can be implemented efficiently in 
the clinic. 
 
2.6 Nutrients and Metabolic Characteristics of Cancer 
One of the major issues with anticancer therapies is their lack of tumor specificity. 
Therefore, a fundamental understanding of the unique physiological properties of cancer 
is needed.  
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Table 2.2 A summary of some miRNAs in different cancers (adapted from (90)) 
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In normal cells, microvasculature develops with order, and exhibits regular blood 
flow. But, in tumors, these vessels are tortuous, leaky, and often sluggish with irregular 
blood flow, resulting in poor drug delivery due to high interstitial pressure (103). 
Selective cytotoxic studies revealed that cancer cells are highly heterogeneous with 
hypoxic regions that reduce tumor sensitivity to radiation therapy. Furthermore, necrosis 
(premature cell death) is more common in cancer than in normal cells (104). 
Understanding the causes underlying each of these distinctive features, together with 
cancer-associated metabolic pathways, may help to develop more cancer specific 
therapeutics. The most obvious feature that separates tumor cells from normal cells is 
their accelerated metabolic rate, resulting in uncontrolled growth (105) and proliferation 
(106). The elevated metabolism of cancer cells can be tracked back to their unique ability 
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to reprogram the traditional mechanisms of energy production, which leads to cellular 
stress (107).  
Because metabolic pathways are connected, and therefore interdependent, 
alteration of a single pathway can have a significant impact on the regulation of others. 
These reprogrammed pathways not only widen the options to consume energy in different 
forms, but also facilitate utilization of inorganic nutrients to augment proliferation. Even 
though cancer cells are notorious for chaos and instability, metabolically they are very 
well-organized to satisfy their need for growth and support (105).  
 
2.6.1 Organic Players: How Tumors Feed and Grow 
2.6.1.1 Carbohydrates  
Sugars such as glucose, fructose, and sucrose are primary sources of fuel for any 
cell. Moreover, glucose can coordinate gene transcription, hormone secretion, enzyme 
activity, and glucoregulatory neurons (108, 109). 
 
2.6.1.1.1 Warburg Effect 
Cancer cells develop several unconventional mechanisms to employ glucose and 
its downstream metabolites to dominate their functions for amplified cell growth. 
Warburg effect is one of the prime cancer reprogramming models associated with glucose 
and respiration. In the presence of adequate oxygen, normal cells produce energy by 
breaking down glucose into carbon dioxide and water, a process called aerobic 
respiration. Aerobic respiration begins with the conversion of glucose to pyruvate via 
glycolysis in the cytosol, followed by oxidative phosphorylation to yield a maximal 
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amount of ATP.  When an adequate supply of oxygen is not available, cells break down 
glucose to lactate by fermentation at the expense of ~18 fold less energy production than 
aerobic respiration (105). However, the same rule does not apply to cancer cells. In the 
early 20
th
 century, a German scientist named Otto Warburg first noticed an aberrant 
biochemical characteristic in cancer cell metabolism (107). Warburg observed that even 
under aerobic conditions, rat sarcomas and human tumors were generating copious 
amounts of lactate compared to normal cells (110). This finding together with others 
confirmed that cancer cells restrict their metabolic energy largely to glycolysis, leading to 
a condition termed “aerobic glycolysis,” more commonly known as Warburg effect. 
Warburg effect is depicted in Figure 2.4. In 1931, Warburg won the Nobel prize in 
Physiology or Medicine for the discovery of the hydrogen-transferring function of flavine 
and nicotinamide (107). Warburg’s finding changed the scientific perspective of cancer 
with his first step that distinguishes tumor metabolic features from normal cells. From 
this, numerous questions arise: Do cancer cells consume more glucose than normal cells? 
If they do, which proteins facilitate the high uptake of glucose? How does this 
overconsumption affect neighboring normal cells? Is glucose the only essential nutrient 
required for tumor growth and survival? What other metabolic characteristics can be 
unraveled to specify malignant transformation? 
 
2.6.1.1.2 Glucose and its Transporters 
To detect glucose uptake, positron emission tomography (PET) has been widely 
used to diagnose tumor staging and to monitor treatment progression (111). 2- fluoro-2-
deoxy-D-glucose (FDG) labeled with 
18





Figure 2.4 Reprogramming carbohydrate metabolism in cancer. Overexpression of 
glucose transporter 1 (GLUT1) facilitates import of excess glucose for accelerated 
glycolysis. Pyruvate kinase M2 (PK M2) favors accumulation of biosynthetic precursors 
fructose-6-phosphate and glyceraldehyde-3-phosphate for nucleotide synthesis, and 
glycerate-3-phosphate for amino acid and phospholipid synthesis. The oncoprotein myc 
upregulates lactate dehydrogenase A (LDH A) to alleviate Warburg effect, and hypoxia-
inducible factor 1, alpha subunit (HIF-1α) inhibits pyruvate dehydrogenase (PDH) to 
prevent cytosolic pyruvate export to the mitochondria. Monocarboxylate transporter 4 




Once inside the cell, FDG is catalyzed by hexokinase, and is converted to a 6-
phosphate derivative which is chemically stable and resistant to further catalysis (112). 
Signal from the resultant compound correlates directly to the amount of glucose uptake in 
the cell. PET diagnosis of cancer patients reported increased uptake of FDG at the cancer 
site, confirming that cancer cells indeed consume more glucose than normal cells (113).  
Because of limited passive diffusion through membranes, cells largely rely on 
specific transporters for the exchange of vital substances such as glucose to achieve high 
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glucose uptake (114). The uptake of glucose into cells is facilitated by the Glut family of 
transporters. Among the 14 members of this family, the Glut1 isoform is the most studied 
transporter due to its critical role in providing nutrients for cancer cells. Glut1, encoded 
by solute-linked carrier gene family member SLC2A1, is a facilitated glucose transporter 
ubiquitously expressed in human tissues (115). Since the brain depends solely on glucose 
as the energy source, Glut1 is more highly expressed in the blood-brain barrier compared 
to all other tissues (116). Cancer cells mimic the same strategy to meet their excessive 
glucose requirement by upregulating Glut1 expression via RAS and SRC oncogenes 
(117). Thus, Glut1 can be signified as a metabolic marker for malignant transformation. 
Clinical reports showed that Glut1 expression correlates reciprocally with cancer patient 
survival (118-120) and directly to tumor aggressiveness (121). With further advancement 
in modern technologies, overexpression of several other Glut family members in cancers 
have been identified, including Glut3 in cervical cancers (122) and Glut4 in thyroid 
carcinoma and alveolar rhabdomyosarcoma (117). 
 
2.6.1.1.3 Pyruvate and its Regulatory Enzyme, Pyruvate Kinase M2 
Besides glucose, pyruvate is at the heart of cellular metabolism. Despite being the 
final product of glycolysis, pyruvate plays a central role in interconnecting biosynthetic 
pathways. In cancer cells, HIF-1α inactivates pyruvate dehydrogenase (PDH) to prevent 
mitochondrial matrix import, confining pyruvate to the cytosol (123). At the same time, 
oncogenic myc upregulates lactate dehydrogenase A (LDH A) expression for the 
conversion of cytosolic pyruvate to lactate, securing NAD
+
 regeneration for tumor 
propagation, and avoiding pyruvate-related cytotoxicity (124) as illustrated in Figure 2.4. 
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For the last decade, the pyruvate kinase M2 (PK M2) isoform has received 
attention as an indicator of malignant transformation. Pyruvate kinase is the rate-limiting 
enzyme in glycolysis for pyruvate generation, and therefore a major regulator of 
pyruvate-linked pathways. Depending on the tissue, different isoforms of PK are 
expressed to perform designated tasks. For instance, PK M1 is mostly found in brain and 
muscle for instant energy generation, whereas PK M2 is present mainly in multiplying 
cells such as embryonic cells, which require constant nucleic acid synthesis. Not 
surprisingly, tumor cells replace PK M1 with PK M2 for rapid cell proliferation (125, 
126). Being the key glycolytic enzyme, PK M2 dominates glycolysis either directly or 
indirectly. By generating pyruvate, PK M2 favors pyruvate-alanine conversion via a 
glutamate intermediate to synthesize purines and pyrimidines (127), and simultaneously 
controls the glutaminolysis cycle (truncated Krebs cycle) for ATP production (128). 
Conversely, limiting pyruvate production results in accumulation of preceding 
metabolites such as fructose-6-phosphate, glyceraldehyde-3-phosphate, and glycerate-3-
phosphate (precursors of biosynthetic pathways). PK M2 canalizes glyceraldehyde-3-
phosphate and fructose-6-phosphate to the nonoxidative pentose phosphate cycle for 
ribose-5-phosphate production, necessary for nucleic acid synthesis. PK M2 also 
channels glycerate-3-phosphate to amino acid and phospholipid synthesis as depicted in 
Figure 2.4 (126). Further, the role of PK M2 is not limited to its glycolytic function in the 
cytosol. With the help of a nuclear localization signal (NLS) located at the C-terminus, 
PK M2 can translocate to the nucleus upon epidermal growth factor (EGF) receptor  
activation (129). Once inside the nucleus, PK M2 phosphorylates Stat3 for MEK5 
transcription, leading to cell proliferation (130).   
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Since PK M2 is predominantly expressed in cancer cells, targeting it may provide 
tumor specificity with minimal cytotoxicity to normal cells. Theoretically, inhibition of 
PK M2 should deplete pyruvate production in cancer cells. Therefore, this precludes 
subsequent anabolic pathways such as amino acid and phospholipid biosynthesis, and 
hence could manifest anticancer activity. Lactate, the final product of “aerobic 
glycolysis,” is primarily associated with biosynthesis, metastasis, and immune 
suppression. Similar to pyruvate and glucose, lactate requires an efficient shuttling 
system to augment tumorigenic effects. Monocarboxylate transporters (MCT), encoded 
by SLC family genes, are transmembrane proteins responsible for lactate and pyruvate 
transport (131). Unlike glucose transporters, MCT isoforms are involved in both import 
and export of lactate, therefore expressed selectively in different cell types. Recent 
studies have established that cancer cells upregulate the proton-coupled MCT-4 isoform 
in a HIF-1α-dependent fashion (132) for the export of excess lactate, and epigenetically 
suppress sodium-coupled MCT 1 (SMCT1) to prevent lactate import inside the cell (133). 
Moreover, MCT shuttles lactate to fibroblasts, and imports pyruvate back to the cancer 
cell. This conserves a high lactate to pyruvate ratio, which is proposed to be essential for 
tumor survival (134). Besides MCT, several other lactate shuttling proteins have been 
identified over the past few of decades, such as the lactate-alanine shuttle for amino acid 
synthesis (135, 136). 
Release of excessive lactate into the extracellular milieu decreases the pH of the 
surroundings as shown in Figure 2.4, and thereby causes acidification of adjacent normal 
cells. Removal of normal cells reduces competition for nutrients and provides additional 
space for tumors to grow. This explains how overconsumption of glucose by cancer cells 
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can be pernicious to normal cells. Moreover, reduction in pH facilitates angiogenesis and 
metastasis through up-regulation of EGFR and HIF-1α (137, 138), and inhibits T-cell 
proliferation via blockade of lactate efflux thus evading the immune response.  
 
2.6.1.2 Protein: mTOR 
Mammalian target of rapamycin, also known as mechanistic target of rapamycin 
(mTOR), is an atypical serine/threonine kinase at the border of cell growth and 
starvation. In presence of a plethora of nutrients, mTOR is advantageous to cells with 
uncontrolled growth and deregulated metabolism such as cancer cells. However, mTOR 
is unaffordable to nutrient-deprived cells due to its high energetic requirements. Since the 
first discovery in yeast (139), mTOR has gained a considerable reputation throughout the 
years for its reprogrammed expansive signaling array to fuel cancer cell growth, 
proliferation, survival, metabolism, and  transcription (140). Structurally, mTOR has two 
distinct catalytic domains, mTOR complex 1 (mTORC1), and mTOR complex 2 
(mTORC2), which may exist as dimers (141, 142). Regulatory-associated protein of 
mTOR (RAPTOR) and rapamycin-insensitive companion of mTOR (RICTOR) serve as a 
scaffold for mTORC1 and mTORC2, respectively, to form complexes with their 
substrates and regulators. Growth factors and amino acids such as insulin regulate 
mTORC1 activation. Another key protein, GTPase RHEB, when loaded with GTP can 
activate mTORC1 as well. In fact, overexpression of RHEB can maintain mTORC1 
kinase activity even under starvation conditions (143). However, for mTORC2 
regulation, emerging evidence suggests that the oncogene Ras may be necessary to link 
growth factors to mTORC2 (144).  
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Substrates of mTORC1, mainly S6 kinase (S6K) and initiation factor 4E binding 
protein 1 (elF4E-BP1) are involved in strict regulation of mRNAs. Upon phosphorylation 
by mTORC1, elF4E-BP1 dissociates from elF4E, allowing incorporation of translation 
factors to initiate anti-apoptotic protein synthesis (145, 146). When phosphorylated by 
mTORC1, S6K binds to multiple proteins, including nuclear-capping binding protein 
(CPB) for mRNA translation initiation and progression (147). In addition, phosphorylated 
S6K initiates transcription of rRNA polymerase 1(RNAP I), signifying that mTORC1 
actively up regulates rRNA synthesis (148), which may contribute to oncoprotein 
translation.  mTORC1 is also involved in autophagy, a process of self-degradation of 
damaged cells through the lysosomal machinery. mTORC1 phosphorylates the enzyme 
Atg-13, preventing autophagic action (149). Increasing evidence indicates that autophagy 
facilitates tumor suppression; thus, autophagic evasion implies mTORC1 may favor 
tumorigenesis (150). Unlike mTORC1, mTORC2 directly activates a group of signaling 
pathways that are already known for tumorigenesis. The primary substrates of mTORC2, 
predominantly Akt, serum- and glucocorticoid-regulated kinase (SGK), and protein 
kinase C (PKC) are responsible for cell cycle progression and cell survival (151, 152).  
 
2.6.1.3 Lipids 
To date, the majority of cancer metabolic research has focused on the catabolic 
process of glycolysis. Because cancer cells can proliferate faster than normal cells, they 
seemingly must have a shifted anabolic rate as well. For rapidly proliferating cells such 
as cancer cells, lipid synthesis can be vital for new membrane formation, energy storage, 
hormone production, and growth factor regulation.  
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2.6.1.1.4 Lactate and its Transporter MCT 
Studies of 
14
C-labeled glucose show that most of the esterified acids are derived 
from de novo synthesis (153, 154), confirming that a higher rate of lipid biosynthesis 
takes place in cancer cells. Two key enzymes, ATP citrate lysate (ACL), and most 
importantly, fatty acid synthase (FAS) have been identified as mandatory supporters for 
increased lipid synthesis (155). To stimulate lipid production, the P13/Akt pathway 
inhibits breakdown of fatty acids by blocking β-oxidation, and activates ACL (156) to 
channel oxaloacetate for lipid synthesis. Fatty acid synthase (FAS), encoded by the 
FASN gene, is downregulated in most normal tissues but highly upregulated in cancer 
cells, which makes it a possible candidate as a therapeutic biomarker. Functions of FAS 
include energy storage in liver and adipose tissue, reproduction, and lactation. As the 
name suggests, FAS synthesizes palmitate (16C) from acetyl- CoA (2C) (155) to serve as 
a precursor for longer fatty acid synthesis. Inhibition of FAS in promyelocytic leukemia 
caused cell accumulation in G1 phase, followed by reduction in cell proliferation (157), 
demonstrating the possible role of FAS in cell cycle regulation. Another lipid-associated 
marker protein, Spot-14 was found to be overexpressed in breast cancer cells, and its 
expression level correlates with aggressiveness of the disease state (158). However, the 
role and mechanistic pathway of Spot-14 in lipid synthesis are still unknown (156). 
Recently, Nomura and colleagues reported that monoacylglycerol lipase (MAGL) drives 
tumorigenesis through lipolytic release and remodeling of free fatty acids. Inhibition of 
overexpressed MAGL in vitro impaired cell migration and invasiveness (159). If MAGL 
is proven to be specific for cancer, this finding will add another enzyme to the existing 
list of lipid players in cancer. 
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2.6.2 Inorganic Compounds 
Biological systems are dominated by organic molecules ranging from substrates 
to products. However, trace amounts of inorganic molecules exist in humans, which are 
crucial for maintaining genomic stability and for regulating most organic macromolecules 
such as enzymes. 
 
2.6.2.1 Selenium 
Selenium, an essential trace element, mediates metabolic pathways in conjunction 
with proteins, collectively called selenoproteins. So far, 25 selenoproteins have been 
discovered in humans (160). Most selenoproteins are involved in antioxidant function, 
including glutathione peroxidase-1 (GPX1) (161). GPX1 knockout mice exhibited 
increased susceptibility to H2O2-induced apoptosis (162), and accelerated accumulation 
of mutations (163), suggesting a potential role of selenium in genomic stability. When in 
excess, selenium metabolites can stimulate selenite-induced apoptosis and cell cycle 
arrest via the p53-dependent pathway (164) (165). Moreover, inorganic selenium 
sensitizes cancer cells to apoptotic inducers such as TRAIL through the p53-mediated 
mitochondrial pathway (166).  
 
2.6.2.2 Copper   
The balance of copper is important to maintain regular cell function. Cu
2+
 
deficiency can cause myeloneuropathy, a fatal developmental disease (167). Conversely, 
the elevated serum level of copper observed in cancer patients (168) is caused by an 
excess of free Cu
2+
 radicals, which promotes oxidative stress, leading to genomic 
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instability (169). Surprisingly, when Cu
2+
 binds to its enzyme, CuZnSOD, the resultant 
complex reduces oxidative stress by eliminating O2
-
 directly from mitochondria, 
preventing oxidative DNA damage (170). 
 
2.6.2.3 Zinc  
More than 300 enzymes and proteins require zinc as a cofactor for functional 
activity, including DNA the repair protein, p53. Under oxidative stress, the zinc finger-
domain of p53 responds to DNA damage and assists in sequence-specific recognition of 
DNA repair machinery (171). Nevertheless, above a certain threshold, zinc inhibits DNA 




Most iron found in the body is present in hemoglobin in red blood cells or in 
myoglobin of muscle tissue. In terms of intracellular signaling, iron found in the 
cytochrome of mitochondria is directly involved in ROS formation, which can lead to 
oxidative stress. On the other hand, release of cytochrome c from the mitochondria 
activates the caspase cascade which leads to apoptosis. Additionally, iron is a cofactor of 
several DNA repair proteins, including α-ketoglutarate dependent DNA repair enzyme 







Calcium is the most abundant metal in biological systems. Ca
2+
 is a highly 
versatile intracellular signaling molecule that ensures different cellular processes can 
respond precisely to diverse stimuli. For example, Ca
2+
 signals presynaptic neurons to 
release neurotransmitters in response to a nerve impulse, and the same Ca
2+
 also regulates 
actin for muscle contraction. The elaborate role of Ca
2+
 connects the entire signaling 
network, which makes it a perfect target for cancer to reprogram many metabolic 
pathways. Ca
2+ 
plays a significant role in the metastatic behavior of cancer cells. In order 
to be invasive, cancer cells require focal detachment and proteolysis of the extracellular 
matrix for migration. Ca
2+
 binds to myosin light chain kinase (MLCK) for myosin II 
phosphorylation, and degrades focal adhesion proteins, resulting in focal detachment for 
migration (173). Moreover, upon binding to S1004A (EF-hand calcium binding protein) 
Ca
2+
 exposes the interacting domain to interact with cytoskeleton proteins, which has 
been implicated to be important for cell migration and epithelial to mesenchymal 
transition (EMT) (174, 175). 
 
2.7 The Cancer Microenvironment 
As mentioned, cancer develops after two initiating events in succession (the "two-
hit hypothesis" of tumor suppressor mutation (176)) or after a promoting event, which 
leads to genetic modifications (177) usually in tumor suppressor genes (see Figure 2.5A). 
Growth and invasion of the cancer is promoted by the tumor microenvironment, which 
develops as a result of crosstalk among different cell types. The microenvironment is 
formed and controlled by the tumor itself but also consists of the tumor stroma, blood 
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vessels, inflammatory cells and other associated cells (178) (including cancer-associated 
fibroblasts, vascular and lymphatic endothelial cells). 
 
2.7.1 The Stroma and its Components 
The stroma is the surrounding matrix that supports the tumor (179). The tumor 
stroma consists of the extracellular matrix (ECM) and the surrounding noncancerous cells 
(180). One of the most important types of cells in the stroma are cancer associated 
fibroblasts (CAFs; also known as activated fibroblasts or myofibroblasts). CAFs are 
spindle-shaped, mesenchymal cells with stress fibers and fibronexus (181), and may arise 
from epithelial cells through the epithelial to mesenchymal transition (EMT) (182). CAFs 
synthesize the ECM by producing fibrous proteins such collagens and fibronectin which 
are embedded in a glycosaminoglycan gel (183). CAFs not only secrete growth factors 
that impact cell motility, but also contribute to ECM remodeling by secreting matrix 
metalloproteinases (182). This may allow cancer cells to get across tissue boundaries, and 
create cancer cell niches and initiate angiogenesis (183). CAFs also secrete laminin and 
type IV collagen to make up the basement membrane (also known as the basal lamina). 
Infiltrating inflammatory cells in the tumor microenvironment include those that 
mediate adaptive immunity, including tumor-infiltrating T lymphocytes, dendritic cells, 
and B cells (to a lesser extent), and those that mediate innate immunity, including tumor-
associated macrophages, polymorphonuclear leukocytes (PMLs), and rare natural killer 
(NK) cells (178). Many tumor-infiltrating T lymphocytes are specific for tumor-
associated antigens, implying host immune surveillance, but are incapable of halting 
tumor growth (178).  
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Tumor-associated macrophages (TAMs) are reprogrammed to inhibit lymphocyte 
functions (by the release of inhibitory cytokines) (184). A version of immature dendritic 
cells known as myeloid suppressor cells (MSCs) produces arginase 1, which facilitates 
tumor growth and suppresses immune cell functions (185). Important mediators of cancer 
are cytokines (and their cognate receptors), which  may promote or inhibit cancer, and in 
general, regulate immunity and inflammation (186). Chemokines are chemoattractant 
cytokines that play important roles in allowing cells to traffic in and out of the tumor 
microenvironment. The chemokine system is subjugated by cancer cells for this purpose 
(187, 188). Interestingly, the chemokine receptor CXCR4 has been found to be 
overexpressed on many cancer cell types including breast, prostate, and pancreatic 
cancers; melanomas; and certain leukemias (187). Overall, the tumor subverts 
inflammatory cells which leads to tumor growth and evasion of the host immune system, 
allowing the tumor to proliferate. 
Cells that form the tumor-associated vasculature (vascular endothelial cells) may 
have altered characteristics compared to normal vasculature, including differences in 
gene expression profiles and cell surface markers. On the other hand, the role of 
lymphatic endothelial cells (that form lymphatic vessels) is poorly understood in terms of 
tumor growth. Lymphatic vessels in the tumor itself are often collapsed and non-
functional, while lymphangiogenesis is occurring on the periphery of the tumor and on 
adjacent normal cells. This suggests that these lymphatics form channels that allow 
seeding of metastasis (105).  
Regardless, studies of proteins and factors involved in either vascular or 
lymphatic endothelial cells lead to identification of new therapeutic targets (anti-
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angiogenic or anti-metastatic therapies). One key protein secreted by endothelial cells is 
SPARC (secreted protein acidic and rich in cysteine; also termed osteonectin), involved 
in cell-cell, and cell-matrix interaction without participating structurally in the ECM 
(189). SPARC can modulate focal-adhesion and metalloproteinase expression, and 
interact with growth factors such as vascular endothelial growth factor (VEGF) and 
platelet-derived growth factor (PDGF) (190) to determine cell shape, cytoskeleton 
architecture, and proliferation (191) Histological studies have also validated 
overexpression of SPARC (192), and its importance in epithelial-mesenchymal transition 
for metastasis (193, 194).  In addition to endothelial cells, pericytes are another type of 
cell that wrap around the endothelium of blood vessels. Pericytes secrete antiproliferative 
signals, produce vascular endothelial growth factor (VEGF), and work with endothelial 
cells to stabilize vessel walls (195, 196). In tumors, pericytes help support the tumor 
endothelium, and are thus another target for pharmacological intervention (105). Some of 
the components of the tumor microenvironment are depicted in Figure 2.5C. 
Paramount to tumor malignancy is the process of angiogenesis (197), where new 
blood vessels form to supply nutrients/oxygen to the existing tumor and allow for the 
removal of waste products (Figure 2.5C). Folkman and colleagues demonstrated the need 
for inducing and sustaining angiogenesis in tumors (105, 197, 198). In cancer, the 
angiogenic switch can be activated by altering the balance of angiogenic inducers and 
inhibitors. Angiogenic inducer and inhibitor prototypes include VEGF-A (vascular 
endothelial growth factor-A) and TSP-1 (thrombospondin-1), respectively (105, 199). In 
the last decade, many other angiogenic factors have been identified and summarized 
(200). Angiogenic inhibitors are being actively pursued for cancer therapy, with the 
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concept of cutting off the blood supply to the tumor (200, 201). 
 
2.7.2 The Invasion-Metastasis Cascade 
Further cancer progression into metastases involves the tumor cells’ ability to 1) 
invade through the ECM and stromal cells, 2) intravasate into the blood vessel lumen, 3) 
survive in the bloodstream, 4) seed at an organ site, 5) extravasate into these organs, 6) 
survive and form micrometastases, and 7) form metastatic colonies (177, 202, 203). The 
end result is the spread of cancer to new sites/organs, or metastasis (204) (Figure 2.5). 
 
 
Figure 2.5 The major steps in cancer.  A) Initiating events; B) Uncontrolled cell division; 







2.7.2.1 Epithelial-to-Mesenchymal Transition (EMT) 
For the invasion through the ECM and stroma, tumor epithelial cells must 
undergo an epithelial-to-mesenchymal transition (205) which allows for an increased 
capacity to migrate, an enhanced resistance to apoptosis, increased invasiveness, and an 
ability to remodel the extracellular matrix (206-208). 
Of the 2 types of EMTs, type 3 EMT is associated with cancer progression and 
metastasis (207). EMT may be the activating factor for acquisition of malignancy for 
epithelial cancers. These cancer cells appear to have a mesenchymal phenotype, express 
typical mesenchymal markers such as vimentin, desmin, FSP1 (fibroblast-specific protein 
1), andSMA (smooth muscle-actin)  (209), and appear at the invasive front of 
tumors. After the invasion-metastasis cascade, to form a secondary tumor, these cells 
have to shed their mesenchymal phenotype and return to their epithelial phenotype (207) 
(Figure 2.5F). It is thought that EMT-inducing signals (including HGF; EGF, epidermal 
growth factor; PDGF; TGF-) may emanate from tumor stroma, resulting in a complex 
cascade, starting with transcription factor activation (of Snail; Slug; ZEB1, zinc finger E-
box binding homeobox 1; Twist; Goosecoid; FOXC2, Forkhead 1) followed by further 
signal transduction (by ras; c-Fos; LEF, lymphoid enhancer factor; ERK, extracellular 
signal-regulated kinase; MAPK, PI3K, Akt, Smads, RhoB, -catenin). Cell surface 
proteins (integrins) are also activated which disrupt several cell-cell or cell-ECM 
junctions (207). Lastly, E-cadherin loss is central in the EMT program (210).  TGF-
exposure induces transcription factors Snail, Slug, SIP1 (Smad-interacting protein 1), 
and E12 (E2A transcription factor family member), which in turn, repress E-cadherin 
expression.  Lack of E-cadherin correlates with increased tumorigenicity and metastasis 
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in some models (211). Finally microRNAs miR-200 and miR-205 increase E-cadherin 
expression, and help maintain the epithelial phenotype, while miR-21 upregulation 
facilitates TGF--induced EMT (212). The EMT's role in cancer progression is depicted 
in Figure 2.5D. 
 
2.7.2.2 Entering and Surviving the Circulation 
Intravasation of cancer cells into the lymphatic lumen represents the main 
mechanism of dispersion of such cells (213). This process is facilitated by changes that 
allow these cancer cells to cross the pericytes and endothelial cells that make up the 
vessels (203). Tumor-associated blood vessels (neovasculature) are leaky and are 
continuously being reconfigured. These weak interactions between the endothelial cells 
and pericytes facilitate intravasation (214). Once in the bloodstream, these circulating 
tumor cells (CTCs) are thought of as “metastatic intermediates” (203) and use particular 
signaling pathways to avoid anoikis (a form of apoptosis caused by anchorage loss). 
These CTCs must also avoid damage by hemodynamic shear and attack by the immune 
system. They do so by using the blood coagulation process, forming microemboli, a 
process likely mediated by L- and P-selectins expressed by the CTCs (215). See Figure 
2.5D and E. 
 
2.7.2.3 Seeding, Extravasation, Micrometastasis,  
and Metastatic Colonization 
CTCs may either be physically trapped in microvessels, or are “predetermined” to 
lodge in certain organs/tissues. Predetermined lodging is based on formation of specific 
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adhesive interactions between the CTC and the organ. After honing to a specific organ, 
CTCs may form microcolonies that disrupt the surrounding vessels, or extravasate by 
entering the vessel by penetrating the endothelial and pericytes in the stroma. To facilitate 
this process, primary tumors may secrete a number of factors that disrupt distant 
metastatic sites and induce permeability at these distant sites (203). Cancer cells may 
establish a “premetastatic niche” (216) where primary tumors secrete systemic signals 
that induce fibronectin expression from specific organs, which leads to mobilization of 
VEGFR-1 and its ligand, secretion of MMPs, integrins, and other ECM factors, prior to 
the arrival of the CTCs (203). Further stimulation of signaling allows the cells to survive 
in this foreign environment. Finally, colonization of large macrometastases occurs 
following Paget’s “seed and soil” hypothesis where the “soil” represents a hospitable 
tissue environment for the “seed” (micrometastases) to form (217). Recently, gene 
expression of factors that help metastatic colonization have been identified for bone, 
lung, liver, and brain (203). An example of the implication of this is that breast cancer 
cells that metastasize to the bone use different mechanisms for colonization than those 
that metastasize to the lung. The ability of cells to undergo high self-renewal (e.g., tumor 
initiating cells) are more likely to undergo metastatic colonization. Several transcription 
factors (EMT-inducing and those involved in inhibition of cell differentiation) have been 
implicated in this self-renewal process. The process of metastasis is depicted in Figure 
2.5F. Factors involved in the metastatic process are indeed being actively pursued as 






In the late 1800s, since the “two-hit hypothesis” of cancer initiation was 
postulated, our understanding of cancer initiation and progression has truly evolved. A 
basic summary of events occurring in cancer is depicted in Figure 2.5. Initiating events 
trigger DNA damage, leading to genetic modification, and changes in the cell including 
altered metabolism (Figure 2.5A). Uncontrolled cell division leads to cell proliferation 
(Figure 2.5B). The tumor microenvironment depicts recruitment of other cells, and 
angiogenesis that occurs when tumors form. Nutrients, cytokines, etc. are released 
(Figure 2.5C). EMT is a program where proliferating cells undergo an epithelial to 
mesenchymal transition, and intravasate out of the primary locale (Figure 2.5D). Cancer 
invasion and progression continue, and cells extravaste (Figure 2.5E). Finally, metastasis 
occurs when cells extravasate to a new site, shed their mesenchymal phenotype, and form 
secondary tumors (Figure 2.5F). A fundamental understanding of tumor development has 
come from detailed investigation of cancer biology, and has identified many of the genes, 
proteins, signals, and other factors involved in cancer. With this arsenal of knowledge, 
scientists will continue to find ways to halt cancer in its tracks. Paramount to this will not 
only be the discovery of novel drug targets, but approaches to deliver new drugs 
specifically to tumor cells. 
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A CHIMERIC P53 EVADES MUTANT P53 TRANSDOMINANT 
 INHIBITION IN CANCER CELLS 
 
3.1 Abstract 
Due to the dominant negative effect of mutant p53, there has been limited success 
with wild-type (wt) p53 cancer gene therapy. Therefore, an alternative oligomerization 
domain for p53 was investigated to enhance the utility of p53 for gene therapy. The 
tetramerization domain of p53 was substituted with the coiled-coil (CC) domain from Bcr 
(breakpoint cluster region). Our p53 variant (p53-CC) maintains proper nuclear 
localization in breast cancer cells detected via fluorescence microscopy and shows 
similar expression profile of p53 target genes as wt-p53. Additionally, similar tumor 
suppressor activities of p53-CC and wt-p53 were detected by TUNEL, annexin-V, 7-
AAD, and colony forming assays. Furthermore, p53-CC was found to cause apoptosis in 
4 different cancer cell lines, regardless of endogenous p53 status. Interestingly, the 
transcriptional activity of p53-CC was higher than wt-p53 in 3 different reporter gene 
assays. We hypothesized that the higher transcriptional activity of p53-CC over wt-p53 
was due to the sequestration of wt-p53 by endogenous mutant p53 found in cancer cells. 
Co-immunoprecipitation revealed that wt-p53 does indeed interact with endogenous 
mutant p53 via its tetramerization domain, while p53-CC escapes this interaction. 
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Therefore, we investigated the impact of the presence of a transdominant mutant 
p53 on tumor suppressor activities of wt-p53 and p53-CC. Overexpression of a potent 
mutant p53 along with wt-p53 or p53-CC revealed that unlike wt-p53, p53-CC retains the 
same level of tumor suppressor activity. Finally, viral transduction of wt-p53 and p53-CC 
into a breast cancer cell line that harbors a tumor derived transdominant mutant p53 
validated that p53-CC indeed evades sequestration and consequent transdominant 
inhibition by endogenous mutant p53.  
 
3.2 Introduction 
The tumor suppressor p53, a 393 amino acid sequence-specific transcription 
factor, stimulates a wide network of signals including cell cycle arrest, DNA repair, and 
apoptosis. p53-dependent apoptosis is achieved through two distinct apoptotic signaling 
pathways; the extrinsic pathway through death receptors and the intrinsic pathway 
through the mitochondria (1). While p53 is able to induce apoptosis when targeted to the 
mitochondria (2-4), its tumor suppressor function mainly depends on localization to the 
nucleus and formation of p53 tetramers leading to its function as a transcription factor of 
several target genes (5). The p53 protein is commonly divided into three regions: an 
acidic N-terminal region (codons 1-101), a DNA binding domain (DBD, codons 102-
292), and a basic C-terminal region (codons 293-393) (6). The C-terminus contains three 
nuclear localization signals (NLSs), a nuclear export signal (E), and a tetramerization 
domain (TD) (Figure 3.1A). In response to cellular stimuli such as DNA damage and 
oncogene activation (7), the MDM2-p53 degradation pathway is inactivated leading to 
increased concentration of p53 followed by rapid accumulation in the nucleus, which is 
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essential for regulating cell cycle arrest, DNA repair, senescence, and apoptosis (8, 9). 
Current strategies to enhance the anti-cancer/tumor-suppressor function of p53 are 
focused on introducing additional wt-p53 to the affected cells or tumor. This treatment 
modality introduces wt-p53 as a gene into cancer cells using various delivery vehicles. 
Wild-type p53 is a currently approved gene therapeutic for head and neck cancer in China 
(10). While a promising approach, there are significant limitations to the efficacy of this 
method, namely the presence of mutations in the endogenous p53 molecule.  
The tumor suppressor p53 is inactivated in more than half of all human tumors 
(11). Acquisition of missense mutations in the TP53 gene results in aberrant p53 that is 
transcriptionally inactive (12-14). Mutant p53 can also contribute to cancer drug 
resistance due to its inhibition of wild-type (wt) p53 via a dominant negative effect and 
the acquisition of gain of function properties (15). Since p53 binds DNA as a tetramer 
consisting of a dimer of dimers (16), when endogenous mutant p53 oligomerizes with 
exogenous wt-p53 the resulting tetramer is inactive (17-19). Such hetero-tetramerization 
is possible as the TD retains functionality in mutant p53. This dominant negative effect, 
wherein mutant p53 inactivates therapeutic wt-p53, represents a key problem with using 
wt-p53 for gene therapy. The dominant negative effect of p53 has shown to be operative 
in vivo using knock-in mice expressing mutant p53 (20). 
Because sequestration of wt-p53 into inactive hetero-tetramers with mutant p53 
forms a critical barrier to the efficacy of utilizing p53 for cancer therapy, improvements 
to advance the efficacy of this therapy even in the presence of p53 mutants is needed 
(11). Our approach to bypass the dominant negative effect of tumor-derived p53 is to 
engineer a p53 variant that relies on a different oligomerization motif to prevent hetero-
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oligomer formation. To our knowledge, only one attempt has been made to eliminate the 
dominant negative effect of mutant p53 in hetero-tetramers via substituting its TD, with 
marginal success (21). Whereas the native TD of p53 drives the formation of antiparallel 
tetramers (21-23), this previous work utilized an oligomerization domain that led to 
parallel tetramer formation which resulted in a significant reduction in p53 function. We 
recognized that the oligomerization domain from breakpoint cluster region (Bcr) protein, 
a 72 amino acid coiled-coil (CC), tetramerizes as two dimers of two antiparallel-oriented 
monomers (24), in a similar fashion to the TD of wt-p53. This would be a suitable 
candidate for TD substitution (22), forming a chimeric p53-Bcr fusion. Table 3.1 depicts 
the oligomerization domains for p53 (TD) and the CC domain from Bcr.  
 
Table 3.1 Comparison of the native TD from wt-p53 to the CC domain from Bcr. 
Snapshots were taken with molecular visualization software PyMOL (PyMOL Molecular 
Graphics System Version 1.5.0.4 Schrodinger, LLC.) initiated from the 1C26 for p53 TD 





This report demonstrates that our p53 variant, namely p53-CC, shows higher 
levels of transcriptional activity in reporter gene assays, and exhibits similar tumor 
suppressor activity compared to wt-p53 in cell lines with varying p53 status. Lastly, we 
show the ability of p53-CC to circumvent the dominant negative effect in cancer cells 
harboring a strong transdominant mutant p53.  
 
3.3 Materials and Methods 
3.3.1 Construction of Plasmids 
To construct pEGFP-p53-CC (p53-CC), a truncated version of wt-p53 that lacks 
the tetramerization domain (amino acids 1-322) was amplified via PCR with primers 5’-
gcgcgcgcgctccggaatggaggagccgcagtca-3’ and 5’-gcgcgcgcgctccggatggtttcttctttggctggggaga-3’ 
using the previously cloned pEGFP-p53 (wt-p53) as the template DNA (4). The PCR 
product was then subcloned into the BspEI site of pEGFP-CC (CC) (26). 
To create pEGFP-p53-∆TDC (p53-∆TDC), the same truncated version of wt-p53 
(amino acids 1-322) was amplified via PCR with primers 5’-
gcgcgcgcgctccggaatggaggagccgcagtca-3’ and 5’-gcgcgcgcgcggtacctcatggtttcttctttggctgggg-3’ 
using pEGFP-p53 as the template DNA (4). The PCR product (insert) was then subcloned 
into the digested pEGFP-C1 vector (Clontech, Mountain View, CA) at the BspEI and 
KpnI sites.  
To design pTagBFP-mut-p53, wt-p53 was amplified via PCR with primers 5’-
gcgcgcgcgctccggagccatggaggagccgcagt-3’, and 5’-gcgcgcgcgcggtacctcagtctgagtcaggcccttctgtc-3’ 
using pEGFP-p53 as a template. This insert was then subcloned into the digested 
pTagBFP-C vector (Evrogen, Moscow, Russia) at the BspEI and KpnI sites. Three hot 
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spot mutations (R175H, R248W, and R273H) (27, 28) were then introduced into 
pTagBFP-p53 via QuikChange II XL Site- Directed Mutagenesis Kit (Agilent, Santa 
Clara, CA). The following primers were used: for the R175H mutation, 5’-
tgacggaggttgtgaggcactgcccccaccatgagcgc-3’ and 5’-gcgctcatggtgggggcagtgcctcacaacctccgtca-
3’; for R248W, 5′- ctgcatgggcggcatgaactggaggcccatcctcacca-3′ and 5’-
tggtgaggatgggcctccagttcatgccgcccatgcag-3’; and for R273H, 5’-
ggaacagctttgaggtgcatgtttgtgcctgtcctggg-3’ and 5’-cccaggacaggcacaaacatgcacctcaaagctgttcc-3’. 
 
3.3.2 Cell Lines and Transient Transfection 
T47D human ductal breast epithelial tumor cells (ATCC, Manassas, VA), MCF-7 
human breast adenocarcinoma cells (ATCC), HeLa human epithelial cervical 
adenocarcinoma cells (ATCC), H1373 human non-small cell lung carcinoma cells (a kind 
gift from Dr. Andrea Bild, University of Utah),  and MDA-MB-231 human breast 
adenocarcinoma cells (ATCC) were grown as monolayers in RPMI (Invitrogen, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (Invitrogen), 1% penicillin-
streptomycin-glutamine (Invitrogen), 0.1% gentamicin (Invitrogen). T47D and MCF-7 
were also supplemented with 4 mg/L insulin (Sigma, St. Louis, MO). 1471.1 murine 
breast adenocarcinoma cells (gift of Dr. Gordon Hager, NCI, NIH), HEK293 human 
embryonic kidney (ATCC), MDA-MB-468 human breast adenocarcinoma cells (ATCC), 
and 4T1 murine breast carcinoma cells were grown as monolayers in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin-glutamine, and 
0.1% gentamicin. MDA-MB-468 cells were also supplemented with 1% MEM non-
essential amino acids (Invitrogen). All cells were incubated in 5% CO2 at 37ºC. The cells 
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were seeded at a density of 7.5 × 10
4
 cells (for 1471.1, MDA-MB-231, HeLa, and 4T1 
cells) and 3.0 × 10
5
 cells (for MCF-7, T47D, HEK293, MDA-MB-468 and H1373 cells) 
in 6-well plates (Greiner Bio-One, Monroe, NC). Transfections of 1 pmol DNA were 
carried out 24 h after seeding using Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s recommendations (4). 
 
3.3.3 Microscopy 
All microscopy was performed using 1471.1 cells due to their ideal microscopic 
morphology (4). 24 h post transfection, media in 2-well live-cell chambers (Nalgene 
Nunc, Rochester, NY) was replaced with phenol red-free DMEM (Invitrogen). Cells were 
then incubated with 2 µg/mL Hoechst 33342 nuclear stain (Invitrogen) for 30 minutes at 
37
o
C. Images were taken using an Olympus IX71F fluorescence microscope (Scientific 
Instrument Company, Aurora, CO) with high-quality narrow band GFP filter (excitation, 
HQ480/20 nm; emission, HQ510/ 20 nm) to detect EGFP and cyan GFP v2 filter 
(excitation HQ436/20 nm, emission HQ480/40 nm, with beam splitter 455dclp) to detect 
H33342 as previously described (29). 
 
3.3.4 qRT-PCR 
Twenty-four h following transfection of T47D cells, mRNA from cell lysates was 
isolated using RNeasy
®
 Mini Kit (Qiagen, Valencia, CA). cDNA was then obtained using 
RT
2®
 First Strand Kit (Qiagen) and mixed with RT SYBR
®
 Green qPCR Mastermix 
(Qiagen). Equal volumes were then aliquoted into a 384-well p53 Signaling Pathway 
PCR Array
®
 (Qiagen). Roche LightCycler 480 was used for real-time PCR cycling. 
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Analysis of the PCR array was performed using the manufacturer’s web-based analysis 
software (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Genes outside 
of a 2-fold range were considered to be statistically different per the manufacturer.  
 
3.3.5 Western Blotting 
Twenty-four h following transfection of T47D cells, EGFP-positive cells were 
sorted using the FACSAria-II (BD-BioSciences). 3 x 10
5
 cells were pelleted and 
resuspended in 200 μL lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 1 % 
protease inhibitor). Standard western blotting procedures (30) were followed using 
primary antibodies to detect p21/WAF1, Bax, and actin as a loading control. The primary 
antibodies anti-p21 (ab16767, Abcam, Cambridge, MA), anti-Bax (ab7977, Abcam), 
anti-actin (mouse, ab3280, Abcam), and anti-actin (rabbit, ab1801, Abcam) were detected 
with anti-rabbit (#7074S, Cell Signaling Technology, Danvers, MA) or anti-mouse 
(ab6814, Abcam) HRP-conjugated antibodies before the addition of SuperSignal West 
Pico chemiluminescent substrate (Thermo Scientific, Waltham, MA). Signals were 
detected using a FluorChem FC2 imager and software (Alpha Innotech, Sanata Clara, 
CA). 
 
3.3.6 TUNEL Assay 
As previously described (4), T47D cells were prepared 48 h after transfection 
using In Situ Death Detection Kit, TMR red (Roche, Mannheim, Germany). Cells were 
EGFP gated and analyzed using FACSAria-II (BD-BioSciences, University of Utah Core 
Facility) and FACSDiva software. EGFP and TMR red were excited at 488 nm and 563 
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nm wavelengths and detected at 507 nm and 580 nm, respectively. The TUNEL assay 
was repeated three times (n=3) and analyzed using one-way ANOVA with Bonferroni’s 
post hoc test. 
 
3.3.7 Annexin-V Assay 
The annexin-V assay was performed as before (4). Briefly, 48 h post transfection, 
T47D cells were suspended in 400 μl annexin binding buffer (Invitrogen) and incubated 
with 5 μl annexin-APC (annexin-V conjugated to allophycocyanin, Invitrogen) for 15 
minutes. The incubated cells were EGFP gated and analyzed using FACSCanto-II. EGFP 
and APC were excited at 488 nm and 635 nm wavelengths and detected at 507 nm and 
660 nm, respectively. Each construct was tested three times (n=3) and analyzed using 
one-way ANOVA with Bonferroni’s post hoc test (4). 
 
3.3.8 7-AAD Assay 
As before (4), following manufacturer’s instructions, T47D, MCF-7, H1373, and 
MDA-MB-468 cells were stained with 7-aminoactinomycin D (7-AAD, Invitrogen) 48 h 
after transfection. Since HeLa, MDA-MB-231, and 4T1 cells are highly proliferating 
cells, thesecell lines were assayed 24 h post transfection. Cells were analyzed and gated 
for EGFP (with same fluorescence intensity to ensure equal expression of proteins) using 
the FACSCanto-II (BD-BioSciences, University of Utah Core Facility) and FACSDiva 
software. Excitation was set at 488 nm and detected at 507 nm and 660 nm for EGFP and 
7-AAD, respectively. The means from three separate experiments (n=3) were analyzed 
using one-way ANOVA with Bonferroni’s post hoc test. 
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3.3.9 Colony Forming Assay (CFA) 
CFA was carried out using the Cytoselect
®
 96-well cell transformation assay (Cell 
Biolabs, San Diego, CA). A base agar layer was prepared per manufacturer’s directions, 
and 50 µL was transferred to each well of a clear-bottom 96-well plate. T47D cells were 
transfected as described above with wt-p53, p53-CC, or CC and harvested 24 h post 
transfection. The cells were resuspended in RPMI medium (Invitrogen) at a concentration 
of 3.0 x 10
5
 cells/mL per the manufacturer’s instructions. A cell agar layer was then 
prepared as recommended, and 75 µL of the mixture was transferred to each well of the 
96-well plate containing the base agar layer. To each well, 100 µL of complete culture 
medium was added and plates were then incubated at 37ºC and 5% CO2 for 7 days. The 
culture medium was removed, solubilized, and lysed. Into a new black-bottom 96-well 
plate, 10 µL of cell lysates were transferred. CyQuant GR dye working solution (1:400 in 
PBS) was added to each well (90 µL) and incubated for 10 min at RT. A Spectra Max M2 
plate reader (Molecular Devices, Sunnyvale, CA) was used to detect fluorescence using a 
485/520 nm filter set. Independent transfections of each construct were tested three times 
(n=3) and analyzed using one-way ANOVA with Bonferroni’s post hoc test. 
 
3.3.10 Reporter Gene Assay 
The following plasmids: wt-p53, p53-CC, CC, or EGFP (3.5 µg of each construct) 
were co-transfected with 0.35 μg of pRL-SV40 plasmid encoding for Renilla luciferase 
(Promega, Madison, WI) to normalize for transfection efficiency in T47D cells. In 
addition to Renilla luciferase, constructs were co-transfected with 3.5 µg of p53-Luc Cis-
Reporter (Agilent Technologies, Santa Clara, CA) (4), p21/WAF1 reporter (a generous 
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gift from Dr. Bert Vogelstein, Addgene plasmid 16451) (31), or PUMA reporter (from 
Dr. Vogelstein, Addgene plasmid 16591, Cambridge, MA) (32); all 3 reporters encode 
the firefly luciferase gene. The Dual-Glo Luciferase Assay System (Promega) was used 
to determine firefly luciferase activity and Renilla luciferase per manufacturer's 
instructions. Luminescence from active luciferase was then detected using PlateLumino 
(Stratec Biomedical Systems, Birkenfeld, Germany) as previously (4). Renilla luciferase 
activity was used to normalize the firefly luciferase values. The highest relative 
luminescence value was set at 100% and untreated cells were set at 0%. The means from 
triplicate samples were taken from 3 independent experiments and analyzed using one-
way ANOVA with Bonferroni’s post hoc test.  
 
3.3.11 Co-Immunoprecipitation (co-IP) 
The co-IP was performed using Dynabeads co-IP Kit (Invitrogen). T47D cells 
transfected with either EGFP-wt-p53 or EGFP-p53-CC were collected and weighed out 
(0.05 g) 20 h post transfection. Anti-GFP antibody (ab290, Abcam) was coupled to 
magnetic beads using Dynabeads Antibody Coupling Kit (Invitrogen). Approximately 0.2 
g of cell pellet was lysed in 1.8 ml extraction buffer B (1x IP, 100 mM NaCl, 2 mM 
MgCl2, 1 mM DTT, 1 % protease inhibitor). The lysate was incubated for 30 min at 4°C 
with 1.5 mg of the dynabeads coupled with anti-GFP antibody. The immune complexes 
were then collected by a magnet and washed three times with extraction buffer B and one 
time with last wash buffer (1x LWB, 0.02% Tween 20). Immune complexes were then 
eluted using 60 µl elution buffer. Finally, the eluted complexes were denatured and 
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blotted using anti-p53 antibody HRP-conjugated (sc-126 HRP, Santa Cruz 
Biotechnology, Santa Cruz, CA). 
  
3.3.12 Overexpression of Mutant p53 
H1373 cells were cotransfected with 1 pmol of the transdominant mutant 
pTagBFP-mut-p53 (R175H, R248W, and R273H) (27, 28) and 1 pmol of wt-p53, p53-
CC, or CC fused to EGFP. Cells were stained as in the 7-AAD assay above 48 h post 
transfection and gated for EGFP and BFP using the FACSCanto-II (BD-BioSciences, 
University of Utah Core Facility) and FACSDiva software. Excitation for BFP was set at 
405 nm and detected at 457 nm. The means from three separate experiments (n=3) were 
analyzed using one-way with Bonferroni’s post hoc test and unpaired t test. 
 
3.3.13 Recombinant Adenovirus Production 
Replication-deficient recombinant adenovirus serotype 5 (Ad) constructs were 
generated using the Adeno-X
®
 Adenoviral Expression System 3 (Clontech). Either wt-
p53 or p53-CC was inserted into a cassette under the control of the CMV promoter. A 
separate CMV promoter controls the expression of ZsGreen1 for visualization. The 
empty virus (vector) was used as a negative control. Wt-p53 and p53-CC were PCR 
amplified with primers containing 15 base pair homology with a linearized pAdenoX 
vector (Clontech) based on an In-Fusion
®
 HD Cloning Kit (Clontech). Stellar
®
 competent 
cells (Clontech) were transformed with the adenoviral vector plasmids containing our 
constructs. Viral DNA was then purified, linearized and transfected into HEK293 cells 
for packaging and amplification. Viral particles were isolated from HEK293 cells by 
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freeze-thawing, purified using Adeno-X
®
 Mega Purification Kit (Clontech), and dialyzed 
against storage and proper tonicity buffer (2.5% glycerol (w/v), 25 mM NaCl, and 20 




3.4.1 p53-CC Localizes to the Nucleus 
Because the nuclear localization of p53 is important for anti-apoptotic function, 
we first chose to investigate if p53-CC also localized to the nucleus. Full length wt-p53 
contains three NLSs encoded by amino acids 305-322, 370-376, and 380-386 (Figure 
3.1A, top). Given that p53-CC (illustrated in Figure 3.1A) lacks most of the C-terminal 
domain (amino acids 323-393), which contains two NLSs, nuclear accumulation of p53-
CC was verified using fluorescence microscopy (Figure 3.1B). Both wt-p53 and p53-CC 
were fused to EGFP to enable visualization of the subcellular localization of each protein. 
Figure 3.1B shows similar nuclear accumulation of p53-CC and wt-p53 in 1471.1 murine 
adenocarcinoma cells. CC alone fused to EGFP showed mostly cytoplasmic localization 
(data not shown). Similar results were obtained in T47D and MCF-7 breast cancer cells 
(data not shown).  
 
3.4.2 Wt p53 and p53-CC Show Similar 
Gene Expression Profiles 
After verifying the nuclear localization of p53-CC via fluorescence microscopy, 
the activity of p53-CC was investigated next.  
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Figure 3.1 p53 domains and translocation to the nucleus. (A) Schematic representation of 
the experimental constructs and controls. Full length p53 (wt-p53) contains a MDM2 
binding domain (MBD), a transactivation domain (TA) in the amino terminus, a proline-
rich domain (PRD), a DNA binding domain (DBD), a strong nuclear localization signal 
(NLS), a tetramerization domain (TD) that also contains a nuclear export signal (E), and a 
carboxy terminus (C-terminus) that includes two weak NLSs. For p53-CC, the TD and C-
terminus were replaced by the coiled-coil (CC) from Bcr. p53-ΔTDC lacks both the TD 
and the C-terminus. (B) Representative fluorescence microscopy images of 1471.1 cells 
confirm exclusive nuclear accumulation of EGFP-p53-CC similar to EGFP-wt-p53. 
EGFP Fluorescence, nuclear staining with H33342, and phase contrast images are shown, 
left to right. White scale bars on top left corners are 10 µm. 
 
 
The Human p53 Signaling Pathway RT² Profiler™ PCR Array (Qiagen, Valencia, 
CA) (33) was used to compare the transcription profiles between wt-p53 and p53-CC in 
T47D human breast cancer cells. T47D cells contain mutant p53 (a L194F mutation) that 
does not exhibit a strong transdominant effect (34). Exogenously added wt-p53 has been 
shown to be functional in this cell line (4, 30), and hence these cells can be used for 
comparing wt-p53 activity with p53-CC. The PCR array uses real-time PCR to measure 
the expression profiles of 84 genes directly related to p53-mediated signal transduction, 
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including genes involved in apoptosis, cell cycle, DNA repair, cell proliferation, and 
differentiation.  
Analysis of the PCR array indicated that p53-CC showed a similar expression 
profile of 83 out of 84 genes compared to wt-p53 (Figure 3.2A), with the exception of the 
p53AIP1 gene (circled in black), whose protein product is one of many involved in the 
intrinsic apoptotic pathway. A tetramerization-deficient form of p53 (p53-ΔTDC) was 
included as a negative control in these assays to validate that the activity of p53-CC is 
due to proper tetramer formation, along with CC (also a negative control). As expected, 
both p53-ΔTDC and CC had significantly different expression profiles from wt-p53 
(Supplementary Figures 3.1 and 3.2) in the p53 signaling pathway PCR array.  
To verify the array results, the protein expression of two typical genes involved in 
two different pathways that are directly regulated by p53, Bax and p21/WAF1, were 
examined by western blotting. Bax is involved in the p53-dependent intrinsic apoptosis 
pathway (1), while p21/WAF1 is involved in cell cycle arrest (35). Figure 3.2B shows 
that T47D cells transfected with wt-p53 (first lane) or p53-CC (second lane) 
demonstrated overexpression of Bax and p21, while the monomeric form of p53 (p53-
ΔTDC, third lane) and the CC (fourth lane) negative controls did not significantly induce 
expression of the Bax and p21/WAF1. Faint p21/WAF1 bands are observed with 
negative controls and represent background levels of this protein. Due to its inactivity, 





Figure 3.2 p53-CC is capable of transactivating several p53 target genes. (A) Scatter plot 
representation of mRNA levels of 84 p53 target genes in T47D cells transfected with wt-
p53 or p53-CC. Each dot represents one of the 84 genes assayed in this PCR array. The 
two magenta lines represent a boundary of two fold upregulation or downregulation in 
mRNA levels. Cells treated with wt-p53 or p53-CC showed similar levels of mRNA for 
all 84 genes except for one, p53AIP1, which is circled on the scatter plot. (B) 
Representative cropped western blots of T47D cell lysates 24 h post transfection with wt-
p53, p53-CC, p53-∆TDC, or CC. Similar levels of Bax and p21/WAF1 protein 
expression were detected from cells treated with wt-p53 or p53-CC. 
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3.4.3 p53-CC Exhibits Tumor Suppressor Activity 
To determine if the similar gene expression profiles between p53-CC and wt-p53 
correlate with comparable tumor suppressor activity, the apoptotic potential (TUNEL, 
annexin V, 7-AAD) and transformative ability (colony formation) were tested in T47D 
cells. As mentioned before, T47D cells were chosen to compare the activity of p53-CC 
and wt-p53, since we have shown before that wt-p53 is active in these cells (4, 30). 
The TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) 
assay, which measures DNA fragmentation into nucleosomal segments, is a hallmark of 
apoptosis (36). Figure 3.3A shows that p53-CC has a similar ability to induce DNA 
fragmentation as wt-p53 compared to CC control. Next, the apoptotic potential of p53-
CC was also validated in the annexin-V assay, which evaluates the externalization of 
phosphatidylserine on the cell surface of apoptotic cells (37, 38). Similar levels of 
annexin-V positive staining were detected between cells transfected with p53-CC and wt-
p53 (Figure 3.3B), and were significantly higher than positive staining in cells transfected 
with CC negative control.  
The last apoptotic assay tested was the 7-AAD viability assay. In apoptotic or 
necrotic cells, the plasma membrane is disrupted allowing intercalation of the 7-AAD 
stain into DNA in the nucleus of these damaged cells (39, 40). In this assay, p53-CC 
maintains the same level of apoptotic activity as wt-p53, and is able to induce higher 
levels of cell death compared to the control (CC). Finally, the decrease in transformative 
ability (or oncogenic potential) of cells treated with p53-CC or wt-p53 were tested via a 
colony forming assay. In this assay, treatment with a tumor suppressor would be expected 
to reduce the number of cell colonies formed in an agar matrix.  
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Figure 3.3 Apoptotic and cell proliferation assays were performed in T47D cells 48 h 
after transfection. (A) TUNEL assay shows similar apoptotic activity of p53-CC 
compared to wt-p53. Both p53-CC and wt-p53 demonstrate a significantly higher activity 
compared to CC negative control. Similar results were obtained from (B) annexin V 
staining and (C) 7-AAD staining. (D) The colony forming assay shows the transformative 
ability of T47D cells post treatment with wt-p53, p53-CC, and CC. Cells treated with wt-
p53 and p53-CC show significant reduction in transformative ability (oncogenic 
potential) of T47D cells compared to untreated cells or cells treated with CC. Mean 
values were analyzed using one-way ANOVA with Bonferroni’s post test; * p < 0.05, ** 
p < 0.01, and *** p < 0.001. Error bars represent standard deviations from at least three 











Indeed, as shown in Figure 3.3D, both p53-CC (second bar) and wt-p53 (first bar) 
significantly reduced the number of colonies formed compared to the negative controls 
(CC and untreated cells, third and fourth bars, respectively). Overall, these results 
indicate that p53-CC shows similar ability to induce statistically significant levels of 
apoptosis and reduce oncogenic potential as wt-p53. 
To ensure that the potential for p53-CC to induce apoptosis is neither dependent 
on endogenous p53 status nor cancer cell line specific, p53-CC was tested in several 
different cell lines. Human epithelial cervical adenocarcinoma cells (HeLa), which 
express endogenous wt-p53 (41), MDA-MB-231 metastatic triple-negative breast cancer 
cells harboring mutant p53 (42), MCF-7 breast cancer cells with wild type but 
mislocalized p53 (43), and H1373 nonsmall cell lung carcinoma cells that are p53 null 
(44) (Table 3.2), were tested in the 7-AAD assay. In all four cell lines, p53-CC and wt-
p53 were able to induce similar levels of apoptosis, and were higher than the negative 
control (CC), as shown in Figures 3.4A-D. 
 
Table 3.2 Comparison of the four different cell lines (HeLa, MDA-MB-231, 





Figure 3.4 7-AAD assay was conducted in four different cell lines with varying p53 
status (A) Hela, (B) MDA-MB-231, (C) MCF-7, and (D) H1373. In all four cases, p53-
CC is capable of inducing cell death in a similar fashion compared to wt-p53, regardless 
of the endogenous p53 status or the cancer cell line used. Statistical analysis was 















3.4.4 p53-CC Maintains Transcriptional 
Activity of p53 Target Genes 
While p53-CC exhibited similar apoptotic activity as wt-p53, we wanted to 
determine if p53-CC was capable of activating promoters of p53-dependent target genes. 
Tetramerization of p53 is a prerequisite to transcriptional activity, thus transcriptional 
activation will indicate tetramerization ability (of both wt-p53 and p53-CC) (45). The 
transcriptional activity of p53-CC was tested in T47D cells using three different reporter 
gene assays. The first was the p53 cis-reporter system, a common reporter for measuring 
p53 activity, which relies on a synthetic promoter consisting of repeats of the 
transcription recognition consensus for p53 (TGCCTGGACTTGCCTGG)14 (46). The 
second and third reporter systems utilized the binding consensus sequences from 
p21/WAF1 and PUMA promoters, respectively. p21/WAF1 is a cyclin-dependent kinase 
inhibitor that mediates p53-dependent G1 cell cycle arrest (31, 35), while PUMA 
translocates to the mitochondria, deactivates antiapoptotic Bcl-2 and Bcl-XL proteins and 
induces p53-dependent apoptosis (47). In all three reporter gene assays, p53-CC showed 
higher transcriptional activity compared to wt-p53, and both were higher than the 
negative controls CC and EGFP (Figures 3.5A-C) in T47D cells.   
 
3.4.5 p53-CC Avoids Interaction with Endogenous p53 
We hypothesized that the higher level of transcriptional activity of p53-CC over 
wt-p53 was due to the possible hetero-oligomerization of wt-p53 with endogenous 
mutant p53 in this cell line. Therefore, a co-IP assay was performed to determine if 
exogenously added wt-p53 interacts with mutant p53 present in these cells.  
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Figure 3.5 Relative luminescence represents the activation of (A) the p53-cis reporter, 
(B) the p21/WAF1 reporter, and (C) the PUMA reporter in T47D cells. The ability of 
p53-CC to transactivate these promoters is higher than wt-p53. In all three cases, 3.5 µg 
of construct (wt-p53, p53-CC, CC, or EGFP) was co-transfected with 0.35 μg of pRL-
SV40 plasmid encoding for Renilla luciferase to normalize for transfection efficiency. In 
addition to Renilla luciferase, constructs were co-transfected with 3.5 µg of p53-Luc Cis-
Reporter, p21/WAF1 reporter, or PUMA reporter encoding for firefly  luciferase. Mean 
values were analyzed using one-way ANOVA with Bonferroni’s post test; ** p < 0.01, 
and *** p < 0.001. Error bars represent standard deviations from three independent 
experiments (n=3). (D) Interaction of endogenous p53 with exogenous wt-p53 or p53-CC 
was investigated in T47D via co-IP. A representative cropped western blot of protein 
complexes co-immunoprecipitated using anti-GFP antibody is shown. Left lane, 
endogenous p53 (53 kDa) co-immunoprecipitates with exogenous EGFP-wt-p53 (70 
kDa). Right lane, endogenous p53 fails to co-immunoprecipitate with exogenous EGFP-







To this end, mutant p53 in T47D cells would not be expected to co-
immunoprecipitate with p53-CC. Cell lysates transfected with either EGFP-wt-p53 or 
EGFP-p53-CC were incubated with anti-GFP antibody to selectively immunoprecipitate 
our fusion EGFP proteins (Figure 3.5D). Endogenous p53 that could potentially co-
immunoprecipitate with either exogenous EGFP-wt-p53 or EGFP-p53-CC was probed 
using anti-p53 antibody. Figure 3.5D shows that endogenous p53 (53 kDa) co-
immunoprecipitates with exogenous wt-p53 (left lane, 70 kDa) but fails to 
immunoprecipitate with p53-CC (right lane, 71 kDa). These findings indicate that 
endogenous p53 interacts directly with exogenous wt-p53, which is presumably due to 
hetero-oligomerization via their TDs. As expected, p53-CC, which lacks the native TD, 
evaded binding to endogenous p53. It should be noted that a prominent secondary band is 
normally detected by this anti-p53 antibody at about 69 kDa (per Santa Cruz 
Biotechnology). 
 
3.4.6 Bypassing the Dominant Negative Effect 
Since p53-CC did not interact with endogenous wt-p53 in the co-IP assay, the 
ability of p53-CC to bypass the dominant negative effect was tested, first using 
overexpression of a dominant negative mutant p53 in H1373 cells (p53 null), and second, 
in MDA-MB-468 cells that harbor a strong dominant negative p53 mutant (48).  The 
ability of p53-CC to “rescue” the loss of apoptotic activity induced by an inactive mutant 
p53 in H1373 (p53 null) cells was tested; Figure 3.6A shows that in the absence of the 
inactive mutant p53 (first 3 sets of bars), both p53-CC and wt-p53 can similarly induce 
apoptosis (measured by 7-AAD) compared to the negative CC control.  
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Figure 3.6 p53-CC circumvents transdominant inhibition by mutant p53. (A) 
Overexpression of mutant p53 reduces the activity of exogenous wt-p53 but has no 
influence on exogenous p53-CC activity. H1373 cells were chosen for this experiment 
since they are p53 null and hence there will be no additional p53 activity from the cells 
due to lack of endogenous p53. (B) 7-AAD assay was conducted 48 h post transducing 
MDA-MB-468 cells, which harbor a potent transdominant mutant p53 (R273H), with 
adenoviral vectors expressing either wt-p53 or p53-CC with a multiplicity of infection 
(MOI) of 200. As expected, exogenous wt-p53 (Ad-p53) activity is limited in this cell 
line due to the presence of endogenous transdominant tumor derived p53. (C) 7-AAD 
assay was also performed 48 h post transducing 4T1 cells (MOI 250). Interestingly, p53-
CC is more active than wt-p53 in this particular cell line. The adenoviral vector alone was 
used as a negative control. Mean values were analyzed using one-way ANOVA with 
Bonferroni’s post test; ** < p 0.01, and *** p < 0.001. Error bars represent standard 






However, when a transdominant mutant p53 is added (bars 4-6), only p53-CC is 
able to rescue apoptotic activity, while wt-p53 cannot. We engineered this transdominant 
mutant p53 by combining three hotspot mutations (R175H, R248W, and R273H) that are 
known to exhibit a dominant negative effect (27, 28). This supports the notion that p53-
CC can bypass the dominant negative effect of a transdominant mutant p53.  
To further investigate this, the ability of p53-CC to induce apoptosis was tested in 
a cell line known to contain an endogenous strong transdominant mutant form of p53, 
MDA-MB-468 (49). The endogenous p53 in MDA-MB-468 contains the R273H point 
mutation that is known to exhibit transdominant inhibition of wt-p53, so exogenous wt-
p53 in this case would be expected to have limited activity. MDA-MB-468 cells are 
resistant to transient transfection with lipofectamine (used in the majority of these 
studies), so instead, they were transduced with adenovirus (Ad) constructs carrying the 
wt-p53 or p53-CC as genetic cargo. Figure 3.6B shows that indeed, only Ad-p53-CC 
(second bar) is able to significantly induce apoptotic activity measured by 7-AAD 
compared to wt-p53 and empty Ad vector (bars 1 and 3). This suggests that the 
transdominant effect of endogenous mutant p53 found in MDA-MB-468 cells can be 
circumvented by using an oligomerization variant of p53, namely p53-CC.  
Finally, we also tested adenovirally delivered p53-CC in a p53 null cell line 
(Figure 3.6C), where both wt-p53 and p53-CC should be active. Indeed, as shown in 
Figure 3.6C, both constructs are active in this cell line. Interestingly, p53-CC is more 





To summarize, our data show that a version of p53 with an alternative 
tetramerization domain localizes to the correct subcellular compartment (the nucleus, 
Figure 3.1B), and shows a similar gene expression profile as wt-p53 (Figure 3.2A). Two 
genes regulated by p53, Bax and p21/WAF1, also showed similar protein expression 
levels when induced by p53-CC or wt-p53, as demonstrated by western blotting (Figure 
3.2B). Tumor suppressor activity, measuring apoptotic activity (by TUNEL, annexin V, 
and 7-AAD) and reduced oncogenic potential (reduced number of colonies), Figure 3.3 
A-D, was similar between p53-CC and wt-p53.  Importantly, p53-CC was found to 
induce statistically significant levels of apoptosis in 4 different cell lines (Figure 3.4A-D), 
regardless of p53 status, indicating that p53-CC activity is not dependent on p53 status, 
nor is it cell-line specific (see Table 3.2). The transcriptional activity of p53-CC was 
tested using 3 reporter gene assays in Figures 3.5A-C (a standard p53 reporter gene, a 
p21/WAF1 reporter involved in cell cycle arrest, and a PUMA reporter involved in 
apoptosis), and in all 3 cases, was higher than wt-p53. In T47D cells, the transcriptional 
activity of p53-CC was higher than wt-p53 in these reporter gene assays (Figures 3.5A-
C), while the apoptotic activity of p53-CC was similar to wt-p53 (Figures 3.3A-C). This 
is not unexpected, since transcriptional activity does not necessarily linearly correlate 
with apoptotic activity. Transcriptional activity of target genes is a prerequisite step prior 
to the apoptotic cascade; if a threshold of transcriptional activity is met, the downstream 
measure of apoptosis may not change significantly. Interestingly, the negative controls 
(p53ΔTDC and CC) did not have activity in binding, nor were they able to express 
apoptotic or cell cycle arrest genes. 
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A co-IP was performed and showed that p53-CC did not interact with endogenous 
p53 (Figure 3.5D).  Since there was no interaction between p53-CC and endogenous p53, 
the ability of p53-CC to bypass the dominant negative effect was tested, first with 
transdominant mutant p53 overexpression (Figure 3.6A), and second, in MDA-MB-468 
cells that harbor a tumor-derived endogenous transdominant negative p53 mutant (Figure 
3.6B). In both cases, p53-CC appears to not be effected by this endogenous 
transdominant inhibition. Finally, adenovirally delivered p53-CC was also tested in a p53 
null cell line, and was active, as expected (Figure 3.6C). 
Mutant p53 retains its tetramerization capability since its TD remains intact, and 
can form inactive p53 tetramers upon the introduction of exogenous wt-p53 in cancer 
cells (Figure 3.7, left side). These hetero-tetramers have a significantly reduced 
transcriptional activity compared to homo-tetramers of p53-CC. Such a phenomenon 
gives rise to a great barrier that limits the utility of p53 for cancer therapy (11).  
As an approach to prevent hetero-oligomerization, we investigated swapping the 
TD with an alternative oligomerization domain (Table 3.1). The CC from Bcr 
tetramerizes in a similar fashion as the TD; both form dimers of two antiparallel-oriented 
monomers (50). To our knowledge, only one attempt at substituting the TD of p53 to 
eliminate the dominant negative effect of mutant p53 in hetero-tetramers has been made, 
with marginal success (21). This previous work utilized an oligomerization domain that 
leads to parallel tetramer formation, whereas the native TD of p53 drives the formation 
of antiparallel tetramers (21-23). This might offer an explanation to the significant 





Figure 3.7 Proposed mechanism of p53-CC activity. Left side of figure: exogenously 
added wt-p53 can still form hetero-tetramers with mutant p53 due to the presence of the 
TD, and becomes inactivated. Right side of figure: p53-CC can bypass transdominant 




On the other hand, our results show that p53-CC evades hetero-oligomerization 
with mutant p53, allowing it to retain the full tumor suppressor function of wt-p53. 
Figure 3.7 illustrates our hypothesis of bypassing the dominant negative effect with p53-
CC (right side), which maintains functional tumor suppressor activity. 
Bcr, from which the CC was obtained, is a ubiquitous eukaryotic 
phosphotransferase protein that may have a role in general cell metabolism. 
Theoretically, p53-CC could interact with Bcr via its CC domain. While this is a 
possibility, this may be unlikely due to the compartmentation of Bcr (found in the 
cytoplasm) (51) vs. p53-CC (found in the nucleus, shown in Figure 3.1B). Bcr-knockout 
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mice still survive; the major defect in these mice was reduced intimal proliferation in 
low-flow carotid arteries compared to wt mice (52). 
Bcr has mostly been studied in the context of chronic myeloid leukemia (CML) 
where a reciprocal chromosomal translocation with Abl results in the fusion protein Bcr-
Abl, the causative agent of CML (53). The activity of Bcr-Abl is largely due to the 
constitutive activation of the Abl portion of the molecule (54). Generally, Bcr may be 
involved in inflammatory pathways and cell proliferation (52). We have previously 
reported that the isolated Bcr coiled-coil does not in itself induce apoptosis (26). 
Nevertheless, potential inadvertent interaction with the CC oligomerization domain of 
Bcr via any introduced p53-CC is currently being addressed in our lab by introducing 
mutations in the CC domain of p53-CC that will disfavor interactions with Bcr-CC. 
Besides not interacting with endogenous p53, the elevation in p53-CC 
transcriptional activity could also be due to a higher stability of the p53-CC tetramer 
compared to wt-p53 tetramer. We have reported that melting temperature (Tm) for CC is 
about 83°C (26), which is slightly higher than the Tm for TD around 75°C at 
physiological pH (55). In fact, our lab has shown previously that CC forms homo-dimers 
in thermal denaturation studies (26). However, further experiments would be needed to 
definitively prove the biochemical tetramerization of p53-CC.  
Our results corroborate our hypothesis that unlike wt-p53, p53-CC can 
circumvent transdominant inhibition of mutant p53, illustrating the potential of using 
p53-CC as an alternative to wt-p53 for cancer gene therapy. Since the dominant negative 
effect of mutant p53 in cancer cells is currently one of the barriers limiting the use of p53 
in cancer gene therapy (11), our approach offers an alternative to overcome this barrier 
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by swapping the TD of p53 with an alternative oligomerization domain while maintaining 
the tumor suppressor activity. Our designed p53-CC is expected to cause apoptosis in 
many types of cancers, especially in tumors with transdominant mutant p53, where wt-
p53 has proven to be ineffective. Ultimately, we plan on utilizing the p53-CC construct as 
a gene therapeutic delivered using an adenoviral vector that could replace the current 
limited utility of wild-type p53 as a cancer therapeutic. 
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CHAPTER 4 
 
RE-ENGINEERED p53 ACTIVATES APOPTOSIS IN VIVO  
AND CAUSES PRIMARY TUMOR REGRESSION IN A  




Inactivation of p53 pathway is reported in more than half of all human tumors and 
can be correlated to malignant development. Missense mutation in the DNA binding 
region (DBD) of p53 is the most common mechanism of p53 inactivation in cancer cells. 
The resulting tumor-derived p53 variants, similar to wild-type (wt) p53, retain their 
ability to oligomerize via the tetramerization domain (TD). Upon hetero-oligomerization, 
mutant p53 enforces a dominant negative effect over active wt-p53 in cancer cells. To 
overcome this barrier, we have previously designed a chimeric superactive p53 (p53-CC) 
with an alternative oligomerization domain capable of escaping transdominant inhibition 
by mutant p53 in vitro. In this report, we demonstrate the superior tumor suppressor 
activity of p53-CC and its ability to cause tumor regression of the MDA-MB-468 
aggressive p53-dominant negative breast cancer tumor model in vivo. In addition, we 
illustrate the profound effects of the dominant negative effect of endogenous mutant p53 
over wt-p53 in cancer cells. Finally, we investigate the underlying differential
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mechanisms of activity for p53-CC and wt-p53 delivered using viral-mediated gene 
therapy approach in the MDA-MB-468 tumor model. 
 
4.2 Introduction 
The ability of p53 to achieve tumor suppressor function depends on formation of 
p53 tetramers to act as a transcription factor of several target genes (1, 2). Once activated, 
p53 stimulates a wide network of signals including DNA repair, cell cycle arrest, and 
apoptosis (3). The significance of p53 function is highlighted by the correlation of its 
inactivity and malignant development. Inactivation of p53 pathway is reported in more 
than half of all human tumors and can be achieved via several mechanisms including 
nuclear exclusion and hyperactivation of MDM2, the main regulator of p53 function (4-
6). However, acquisition of missense mutations in one or both alleles of the TP53 gene 
remains the most common mechanism of p53 inactivation (7). The majority of these 
mutations take place in the DNA binding domain (DBD) which is responsible for p53 
interaction with DNA. Although mutant p53 in cancer cells may have impaired tumor 
suppressor function and transcriptional activity, it retains its ability to oligomerize with 
other mutant or wild-type (wt) p53 via the tetramerization domain (TD) (8, 9). When 
mutant p53 oligomerizes with wt-p53 through hetero-oligomerization, the resulting 
tetramer has impaired function in most cases due to transdominant inhibition by mutant 
p53 (Figure 4.1). The outcome of this transdominant inhibition varies significantly based 
on the type of mutant p53 present in cells (10). This phenomenon is known as the 
dominant negative effect of mutant p53 and gives rise to a critical barrier to utilizing wt-
p53 for cancer gene therapy (11). 
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Figure 4.1 Schematic representation of the fates of wt-p53 (left) and p53-CC (right) in 
the presence of endogenous mutant p53 in cancer cells. Wt-p53 (left) is sequestered into 
hetero-oligomers that have an impaired transcription function, while p53-CC (right) can 
exclusively form homo-oligomers that retain full tumor suppressor activity. 
 
 
Our goal was to design a new, chimeric superactive p53 with the following 
activity: wt-p53 like functional transcriptional activity; promotion of improved, highly 
potent p53-dependent apoptosis; and circumvention of the dominant negative inactivating 
effect of endogenous mutant p53 in cancer cells.  To this end, we engineered a chimeric 
p53 (p53-CC) that has an alternative tetramerization domain and showed its ability to 
escape transdominant inhibition by mutant p53 in vitro (12). The Bcr coiled-coil (CC) 
alternative oligomerization domain of p53-CC evades hetero-oligomerization with 
endogenous mutant p53, and hence, bypasses the dominant negative effect reported in 
cancer cells. The CC domain itself was tested as a control previously, and was found to 
be nontoxic (12). p53-CC activity was found to retain similar tumor suppressor activity 
compared to exogenous wt-p53 in several cancer cell lines harboring different p53 
 126 
statuses (null, wt, wt mislocalized, and mutant nondominant). Finally, we investigated 
potential transdominant inhibition of p53-CC and wt-p53 via co-expression of a potent 
dominant negative mutant p53. As hypothesized, p53-CC retained the same levels of 
activity regardless of the presence of transdominant mutant p53, while wt-p53 showed 
loss of activity (12).   
In this report, we demonstrate the superior tumor suppressor activity of p53-CC in 
vitro and in vivo in MDA-MB-468, an aggressive p53-dominant negative breast cancer 
cell line. Furthermore, we investigate the underlying differential mechanisms of activity 
for p53-CC and wt-p53 in the MDA-MB-468 tumor model.  Our viral-mediated gene 
therapy approach succeeds in demonstrating the effects of the transdominant effect of 
endogenous mutant p53 over p53-CC and wt-p53. 
 
4.3 Materials and Methods 
4.3.1 Recombinant Adenovirus Production 
Replication-deficient recombinant adenovirus serotype 5 (Ad) constructs were 
generated using the Adeno-X
®
 Adenoviral Expression System 3 (Clontech, Mountain 
View, CA) As we have done before .(12) Either wt-p53 or p53-CC was inserted into a 
cassette under the control of the CMV promoter. A separate CMV promoter controls the 
expression of ZsGreen1 fluorescent protein for visualization. The empty virus (vector) 
was used as a negative control. Wt-p53 and p53-CC were PCR amplified with primers 
containing 15 base pair homology with a linearized pAdenoX vector (Clontech) based on 
an In-Fusion
®
 HD Cloning Kit (Clontech). Stellar
®
 competent cells (Clontech) were 
transformed with the adenoviral vector plasmids containing our constructs. Viral DNA 
 127 
was then purified, linearized and transfected into HEK293 cells for packaging and 
amplification. Viral particles were isolated from HEK293 cells by freeze-thawing, 
purified using Adeno-X
®
 Mega Purification Kit (Clontech), and dialyzed against storage 
and proper tonicity buffer (2.5% glycerol (w/v), 25 mM NaCl, and 20 mM Tris-HCl, pH 
7.4). The viral titer was determined using flow cytometry per the manufacturer’s 
recommendation. 
 
4.3.2 Cell Lines and Viral Transductions 
HEK293 human embryonic kidney cells (ATCC, Manassas, VA) were used for 
viral production and MDA-MB-468 human breast adenocarcinoma cells (ATCC) 
harboring a dominant negative mutant p53 were grown as monolayers in DMEM 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 1% penicillin-
streptomycin-glutamine, and 0.1% gentamicin. MDA-MB-468 cells were also 
supplemented with 1% MEM non-essential amino acids (Invitrogen). All cells were 
incubated in 5% CO2 at 37ºC. The cells were seeded at a density of 3.0 × 10
5
 cells in 6-
well plates (Greiner Bio-One, Monroe, NC). Viral transductions were carried out 
immediately after seeding the cells at multiplicity of infection (MOI) of 200. 
 
4.3.3 7-AAD Assay 
Following manufacturer’s instructions and as previously described, (13) MDA-
MB-468 cells were stained with 7-aminoactinomycin D (7-AAD, Invitrogen) 48 h after 
transfection. Cells were analyzed and gated for ZsGreen1 (with same fluorescence 
intensity to ensure equal expression of proteins) using the FACSCanto-II (BD-
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BioSciences, University of Utah Core Facility) and FACSDiva software. Excitation was 
set at 488 nm and detected at 507 nm and 780 nm for ZsGreen1 and 7-AAD, respectively. 
The means from three separate experiments (n=3) were analyzed using one-way ANOVA 
with Bonferroni’s post-hoc test. 
 
4.3.4 TMRE Assay 
MDA-MB-468 cells were incubated with 100 nM tetramethylrhodamine ethyl 
ester (TMRE) (Invitrogen) for 30 min at 37 °C 36 h after infection. (14) The time point 
was determined to be 36 h as a result of several optimization pilot studies for the TMRE 
assay, and since mitochondrial outer membrane permeabilization occurs prior to caspase-
3/7, annexin-V, and 7-AAD detection (48 h). MDA-MB-468 cells were pelleted and 
resuspended in 300 μL of annexin-V binding buffer (Invitrogen). Only ZsGreen1 positive 
cells were analyzed by using the FACS Canto-II (BD BioSciences, University of Utah 
Core Facility) with FACS Diva software. ZsGreen1 was excited with the 488 nm laser 
with emission filter 530/35, and TMRE was excited with the 561 nm laser with the 
emission filter 585/15. Mitochondrial depolarization (loss in TMRE intensity) correlates 
with an increase in MOMP (15). Independent transfections of each construct were tested 
three times (n = 3). 
 
4.3.5 Caspase-3/7 Assay 
MDA-MB-468 cells were probed 48 h after treatment using FLICA® 660 
Caspase-3/7 Assay Kit (Immunochemistry Technologies, Bloomington, MN). Cells were 
pelleted, resuspended in 300 μL of 1× wash buffer (Immunochemistry Technologies), 
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and incubated with FLICA® 660 Caspase-3/7 reagent for 45 min per the manufacturer’s 
recommendations. Only ZsGreen1 positive cells were analyzed using the FACS Canto-II 
(BD BioSciences, University of Utah Core Facility) with FACS Diva software. ZsGreen1 
and FLICA® 660 were excited with the 488 nm (emission filter 530/35) and the 635 laser 
(emission filter 670/30), respectively. Independent transfections of each construct were 
tested three times (n = 3). 
 
4.3.6 Annexin-V Assay 
The annexin-V assay was performed as before (12, 13). Briefly, 48 h post 
infection, MDA-MB-468 cells were suspended in 400 μl annexin binding buffer 
(Invitrogen) and incubated with 5 μl annexin-APC (annexin-V conjugated to 
allophycocyanin, Invitrogen) for 15 minutes. The incubated cells were ZsGreen1 gated 
and analyzed using FACSCanto-II. ZsGreen1 and APC were excited at 488 nm and 635 
nm wavelengths and detected at 507 nm and 660 nm, respectively. Each construct was 
tested three times (n=3) and analyzed using one-way ANOVA with Bonferroni’s post hoc 
test (13). 
 
4.3.7 In Vivo Study 
The experimental protocol was approved by the Institutional Animal Care and 
Use Committee (IACUC) at the University of Utah. All experiments were performed in 
Female nu/nu athymic mice (6-8 weeks old, Jackson Laboratories, Bar Harbor, ME). 
Human MDA-MB-468 cells (1x10
7
 cells/mouse in 100 µl of serum-free RPMI-1640 
medium) were injected subcutaneously into the mammary fat pad located in the right 
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inguinal area. When tumors reached a mean size of 50mm
3
, animals were randomized 
into 4 treatment groups and received single peritumoral injections of adenoviral 
constructs (5.0x10
8 
pfu) in a 50 µl volume prepared fresh on days 0-4 and 7-11. Twenty-
four hours after the last injection the mice were sacrificed and the tumors as well as the 
organs were harvested for analyses. Tumor volumes were measured daily using Vernier 
calipers along the longest width (W) and the corresponding perpendicular length (L).  
The tumor volume was calculated using V= (L x W (0.5W)). All procedures were 
performed according to established NIH guidlines and University of Utah Institutional 
Animal Care and Use Committee approved protocols.   
 
4.3.8 Histology 
Animal tumor tissue samples and organs were fixed in 10% formalin for 24 h 
followed by tissue preparation and embedded in paraffin. Embedded tissues were then 
sectioned to cut at 4 μm thick sections and mounted on plus slides. Slides from each 
tumor tissue from all mice in the three treatment groups as well as the untreated group 
were stained using hematoxylin and eosin and p21 immunohistochemistry stain. Tissue 
and histological slide preparation was conducted in collaboration with ARUP 
Laboratories (Salt Lake City, Utah) (16).  
 
4.3.9 Western Blotting 
In vivo: fresh tumor tissue samples from animals of each treatment group were 
collected, snap-frozen in liquid nitrogen, ground with mortar and pestle, resuspended in 
200 mL lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% glycerol, 1 % protease 
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inhibitor) followed by sonication on ice. Recovered tissue lysates were then centrifuged 
for 45 min at 14,000 rpm and the supernatants were used for immunoblotting. Standard 
western blotting procedures (12, 17) were followed using primary antibodies to detect 
p21/WAF1, cleaved caspase-3, and actin as a loading control. The primary antibodies 
anti-p21 (ab16767, Abcam, Cambridge, MA), anti-cleaved caspase-3 (#9665P, Cell 
Signaling Technology, Danvers, MA ), anti-actin (mouse, ab3280, Abcam), and anti-actin 
(rabbit, ab1801, Abcam) were detected with anti-rabbit (#7074S, Cell Signaling 
Technology) or anti-mouse (ab6814, Abcam) HRP-conjugated antibodies before the 
addition of SuperSignal West Pico chemiluminescent substrate (Thermo Scientific, 
Waltham, MA). Signals were detected using a FluorChem FC2 imager and software 
(Alpha Innotech, Sanata Clara, CA). All experiments were conducted in triplicates. 
In vitro: 24 h following infection of MDA-MB-468 cells, 3x10
5
 cells were 
pelleted and resuspended in 200 μL lysis buffer (62.5 mM Tris-HCl, 2% w/v SDS, 10% 
glycerol, 1 % protease inhibitor), sonicated on ice, and centrifuged for 15 min at 14,000 
rpm.  The supernatants were used for immunoblotting as described above and 
densitometry analysis was performed as described before (18).  
 
4.3.10 Statistical Analysis 
One-way ANOVA with Bonferroni’s post test was used to compare the different 
treatment groups and controls. A value of p < 0.05 was considered statistically 
significant. Error bars represent standard deviations from at least three independent 




4.4.1 p53-CC Induces Higher Levels of 
Cell Death Compared to Wt-p53 
We (12) and others (19, 20) have shown that the MDA-MB-468 human breast 
adenocarcinoma cell line serves as a suitable dominant negative mutant p53 model for 
testing the effect of p53-CC and wt-p53. The endogenous p53 in MDA-MB-468 contains 
the R273H point mutation, which is known to exhibit a dominant negative effect over wt-
p53.(12, 20)  As we have shown previously, p53-CC is capable of inducing cell death in 
this as well as other cancer cell lines, regardless of endogenous p53 status. Figure 4.2 
illustrates the superior tumor suppressor function of p53-CC over wt-p53 in a 7-AAD 
viability assay which stains apoptotic and necrotic cells (21, 22) (compare Figure 4.2A vs 
2B). Wt-p53 activity is not significantly different from that achieved by the negative 
control Ad-ZsGreen1 (Figure 4.2B vs 2C). This observation illustrates the dominant 
negative effect of endogenous mutant p53 over wt-p53 in cancer cells and highlights the 
significance of our approach to escape transdominant inhibition. These results are 
summarized in Figure 4.2D. 
 
4.4.2 p53-CC Caused Cell Death via 
the Apoptotic Pathway 
Figure 4.2 suggests that the MDA-MB-468 cell line is a suitable tumor model to 
test the impact of the dominant negative effect of mutant p53 in vivo. In preceding animal 
studies, we explored the mechanism of cell death, and hypothesized that it occurs via an 
apoptotic pathway.  
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Figure 4.2 7-AAD staining of apoptotic and necrotic cells was performed. 48 h after viral 
transfection, cells were analyzed and gated for ZsGreen1. (A-C) Representative 
individual contour plots from each transfection and treatment group showing only 
ZsGreen1-gated cells. Q1&Q2= 7-AAD positive cells; Q3&Q4= 7-AAD negative cells. 
(D) Percentage of cell death induced by each transfection and treatment group. Mean 
values were analyzed using one-way ANOVA with Bonferroni’s post test; ns= non-
significant, *** p < 0.001. Error bars represent standard deviations from at least three 




Thus, three different apoptosis assays, the TMRE assay (analogous to the JC-1 
assay), activated caspase-3/7 assay, and annexin-V staining were carried out. 
Mitochondrial depolarization as measured by loss in TMRE intensity correlates with an 
increase in mitochondrial outer membrane permeabilization (MOMP) (15). TMRE is a 
cationic, cell-permeant, and fluorescent dye that rapidly accumulates in mitochondria of 
living cells due to the negative mitochondrial membrane potential (ΔΨm) of intact 
mitochondria compared to cytosol (23, 24). Mitochondrial depolarization results in loss 
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of TMRE from mitochondria and a decrease in mitochondrial fluorescence intensity (FI)
7
, 
illustrated as %MOMP induction in Figure 4.3A. Figure 4.3A demonstrates that p53-CC 
induced significantly higher levels of mitochondrial membrane permeabilization, a 
hallmark of intrinsic apoptosis, compared to wt-p53. Wt-p53 also induced mitochondrial 
membrane permeabilization, although not to the same extent as p53-CC. MOMP 
indicates that cells are transitioning to an apoptotic state (25). 
To further investigate the potential apoptotic activity of p53-CC and wt-p53, we 
carried out a flow cytometry-based assay to detect the levels of activated caspase-3/7 in 
MDA-MB-468 cells (Figure 4.3B). Caspase-3/7 activation is downstream from 
mitochondrial outer membrane permeabilization in the intrinsic apoptotic pathway and 
plays a central role at the execution-phase of cell apoptosis.(26-28) Figure 4.3B shows 
that cells treated with p53-CC display increased levels of active caspase-3/7 compared to 
those treated with wt-p53 or the negative control Ad-ZsGreen1.   
Finally, annexin-V staining was performed, which measures externalization of 
phosphatidylserine on the cell surface of apoptotic cells specifically (29, 30). Figure 4.3C 
shows higher levels of annexin-V positive staining in cells treated with Ad-p53-CC 
compared to Ad-wt-p53; wt-p53 apoptotic activity was not significantly different from 
the negative control Ad-ZsGreen1. Cellular apoptosis as indicated in Figure 4.3C parallel 
the results from the 7-AAD staining in Figure 4.2.  
To summarize, Figures 4.3 A, B, and C show MDA-MB-468 cells treated with 
Ad-p53-CC undergo significant apoptosis, validating p53-CC as a potent candidate for 
gene therapy.  
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Figure 4.3 Induction of apoptosis is measured by (A) TMRE, (B) Caspase-3/7, and (C) 
Annexin-V. In all three assays, MDA-MB-468 cells treated with Ad-p53-CC undergo 
higher levels of apoptosis compared to cells infected with Ad-wt-p53 or the negative 
control Ad-ZsGreen1.  Mean values were analyzed using one-way ANOVA with 
Bonferroni’s post test; ns= nonsignificant, *** p < 0.001. Error bars represent standard 
deviations from at least three independent experiments (n = 3). 
 
 
The levels of apoptosis induced by Ad-p53-CC are statistically significant 
compared to that of Ad-wt-p53 or Ad-ZsGreen1 in all three apoptosis assays (Figure 4.3) 
in addition to the 7-AAD assay (Figure 4.2).  
 
4.4.3 In vivo Efficacy in a Dominant Negative 
Breast Cancer Animal Model 
MDA-MB-468 human breast adenocarcinoma represents an aggressive breast 
cancer cell line characterized as triple negative due to the absence of molecular targets 
including estrogen receptor, progesterone receptor, and human epidermal growth factor 
receptor 2 (ref. (31)). In addition, MDA-MB-468 cells harbor a dominant negative mutant 
p53 capable of impairing the function of wt-p53 (12, 19, 20). We therefore used this cell 
line to induce orthotopic breast tumors in mice to compare the impact of the dominant 
negative effect of mutant p53 on the biological activity of p53-CC and wt-p53 in viral-
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mediated gene therapy. Because of the presence of the coxsackievirus and adenovirus 
receptor (CAR), MDA-MB-468 cells can be transfected by adenovirus (32).  
Induced in the mammary fat pad of female athymic nu/nu mice, MDA-MB-468 
tumors orthotopic engraftment fosters tumorigenesis to occur in the appropriate macro- as 
well as microenvironment mimicking the environment of human MDA-MB-468 tumors 
(33, 34). Due to this, MDA-MB-468 is a commonly used xenograft model for triple 
negative breast cancer (35, 36). Tumors were allowed to grow to approximately 50 mm
3 
prior to randomization of treatment groups which received intratumoral injections of Ad-
p53-CC or Ad-wt-p53. The empty viral vector (Ad-ZsGreen1) served as a negative 
control in addition to an untreated control. Injections were made on days 0-4 and 7-11 for 
optimal efficacy(37) and consisted of 5.0x10
8
 PFU of the viral constructs in a 50 µl 
volume. All procedures were performed according to established NIH guidelines and 
followed University of Utah Institutional Animal Care and Use Committee approved 
protocols. Figure 4.4A shows a representative image of a tumor bearing mouse with the 
mammary tumor located in the right inguinal area, while Figure 4.4B shows images of 
representative excised tumors from each treatment group.  
The tumor size reduction expected with these treatments served as a direct 
measure of the tumor suppressor function of our p53 variants. As expected, the Ad-p53-
CC treatment group achieved statistically significant (p < 0.001) reduction in mean tumor 
size compared to Ad-wt-p53, Ad-ZsGreen1, and untreated groups (Figure 4.4C). 
Although tumor reduction induced by Ad-wt-p53 is not statistically significant compared 
to the Ad-ZsGreen1 or untreated groups, Ad-wt-p53 treatment resulted in stable disease, 
halting tumor progression.  
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Figure 4.4 Effect of viral gene therapy using p53-CC and wt-p53 on the aggressive p53-
dominant negative MDA-MB-468 human breast adenocarcinoma in female athymic 
nu/nu mice. (A) A representative image of a mouse in the study. For tumor inductions, 
MDA-MB-468 cells were injected in the right mammary fat pad of the inguinal area 
(highlighted by the black arrow). (B) Representative images of the excised tumors from 
each treatment group scaled to the same ratios. (C) Tumor size measured with calipers 
daily and normalized to Day 0. (D) Animal weights as measured daily and normalized 
relative to weights from Day 0. Six mice per group were used for this study. Mean values 
were analyzed using one-way ANOVA with Bonferroni’s post test; †p < 0.001. Error 
bars represent standard deviations. 
 
 
The findings from Figure 4.4C reveal that p53-CC can achieve tumor regression 
of an aggressive p53-dominant negative breast cancer model in vivo, while wt-p53 is only 
capable of halting tumor progression. In addition, the excised tumors from the Ad-
ZsGreen1 negative control and untreated groups appeared to be more vascularized 
compared to tumors derived from the treatment groups Ad-p53-CC and Ad-wt-p53 
(Figure 4.4B), potentially implying an additional anti-angiogenic effect of p53-CC and 
wt-p53 in vivo. 
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Animal body weights were regularly monitored throughout the study and no 
significant weight loss in animals was observed in any of the groups (Figure 4.4D) 
rendering the treatment as well as the viral carrier safe. Throughout the study, the Ad-
p53-CC treatment group maintained the smallest mean tumor size compared to all other 
groups. Both control groups (Ad-ZsGreen1 and untreated) exhibited the largest mean 
tumor size compared to all other groups throughout the entire study. 
 
4.4.4 Histopathological Evaluation of Tumor Tissues and 
Evidence for Tumor Suppressor Activity 
The tumor size reduction observed in Figure 4.4C indicates tumor suppressor 
functionality of Ad-p53-CC as well as Ad-wt-p53 in vivo. To verify if this activity is 
indeed p53-dependent, we carried out immunohistochemical staining of p21 as it is one 
of the best characterized bona fide p53 target genes. (38) Photomicrographs of 
representative sections from harvested tumor tissues from each group are displayed in 
Figure 4.5A.  
The left column in Figure 4.5A exhibits hematoxylin and eosin (H&E) staining, 
while the middle column represents p21 immunohistochemical staining for each group. In 
addition, the right column in Figure 4.5A shows the intratumoral expression of our gene 
load (i.e., p53-CC or wt-p53) as a function of the ZsGreen1 fluorescent protein co-
expressed with our genes of interest. Microscopic examination of H&E staining revealed 
higher levels of necrosis (solid arrows, necrosis; open arrows, nonnecrotic areas) in all 
tumors harvested from mice injected with Ad-p53-CC compared to the Ad-wt-p53, Ad-
ZsGreen1, or untreated groups (Figure 4.5A).  
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Figure 4.5 Representative photomicrographs showing the effects of the different 
treatment groups on tumor tissues visualized via H&E staining (A) left column, p21 
immunohistochemistry staining (A) middle column, and ZsGreen1 fluorescence (A) right 
column. (A)Solid black arrows (left column) indicate necrotic cells, while open arrows 
indicate nonnecrotic areas. 3,3' diaminobenzidine (DAPI) stains the nuclei of p21-
positive cells brown (middle column). Examination of the H&E staining microscopically 
revealed higher levels of necrosis in all tumor tissues from mice injected with Ad-p53-
CC compared to the Ad-wt-p53, Ad-ZsGreen1, or untreated groups. p21 
immunohistochemistry staining revealed higher levels of p21 induction in the Ad-wt-p53 
treatment group compared to the Ad-p53-CC treatment group. Semiquantitative 
histoscore analyses of (B) tumor necrosis and (C) p21 up-regulation in the excised tumors 
from all groups is shown. Mean values were analyzed using one-way ANOVA with 
Bonferroni’s post test; * p < 0.05. Error bars represent standard deviations (n=6). 
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This implies the detected necrosis may be due to the tumor suppressor activity of 
p53-CC since the tumors did not reach a large enough size to develop a necrotic core, and 
as such the observed necrosis was due to treatment, not hypoxia. 3,3' diaminobenzidine 
(DAP) stains the nuclei of p21-positive cells brown, as shown in photomicrographs 
(middle column, Figure 4.5A). Unexpectedly, p21 immunohistochemistry staining 
revealed higher levels of p21 induction in the Ad-wt-p53 treatment group compared to 
the Ad-p53-CC treatment group. p21 is one of the key factors by which p53 enforces cell 
cycle arrest. The induction of cell cycle arrest by p21 converges with findings from 
Figure 4.4C where tumors from the Ad-wt-p53 treatment group show a halt (arrest) in 
tumor growth. As expected, p21 expression was not detected in the Ad-ZsGreen1 
negative control or untreated groups, which validates that p21 expression is linked to 
direct p53 activation. Similar expression of ZsGreen1 across the different groups (Ad-
p53-CC, Ad-wt-p53, and Ad-ZsGreen1) in the right column of Figure 4.5A indicates 
comparable intratumoral expression of our viral constructs. In addition, p53 
immunohistochemistry staining was performed and equal levels of total (i.e., endogenous 
and exogenous) p53 expression were detected across all groups, including the untreated 
group, which relates to the known presence of endogenous p53 in MDA-MB-468 cells 
(data not shown). Figures 4.5 B and C represent semiquantitative histoscore analyses of 
tumor necrosis and p21 upregulation in the excised tumors from all groups.  
Tissues from additional organs (liver, kidney, spleen, heart, and lungs) harvested 
from animals of all treatment groups showed normal physiology and no abnormalities or 
signs of pathology (data not shown). However, metastases of tumor cells to the 
gastrointestinal region were noted in 2 out of 6 mice in the Ad-ZsGreen1 group and 3 out 
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of 6 mice in the untreated group (data not shown). This may imply an anti-metastatic 
function of p53-CC as well as wt-p53 in this tumor model although further examination is 
necessary.   
 
4.4.5 Detection of Pathway-Specific Markers for 
Cell Cycle Arrest and Apoptosis 
Based on our observations, we postulate that p53-CC is capable of causing tumor 
size reduction in vivo by favoring the apoptotic pathway, while wt-p53 activity is biased 
towards inducing cell cycle arrest. To further investigate this hypothesis, we carried out 
immunoblotting of cleaved (activated) caspase-3 and p21 on samples from in vitro and in 
vivo. It is well known that all apoptotic pathways converge on caspase-3 (the main 
executioner caspase) (39, 40), whereas p21 induction by p53 causes cells to undergo cell 
cycle G1 phase arrest (41-43). Therefore, detection of activated caspase-3 and p21 are 
acceptable biomarkers for apoptosis and cell cycle arrest, respectively. Figure 4.6A 
shows a representative western blot analyses of p21 (middle band) and caspase-3 (bottom 
band) of MDA-MB-468 cells in vitro. MDA-MB-468 cells treated with Ad-p53-CC 
express lower levels of p21 compared to cells treated with Ad-wt-p53 (Figure 4.6B), a 
clear indication of a cell cycle arrest activity of wt-p53. However, higher levels of 
activated caspase-3 are detected in cells treated with Ad-p53-CC compared to Ad-wt-p53 
(Figure 4.6C, a hallmark of apoptosis induction).  
Part of the excised tumor tissues from each animal was homogenized and lysed 
for western blotting. Figure 4.6D shows representative western blotting of MDA-MB-468 
in vivo tumor tissue lysates.  
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Figure 4.6 Representative cropped western blots of MDA-MB-468 (A-C) in vitro cell 
lysates and (D-F) homogenized tumors from the in vivo study treated with Ad-p53-CC, 
Ad-wt-p53, Ad-ZsGreen1, or untreated. Western analyses show that MDA-MB-468 cells 
(A) and tumor tissues (D) treated with Ad-p53-CC both express lower levels of p21, but 
higher levels of activated (cleaved) caspase-3 compared to cells treated with Ad-wt-p53. 
No significant levels of p21 or cleaved caspase-3 induction were observed in cells (A) or 
tumors (D) injected with Ad-ZsGreen1 or untreated. Semiquantitative densitometric 
analyses was carried out as described before(18) to evaluate p21 (B) and cleaved caspase-
3 (C) expression in vitro as well as expression of p21 (E) and cleaved caspase-3 (F) 
expression in vivo. Mean values were analyzed using one-way ANOVA with 
Bonferroni’s post test; * p < 0.05, ** p < 0.01, and *** p < 0.001. Error bars represent 









Similar to the findings obtained from in vitro western blotting (Figures 4.6A-C), 
tumor tissues from the Ad-p53-CC treatment group showed lower p21 expression (Figure 
4.6E) but higher caspase-3 induction (Figure 4.6F).  
 Results from Figure 4.6 corroborate our hypothesis that p53-CC favors induction 




 The data obtained in this report support our hypothesis that chimeric p53-CC has 
superior tumor suppressor function compared to wt-p53 in vitro and in vivo using a 
dominant negative mutant p53 model. Although the concept of a “superactive” p53 was 
reported in 2010 (44), there are no known reports of constructing a p53 capable of 
bypassing the dominant negative effect of mutant p53 in cancer cells and increases 
apoptosis (over wt-p53). p53-CC induces higher levels of cell death  in vitro compared to 
wt-p53 in the 7-AAD assay (Figure 4.2) as well as in the apoptosis assays: TMRE, 
caspase-3/7, and annexin-V (Figure 4.3). To validate if the superior activity of p53-CC in 
vitro translates in vivo, we carried out animal studies using an orthotopic MDA-MB-468 
xenograft breast cancer model in mouse mammary fat pads. Indeed, intratumoral 
injections with Ad-p53-CC achieved substantial tumor regression that is statistically 
significant compared to the Ad-wt-p53, Ad-ZsGreen1, and untreated groups (Figure 
4.4C), without any sign of treatment toxicity (Figure 4.4D). H&E staining of tumor 
tissues revealed higher levels of necrosis in all tumor tissues from mice injected with Ad-
p53-CC compared to the Ad-wt-p53, Ad-ZsGreen1, or untreated groups. 
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To test if the observed tumor suppressor activity of p53-CC in vivo is p53-
dependent, immunohistochemistry staining of p21, the most well studied p53 target gene 
(38), was conducted. As expected, p21-positive staining was observed only in the Ad-
p53-CC and Ad-wt-p53 treatment groups (Figure 4.5) with higher p21 staining with Ad-
wt-p53 treatment. 
Since p53-CC was able to induce apoptosis (including caspase 3/7), and wt-p53 
increased p21 expression, we explored a possible differential mechanism of p53-CC 
(favoring apoptosis) and wt-p53 (favoring cell cycle arrest) in MDA-MB-468 cells. To 
test this premise, immunoblotting was carried out on samples from in vitro (Figures 
4.6A-C) and in vivo (Figures 4.6D-F) to detect expression levels of p21, which induces 
cell cycle arrest, and caspase-3, a major executer of apoptosis. Figure 4.6 revealed that 
tumor tissues treated with Ad-p53-CC expressed low levels of p21 (reduced cell cycle 
arrest) but high levels of active caspase-3 (increased apoptosis). In contrast, tumor tissues 
injected with Ad-wt-p53 expressed high levels of p21 (increased cell cycle arrest) but low 
levels of caspase-3 (decreased apoptosis). 
The transdominant mutant p53 found endogenously in MDA-MB-468 cells 
retains the ability to hetero-oligomerize with exogenous wt-p53, since its tetramerization 
domain remains intact (10). We and others have shown previously that upon hetero-
oligomer formation, the activity of exogenous wt-p53 is impaired due to the dominant 
negative effect of mutant p53 in cancer cells (12, 19, 20). Our chimeric p53-CC was 
designed to overcome this barrier with a use of an alternative oligomerization domain, a 
coiled-coil from Bcr (CC). This CC is known to tetramerize as an antiparallel dimer of 
dimers, similar to the tetramerization domain of wt-p53 (12, 45). 
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The use of this alternative oligomerization domain allows p53-CC to escape any 
possible hetero-oligomerization with mutant p53 and consequent transdominant 
inhibition. Indeed, our previous work validated the ability of p53-CC to exclusively form 
homo-oligomers. From a gene therapy point of view, the ability of p53-CC to evade 
transdominant inhibition gives it an advantage over wt-p53 in dominant mutant p53 
cancer cells such as MDA-MB-468. Our viral-mediated gene therapy in vivo studies 
show that p53-CC has superior tumor suppressor activity compared to wt-p53 in the 
MDA-MB-468 aggressive p53-dominant negative breast cancer model. In fact, p53-CC 
was capable of achieving significant tumor regression, while wt-p53 is only capable of 
halting tumor progression (Figure 4.4C).  
Upon further investigation, we discovered that the difference in outcome of the 
tumor size reduction was due to the ability of p53-CC to activate the apoptotic pathway, 
whereas wt-p53 activates cell cycle arrest via p21 induction (Figure 4.7). These findings 
are supported by western blot analyses from in vitro (Figure 4.6A-C) and in vivo (Figure 
4.6D-F) MDA-MB-468 cells/tumors. Analysis of p53-regulated gene expression patterns 
may possibly offer an explanation for differential pathway activation between p53-CC 
and wt-p53 (apoptosis vs. cell cycle arrest). It has been shown that p53-responsive gene 
expression patterns are highly variable, depending on the p53 protein levels in the cell 
(46). It is also known that higher levels of active p53 lead to activation of apoptotic 
genes, while lower levels of p53 activate cell cycle regulator genes (47). In cells treated 
with p53-CC vs. wt-p53, higher levels of the chimeric p53-CC protein exist compared to 
levels of active wt-p53 protein in cells, due to the ability of p53-CC to escape 
sequestration by mutant p53. 
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Figure 4.7 Schematic representation of the outcomes of wt-p53 (left) and p53-CC (right) 
activation. Wt-p53 induces cell cycle arrest via p21 expression (left), while p53-CC 




Unlike p53-CC, substantial amounts of the wt-p53 protein are forced into inactive 
hetero-oligomers with endogenous mutant p53 (the dominant negative effect). This 
reduction in ‘available’ active wt-p53 could lead to failure in binding promoters of 
apoptotic genes that require higher active p53 protein levels in the cell. Cell cycle 
regulator genes, such as p21, would be activated instead, since wt-p53 possess higher 
binding affinities to these promoters (i.e., requires less p53 to bind and activate). In 
contrast, abundance in active chimeric p53-CC protein levels is found in cells treated 
with p53-CC, which would lead to binding and activation of apoptotic genes promoters. 
The variability of pathway activation (i.e. p53-CC, apoptosis vs wt-p53, cell cycle arrest) 
may be specific to this tumor model due to the dominant negative mutant p53 
endogenously found in MDA-MB-468 cells/tumors. This is because we have shown 
previously (12) that p53-CC and wt-p53 induce similar levels of apoptosis in four 
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different non-p53-dominant negative breast cancer cell lines with varying endogenous 
p53 statuses (H1373 cells: p53 null, HeLa cells: wt-p53, T47D cells: wt-p53 
mislocalized, and MDA-MB-231 cells: mutant p53) (12). Furthermore, qRT-PCR 
analyses and western blotting showed that p53-CC and wt-p53 induced similar levels of 
p21 gene expression in T47D breast carcinoma cells. 
In summary, we have shown for the first time, use of a version of p53 that 
overcomes the limitations of using wt-p53 for gene therapy. A chimeric superactive p53 
has been described as the ‘ultimate cancer therapeutic’ (48). Our p53-CC demonstrates 
comparable functional transcriptional activity to wt p53 (12), shows significantly 
improved apoptosis (Figures 4.2 and 4.33), and successfully circumvents the dominant 
negative inactivating effect of endogenous mutant p53 in vitro (12).  Importantly, our 
compelling in vivo data (Figure 4.4) demonstrates that p53-CC is more effective than wt 
p53, and may serve as a more potent and reliable novel anticancer therapeutic.  
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A RE-ENGINEERED p53 CHIMERA WITH ENHANCED  
HOMO-OLIGOMERIZATION THAT MAINTAINS  
TUMOR SUPPRESSOR ACTIVITY 
 
5.1 Abstract 
The use of the tumor suppressor p53 for gene therapy of cancer is limited by the 
dominant negative inactivating effect of mutant endogenous p53 in cancer cells.  We 
have shown previously that swapping the tetramerization domain (TD) of p53 with an 
alternative oligomerization domain, the coiled-coil from Bcr, allows evasion of hetero-
oligomerization with endogenous p53. This enhances the utility of this construct, p53-
CC, for cancer gene therapy.  Since domain swapping to create p53-CC could result in 
p53-CC interacting with endogenous Bcr, which is ubiquitous in cells, modifications on 
the CC domain are necessary to minimize potential interactions with Bcr.  Hence, we 





mutants and disfavor hetero-oligomerization with wild-type CC (CCwt), with the goal of 
minimizing potential interactions with endogenous Bcr in cells. This involved integrated 
computational and experimental approaches to rationally design an enhanced version of 
our chimeric p53-CC tumor suppressor. Indeed, the resulting lead candidate p53-
CCmutE34K-R55E avoids binding to endogenous Bcr and retains p53 tumor suppressor 
activity. Specifically, p53-CCmutE34K-R55E exhibits potent apoptotic activity in a 
variety of cancer cell lines, regardless of p53 status (in cells with mutant p53, wild-type 
p53, or p53-null cells).  This construct overcomes the limitations of wt p53, and has high 
significance for future gene therapy for treatment of cancers characterized by p53 
dysfunction, which represent over half of all human cancers. 
 
5.2 Introduction 
The tumor suppressor p53 is the most commonly mutated gene of all human 
cancers, making it an ideal therapeutic target (1, 2).  However, the diversity of p53 
mutations precludes finding a single drug that hits all possible variants of the protein (3). 
In cancer cells, mutant p53 may not only impair tumor suppressor function and 
transcriptional activity, but effectively deplete wild-type p53 (wt-p53) since mutant p53 
retains its ability to oligomerize with other p53 via the tetramerization domain (TD) (4, 
5). Upon hetero-oligomerization of mutant and wt-p53 in cancer cells, mutant p53 exerts 
a dominant negative effect over wt-p53 and leads to its inactivation as a therapeutic (6-8). 
To overcome these issues, our alternative approach has been to engineer a chimeric 
version of p53 for cancer gene therapy that can be used universally, regardless of p53 
mutational status in cancer (9). To create this chimeric, transcriptionally active version 
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p53 that can only form homo-tetramers, we searched for possible domain swapping 
motifs, and chose to replace the 31 amino acid TD of p53 (10) with the 72 amino acid 
coiled-coil (CC) of Bcr (breakpoint cluster region protein) (11). Superficially, these 
motifs may appear structurally dissimilar, but both the TD and CC contain a main α-helix 
that orients in an antiparallel fashion and forms a dimer of dimers (10, 11). Due to their 
similar orientation and ability to form tetramers, the CC motif from Bcr was a reasonable 
starting point for domain swapping. We have shown previously (9) that swapping the 
tetramerization domain of p53 with the CC domain enhances the utility of p53 for cancer 
gene therapy in p53-dominant negative breast cancer cells. This alteration of the 
oligomerization motif of the tumor suppressor allowed for our chimeric p53, namely p53-
CC, to evade hetero-oligomerization with endogenous mutant p53 commonly found in 
cancer cells while retaining the tumor suppressor function of p53. This proves to be 
critical since mutant p53 has a transdominant inhibitory effect over wild-type p53 upon 
hetero-oligomerization. 
Bcr, from which the CC was obtained, is a ubiquitous eukaryotic 
phosphotransferase, and has mostly been studied in the context of chronic myeloid 
leukemia (CML) where a reciprocal chromosomal translocation with Abl results in the 
fusion protein Bcr-Abl, the causative agent of CML (12, 13). Generally, Bcr may be 
involved in inflammatory pathways and cell proliferation (14). Although it has been 
shown that Bcr-knockout mice still survive, one of the major defects in these mice was 
reduced intimal proliferation in low-flow carotid arteries compared to wild-type mice 
(14). In addition, Bcr plays a role in arterial proliferative disease in vivo as well as 
differentiation and inflammatory responses of vascular smooth muscle cells (15, 16). 
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Since domain swapping to create p53-CC could result in p53-CC interacting with 
endogenous Bcr, modifications on the CC domain are necessary to minimize potential 
interactions with Bcr.  Hence, the purpose of this work is to modify the CC domain in 
p53-CC to reduce potential interactions with endogenous Bcr. 
Coiled-coil domains are characterized by heptad repeats of amino acids (denoted 
by letters for each residue, (abcdefg)n, for n repeats) that control the specificity and 
orientation of the oligomerization motif (17, 18). Distinct interaction profiles exist 
between the different residues based on the orientation (parallel or antiparallel) of the 
coiled-coil (17, 19). Surface interactions between positions e to e’ (where the ’ denotes a 
residue on the opposing coiled-coil in the dimer) and g to g’ are known to be essential in 
antiparallel coiled-coils, whereas interactions between positions g to e’ are the most 
critical for parallel coiled-coils (17, 19). The coiled-coil domain from Bcr is assembled as 
two 36-residues helices antiparallel to each other (Figure 5.1A) (20, 21). This antiparallel 
orientation gives rise to the aforementioned e to e’ and g to g’ interactions that can be 
utilized to potentially modify electrostatic interactions within a dimer. We investigated 
the possible design of mutations that will form opposing charges on residues e to e’ and g 
to g’ to increase salt bridge formation (see Figure 5.1) in order to improve homo-
dimerization of CC mutants and disfavor hetero-oligomerization with wild-type (CCwt), 
with the goal of minimizing potential interactions with endogenous Bcr in cells. In silico 
examination of CCwt (Figure 5.1A) revealed that Bcr has uncharged Ser-41 at position g 
and Glu-48 (acidic) representing g’ that are within proximity for salt bridge formation. 
Similarly, CCwt has uncharged Gln-60 at position e and Lys-39 (basic) at position e’ 
which are also within proximity for salt bridge formation.  
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Figure 5.1 Helical wheel diagrams of wild-type CC homo-dimers (CCwt) (A), 
CCmutS41R homo-dimers (B), CCmutQ60E homo-dimers (C), CCmutE34K-R55E 
homo-dimers (D), and CCmutE46K-R53E homo-dimers (E). Solid lines indicate possible 
ionic interactions already existing in the wild-type coiled-coil. Dotted (blue) lines 
represent newly formed ionic interactions. Dashed (green) lines indicate reversed ionic 





Therefore, we hypothesized that introducing S41R (Arg, basic) and Q60E (Glu, 
acidic) mutations separately, would potentially form two extra salt bridges per mutation 
(Figure 5.1B and 1C, respectively). These two mutant candidates are referred to as 
CCmutS41R and CCmutQ60E. 
In addition, examination of the coiled-coil interchain salt bridges indicate that two 
more potential compound mutants (i.e., more than one mutation per candidate) could be 
made to improve homo-dimerization of CC mutants. Mutation of Glu-34 to Lys and Arg-
55 to Glu (CCmutE34K-R55E) will preserve all four stabilizing salt bridges found in 
CCwt in the case of CCmut homo-oligomerization (Figure 5.1D).  
However, in the case of CCmutE34K-R55E hetero-oligomerization with CCwt, 
only two stabilizing salt bridges are maintained while two destabilizing charge-charge 
repulsions are formed (further discussed in the results). This allows for increased 
specificity for CCmutE34K-R55E towards homo-oligomerization over hetero-
oligomerization with CCwt. Similarly, introducing the E46K and R53E compound 
mutation (CCmutE46K-R53E) results in favoring homo-oligomerization (Figure 5.1E). 
Disfavoring hetero-oligomer formation with CCwt represents minimizing interactions 
with endogenous Bcr in cells. 
The resulting designed four mutant candidates: p53-CCmutS41R, p53-
CCmutQ60E, p53-CCmutE34K-R55E, and p53-CCmutE46K-R53E, are listed in Table 
5.1 and were further assessed computationally and tested in vitro for their ability to retain 








5.3 Materials and Methods 
5.3.1 Computational Modeling and Simulation 
Models of the Bcr CC domain were built starting with the crystal structure of the 
N-terminal oligomerization domain of Bcr-Abl (Protein Data Bank code 1K1F, choosing 
residues 1-67 in each of chains A and B).  Using the swapaa tool in Chimera (22), 
selenomethionine residues were reverted back to methionine, and residue 38 was mutated 
back to cysteine, consistent with the wild-type structures. Models of the mutant coiled-
coils were built using the swapaa tool which facilitates placement of modified side chains 
by sourcing the Dunbrack backbone-dependent rotamer library to predict the most 
accurate side-chain rotamers (23). Models were built using ff12SB (24, 25) force field 
parameters and explicitly solvated in truncated octahedron with at least a  10 Å 










atoms were added to achieve an approximate ion concentration of 200 mM.  All models 
were subjected to an extensive minimization and equilibration protocol to relax and steer 
systems towards energetically-favored conformations prior to production molecular 
dynamics (MD).  An initial minimization was performed (500 steps of steepest descent, 
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500 steps of conjugate gradient) prior to heating of the system to 300 K.  A 25 kcal/mol-
Å
2
 restraint was placed upon backbone Cα atoms throughout the initial minimization and 
heating step.  Following the initial minimization and heating, systems were subjected to 
five cycles of minimization (500 steps of steepest descent, 500 steps of conjugate 
gradient) and equilibration, in which restraint weights were lifted sequentially from 5 
kcal/mol-Å
2
 to 1 kcal/mol-Å
2
 following each cycle.  A final equilibration was performed 
for 500 ps with a restraint weight of 0.5 kcal/mol-Å
2
 prior to production MD. Constant 
temperature and pressure were controlled throughout the minimization protocol using a 
Berendsen thermostat (28) with a 0.2 coupling time.  
All production MD simulations were carried out with the AMBER 12.0 modeling 
code suite (29, 30) for 200 ns (using a 2 fs time step) in explicit solvent, using a 
Langeven thermostat (31) with a collision frequency of 1 ps
-1
 to control constant 
temperature and pressure (32), a 10 Å nonbonded cutoff, default particle mesh Ewald 
treatment of electrostatics (33) and SHAKE applied to bonds to hydrogens (34). 
Analysis of the MD trajectories was performed using the PTRAJ and CPPTRAJ 
analysis  tools (35) available in the AmberTools 12.0 and 13.0 distributions:  RMSD and 
2D-RMS analyses were employed to monitor if the protein structure retained the 
expected structure, and clustering analysis of the structures sampled during the MD 
(using the average linkage algorithm) (36) was used to identify the most frequently 
sampled protein conformations of each MD trajectory.  Additionally, a DSSP analysis 
(37) of secondary structure was performed to determine the percent helicity of each 
mutant, and α-helical specific  hydrogen bonds were recorded by monitoring hydrogen 
bonding interactions between peptide backbone atoms of i and i+4 residues.  The atomic 
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positional fluctuations of Cα backbone atoms were recorded to identify regions of 
flexibility in response to the induced mutations.  An MM-PBSA energetic analysis was 
performed to assess the relative binding energies of each mutant (38, 39). 
 
5.3.2 Cell Lines and Transient Transfections 
T47D human ductal breast epithelial tumor cells (ATCC, Manassas, VA), COS-7 
monkey kidney fibroblast cells (ATCC), SKOV-3.ip1 human ovarian adenocarcinoma 
cells (a kind gift from Dr. Margit Janát-Amsbury, University of Utah), and MCF-7 
human breast adenocarcinoma cells (ATCC) were cultured in RPMI 1640 (T47D, COS-7, 
MCF-7) or DMEM (SKOV-3.ip1) (Invitrogen, Carlsbad, CA) supplemented with 10% 
FBS (Invitrogen), 1% penicillin-streptomycin (Invitrogen), 1% glutamine (Invitrogen) 
and 0.1% gentamycin (Invitrogen). Additionally, T47D and MCF-7 cells were 
supplemented with 4 mg/L insulin (Sigma, St. Louis, MO). Cells were maintained in a 
5% CO2 incubator at 37ºC. For all assays, 3.0 x 10
5
 cells for T47D and MCF-7 cells, 2.0 
x 10
5
 for COS-7 and SKOV-3.ip1 cells were seeded in 6-well plates (Greiner Bio-One, 
Monroe, NC). Approximately 24 h after seeding, transfection was performed using 1 
pmol of DNA per well and Lipofectamine 2000 (Invitrogen) following the 
manufacturer’s recommendations.  
 
5.3.3 Plasmid Construction 
The plasmids pEGFP-wt-p53 (wt-p53), pEGFP-p53-CC (p53-CCwt), and pEGFP-
CC (CCwt) were subcloned as previously (9, 40). pEGFP-p53-CCmutS41R (p53-
CCmutS41R), pEGFP-p53-CCmutQ60E (p53-CCmutQ60E), pEGFP-p53-CCmutE34K-
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R55E (p53-CCmutE34K-R55E), and pEGFP-p53-CCmutE46K-R53E (p53-CCmutE46K-
R53E) were created through site directed mutagenesis using pEGFP-p53-CC as the 
template. 
The following primers were used for the p53-CCmutS41R mutation: 5’-
ggagcgctgcaaggccCGCtccattcggcgcctgg-3’ and 5’-ccaggcgccgaatggaGCGggccttgcagcgctcc-3’; 
for the p53-CCmutQ60E mutation, 5’-tccgcatgatctacctggagacgttgctggccaag-3’ and 5’-
cttggccagcaacgtctccaggtagatcatgcggA-3’ primers were used. 
For the p53-CCmutE34K-R55E compound mutant, sequential site directed 
mutagenesis was carried out using the following primers: for the E34K mutation, 5’-
gtgggcgacatcgagcagAagctggagcgctgcaagg-3’ and 5’-ccttgcagcgctccagctTctgctcgatgtcgcccac-3’; 
for the R55E mutation, 5’-aggtgaaccaggagcgcttcGAGatgatctacctgcagacgtt-3’ and 5’-
aacgtctgcaggtagatcatCTCgaagCgctcctggttcacct-3’ primers were used. 
For the p53-CCmutE46K-R53E compound mutant, sequential site directed 
mutagenesis was carried out using the following primers: for the E46K mutation, 5’-
gcctccattcggcgcctgAagcaggaggtgaaccagg-3’ and 5’-CCTGGTTCACCTCCTGCTTCAGGCGCCGAATG- 
GAGGC-3’, for the R53E mutation, primers 5’-agcaggaggtgaaccaggagttccgcatgatctacctgca-3’ and 5’-
tgcaggtagatcatgcggaactcctggttcacctcctgct-3’ were used for deletion of R53; primers 5’-
gcaggaggtgaaccaggagGAGttccgcatgatctacctgc-3’ and 5’-gcaggtagatcatgcggaaCTCctcctggttcacctcctgc-
3’ were used for insertion of 53E. 
The plasmids pBIND-p53-CCwt, pBIND-p53CCmutE34K-R55E, pACT-p53-
CCwt, and pACT-p53-CCmutE34K-R55E were cloned for the mammalian two-hybrid 
assay. For pBIND-p53-CCwt and pBIND-p53-CCmutE34K-R55E, DNA encoding p53-
CCwt and p53-CCmutE34K-R55E was digested from the pEGFP-p53-CC and pEGFP-
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p53-CCmutE34K-R55E vectors respectively, using the BamHI and KpnI restriction 
enzymes and subcloned into the pBIND vector (Promega, Madison, WI) at the BamHI 
and KpnI sites. Similarly, to clone pACT-p53-CCwt and pACT-p53-CCmutE34K-R55E, 
DNA encoding p53-CCwt and p53-CCmutE34K-R55E was also digested from the 
pEGFP-p53-CC and pEGFP-p53-CCmutE34K-R55E vectors respectively, using the 
BamHI and KpnI restriction enzymes and subcloned into the pACT vector (Promega) at 
the BamHI and KpnI sites.  
 
5.3.4 7-AAD Assay 
Following manufacturer’s instructions and as previously described (41), T47D, 
SKOV-3.ip1, and MCF-7 cells were pelleted and resuspended in 500 μL PBS 
(Invitrogen) containing 1 μM 7-aminoactinomycin D (7-AAD) (Invitrogen) for 30 min 
prior to analysis by flow cytometry. The assay was performed 48 h after transfection for 
T47D and MCF-7 (42) and 24 h for SKOV-3.ip1. Cells were analyzed and gated for 
EGFP (with same fluorescence intensity to ensure equal expression of proteins) using the 
FACSCanto-II (BD-BioSciences, University of Utah Core Facility) and FACSDiva 
software. Excitation was set at 488 nm and detected at 507 nm and 660 nm, respectively. 
Each construct was tested three times (n=3). 
 
5.3.5 Mammalian Two-Hybrid Assay 
The pBIND-p53-CCwt (or pBIND-p53-CCmutE34K-R55E) containing the 
Renilla reniformis luciferase gene for normalization, pACT-p53-CCwt (or pACT-p53-
CCmutE34K-R55E), and pG5luc (containing firefly luciferase gene, Promega) plasmids 
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were cotransfected using 3.5 μg of each plasmid following the manufacture’s 
recommendations. The pBIND-Id and pACT-MyoD (Promega) plasmids were used for 
the positive control, and pBIND vector lacking the coiled-coil gene was used as the 
negative control. Approximately 24 h after transfection, the Dual-Glo Luciferase Assay 
(Promega) was used to detect both firefly and renilla luminescence as previously (40). 
The means from duplicate transfections were taken from three separate experiments 
(n=3). As per the manufacturer’s protocol, a relative response ratio was calculated using 









5.3.6 Coimmunoprecipitation (Co-IP) 
Co-IP was performed as we have done before (9). Briefly, T47D cells treated with 
p53-CCmutE34K-R55e or p53-CCwt were prepared using the Dynabeads Co-
Immunoprecipitation Kit (Invitrogen) 24 h post transfection. Approximately 0.2 g of 
T47D treated cell pellet was lysed in 1.8 mL of extraction buffer B (1 x IP, 100 nM NaCl, 
2 mM MgCl2, 1 mM DTT, 1% protease inhibitor). The lysate was incubated for 30 min at 
4ºC with 1.5 mg of dynabeads coupled with anti-GFP antibody (ab290, Abcam). Immune 
complexes were then collected on a magnet, washed, and eluted using 60 μL of elution 
buffer. Finally, the eluted complexes were denatured and western blots were carried out 
as described before (9). The coiled-coil domain was probed using anti-Bcr (sc-885, Santa 
Cruz Biotechnology, Santa Cruz, CA). The primary antibody was detected with anti-
rabbit HRP-conjugated (#7074S, Cell Signaling Technology, Danvers, MA) antibody 
before the addition of SuperSignal West Pico chemiluminescent substrate (Thermo 
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Scientific, Waltham, MA). Signals were detected using a FluorChem FC2 imager and 
software (Alpha Innotech, Santa Clara, CA). Each co-IP was repeated at least three times. 
A semi-quantitative densitometry analysis was carried out by normalizing the detected 
Bcr band to either p53-CCwt or p53-CCmutE34K-R55E as described before (44). 
 
5.3.7 Statistical Analysis 
For in vitro experiments, one-way ANOVA with Bonferroni’s post test was used 
to compare the different groups and controls. A value of p < 0.05 was considered 
statistically significant. Error bars represent standard deviations from at least three 
independent experiments (n = 3). 
 
5.4 Results 
5.4.1 In Silico Modeling of Coiled-Coil Structures 
and Estimation of Binding Free Energies 
Computational modeling and atomistic biomolecular simulations were employed 
to facilitate the design of coiled-coil mutations which serve to enhance homo-
oligomerization of the modified coils while disrupting hetero-oligomerization with the 
native coiled-coil region of Bcr.  Initial simulations estimated differences in relative 
binding free energy of the modified coils to predict the most effective coiled-coil design 
(Table 5.2). All four mutants from Table 5.1 were rationally designed based on 
optimization of the electrostatic interactions and the potential for salt bridge formation 
identified in the helical wheel structure of the CC motif (helical wheel characterized 
previously by Taylor et al.) (20).  
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Table 5.2 Relative Energetic analysis of p53-CC wild type and mutants coiled-coil  




The designed mutations aimed to enhance homo-oligomerization by either 
enhancement of the binding interaction between modified coiled-coils (CCmutS41R and 
CCmutQ60E), or disruption of the interaction between mutant and wild-type coiled-coils 
(CCmutE34K-R55E and CCmutE46K-R53E). Production molecular dynamics were 
carried out on a total of nine independent simulations, in which trajectories were 
generated for each of the modified coils paired with either itself (homo-dimer) or CCwt 
(hetero-dimer). A wild-type coiled-coil homo-dimer was used as a control.   
An MM-PBSA postprocessing energetic analysis of the MD trajectories of the 
dimers (38, 39) was performed on each independent simulation to identify the optimal 
modifications to enhance self-oligomerization (see Table 5.2). Modified coiled-coils 
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which were designed to promote self-oligomerization by increasing the binding stability 
(p53-CCmutS41R and p53-CCmutQ60E)  significantly enhanced the binding affinities of 
the  homo-dimers (Table 5.2, ∆∆G= -20.5 kcal/mol and ∆∆G= -17.1 kcal/mol, 
respectively) relative to the affinity of the wt/wt homodimers. However, the modified 
coils failed to disrupt binding to the native CCwt (Table 5.2, ∆∆G= -4.7  kcal/mol and 
∆∆G= -0.1 kcal/mol, respectively), suggesting that creating additional salt bridges will 
not prevent p53-CC from binding to endogenous Bcr. Results (Table 5.2) suggest that the 
best approach to increase self-oligomerization among the modified coiled-coils while 
minimizing hetero-oligomerization with Bcr is to increase the binding specificity of the 
coiled-coil for itself through the reversing of existing salt bridges (resembled by 
CCmutE34K-R55E and CCmutE46K-R53E). Energetic analyses of the modified coiled-
coils featuring a reversal of salt bridges (p53-CCmutE34K-R55E and p53-CCmutE46K-
R53E) revealed minimal de-stabilization of the homo-dimers p53-CCmutE34K-R55E and 
p53-CCmutE46K-R53E (Table 5.2, ∆∆G= 7.6 kcal/mol and ∆∆G= 1.3 kcal/mol, 
respectively) relative to the wt homodimer, and in the case of the p53-CCmutE34K-R55E 
mutant, a significant de-stabilization of the hetero-dimer with CCwt (Table 5.2, ∆∆G= 
22.0 kcal/mol).  The p53-CCmutE46K-R53E mutant hetero-dimer with CCwt was 
minimally destabilized (∆∆G= 8.5 kcal/mol) when compared with the wt homodimer.  
Therefore, of the four rationally designed mutants, p53-CCmutE34K-R55E is the only 
variant which displays both of the desired characteristics of homo-dimer stabilization and 
disruption of CCwt binding, suggesting that the CCmutE34K-R55E mutant provides the 
most effective strategy to promote self-oligomerization and prevent interaction with 
native Bcr. 
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5.4.2 Initial Screening for In Vitro Activity 
Next, we carried out initial in vitro screening of the activity of each p53-CCmut to 
examine if our proposed mutations abrogate the tumor suppressor function of p53-CC. 
Active p53-CC has been shown previously to induce significant levels of cell death in 
T47D breast cancer cells (9). Hence, the 7-AAD assay, which stains apoptotic and 
necrotic cells (45, 46), served as a screening tool to measure tumor suppressor function of 
the different p53-CC mutants (Figure 5.2). Surprisingly, all of the designed mutations led 




Figure 5.2 Tumor suppressor activity screening using the 7-AAD assay was conducted in 
T47D cells 48 h post transfection. p53-CCmutE34K-R55E is the only candidate that 
retains the ability to induce cell death in a similar way to p53-CCwt and the wt-p53 
control. CCwt was used as a negative control. Statistical analysis was performed using 
one-way ANOVA with Bonferroni’s post test; *** p < 0.001 compared to CCwt. Error 
bars represent standard deviations (n=3). 
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Figure 5.2 illustrates that p53-CCmutE34K-R55E (fifth bar) retains the apoptotic 
activity of p53-CCwt and wt-p53 (first two bars). As expected, the negative control CCwt 
alone shows no apoptotic activity in the 7-AAD assay (last bar). These findings suggest 
that the S41R, Q60E, and E46K-R53E mutations may disrupt the oligomerization of CC, 
lead to instability of the coiled-coil domain, or alter the conformation of p53, resulting in 
loss of tumor suppressor function (third, fourth and sixth bars, respectively). 
Although computational design and modeling implies that S41R, Q60E, and 
E46K-R53E may be candidates for increasing salt bridge formation and binding stability, 
the data in Figure 5.2 illustrate that introducing any of these mutations on the CC domain 
leads to biological inactivation of the chimeric p53-CC. Therefore, we narrowed down 
our mutant candidate to p53-CCmutE34K-R55E, which favors homo-oligomer formation 
over hetero-dimerization with CCwt of Bcr (Table 5.2), while retaining the biological 
activity of p53-CCwt (Figure 5.2). Figure 5.3 shows ribbon diagrams with corresponding 
helical wheels (below) of CCwt homo-dimer (Figure 5.3A), CCwt:CCmutE34K-R55E 
hetero-dimer (Figure 5.3B), and CCmutE34K-R55E homo-dimer (Figure 5.3C). As 
expected from our computational design, the compound mutant CCmutE34K-R55E does 
not lead to formation of new additional ionic interactions (salt bridges). Instead, the same 
two salt bridges found in the CCwt:CCwt homo-dimer (Figure 5.3A) are preserved (but 
reversed) in CCmutE34K-R55E:CCmutE34K-R55E homo-dimer (Figure 5.3C). 
However, Figure 5.3B illustrates that two possible charge-charge repulsions in the 
CCwt:CCmutE34K-R55E hetero-dimer could form, which have the potential to reduce 
p53-CCmutE34K-R55E interaction with Bcr (aka CCwt). Results were obtained using 




Figure 5.3 Ribbon diagrams with corresponding helical wheels of CCwt homo-dimer 
(A), CCwt-CCmutE34K-R55E hetero-dimer (B), and CCmutE34K-R55E homo-dimer 
(C). Gray ribbons represent the CCwt domain, and cyan ribbons represent the 
CCmutE34K-R55E domain. The side chains of key residues (Glu/Lys-34 and Arg/Glu-
55) are shown as red (acidic) or blue (basic). Solid lines indicate salt bridges, while the 
long dash double dotted line represents charge-charge repulsions.   
 
 
Every 20 ns of simulation time, energetic analyses were performed on 5 ns 
snapshots of simulation (0-5 ns, 20-25ns, 40-45 ns, etc.) at 25 ps intervals to examine the 
evolution of relative free binding energies of each system over time.  The results reflect 
the lowest calculated free energies of the nine different MD trajectories relative to the 
CCwt homo-dimers (See Supporting Information 1 for more information). 
 
5.4.3 Global Stability of p53-CCmutE34K-R55E 
Several analyses were performed to evaluate the stability of CCmutE34K-R55E 
homo-dimer relative to the CCwt homo-dimer and the CCwt:CCmutE34K-R55E hetero-
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dimer. RMSD analyses of the MD sampled structures to the initial structures revealed 
that both the mutant homo-dimer and mutant hetero-dimers remained close to their initial 
structures, as was observed with the CCwt homo-dimer (Figure 5.4).   
The atomic positional fluctuations (Supporting Information 2) of Cα backbone 
atoms were recorded to identify regions of flexibility in response to the induced 
mutations, revealing an increase in flexibility of the CCmutE34K-R55E mutant when 
paired to CCwt, in the region of the E34K-R55E mutations. This can be attributed to the 
destabilization of the coiled-coils by the unfavorable electrostatic interactions occurring 
between the mutant and wild-type coiled-coils.  A slight increase in the flexibility of the 
CCmutE34K-R55E homo-dimer is observed at N-termini and C-termini α-helical regions 
(Residues 1-10 & 124-134, respectively); however a DSSP secondary structure analysis 
(37) revealed no loss in coiled-coil helicity in the CCmutE34K-R55E homo-dimer 
relative to the CCwt homo-dimer (Table 5.3, helicity= 71.8% and 71.6%, respectively), 
suggesting that the α-helical dimerization interface remains stable.  
 
 
Figure 5.4 Time course of the deviation of the MD structures of the Bcr coiled-coil 
region (CCwt) and CCmut E34K-R55E to the experimental reference structure. One- 
dimensional RMSD analyses was performed to monitor the structural variance of the 
mutant CCmutE34K-R55E homo-dimer (black) and the CCwt:CCmutE34K-R55E  (blue) 




Table 5.3 Relative helicity of the modified coiled-coil region CCmutE34K-R55E relative 




Analysis of  α-helical specific hydrogen bonding interactions (between backbone 
atoms of i and i+4 residues) revealed no significant difference in hydrogen bonding 
patterns between the CCmutE34K-R55E and CCwt homo-dimers (Table 5.3; i and i + 4 
hydrogen bond = 33.1% and 32.1%, respectively) to indicate a loss of coiled-coil stability 
due to the observed atomic positional fluctuations.   
Together, these results suggest that the compound mutation E34K-R55E does not 
affect the stability of the coiled-coil, supporting the existing evidence (Figure 5.2) that 
p53-CCmutE34K-R55E forms active oligomers, retaining transcriptional and tumor 
suppressor activity of p53. 
 
5.4.6 Binding Assay Validates Design 
To specifically address whether our lead mutant compound CCmutE34K-R55E 
limited hetero-oligomerization with CCwt (found in endogenous Bcr), the widely 
accepted mammalian two-hybrid binding assay (43) was carried out. Figure 5.5 
demonstrates that formation of CCmutE34K-R55E homo-oligomers (third bar) is more 
favored than CCwt:CCmutE34K-R55E hetero-oligomerization (middle bar). 
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Figure 5.5 Binding of CCmutE34K-R55E homo- and hetero-dimers with CCwt tested 
using the mammalian two-hybrid assay. The assay was carried out in COS-7 cells 24 h 
post transfection. Both CCwt and CCmutE34K-R55E have similar binding as indicated 
by the first and third bar, respectively. The mammalian two-hybrid assay revealed weak 
binding of CCmutE34K-R55E hetero-dimerization with CCwt. Statistical analysis was 
performed using one-way ANOVA with Bonferroni’s post test; ** p < 0.01, ns = not 
significant. Error bars represent standard deviations (n=3). 
 
 
While CCmutE34K-R55E homo-dimerization leads to preserving all 4 possible 
salt bridges that normally exist in the CCwt homo-dimer (see Figure 5.3, C vs A), 
CCmutE34K-R55E hetero-dimerization with CCwt may produce two new possible 
charge-charge repulsions (see Figure 5.3B). In addition, Figure 5.5 shows no significant 
difference in the binding between CCwt and CCmutE34K-R55E homo-dimers (first and 
third bars), as expected. This similarity in binding between CCwt vs CCmutE34K-R55E 
homo-dimers converges with the data obtained from our computational modeling of 
binding energies (Table 5.2; also illustrated in Figure 5.3), in which no change of the total 
number of salt bridges occur as a consequence of introducing the E34K-R55E mutation 
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to the coiled-coil domain. 
A DSSP secondary structure analysis was performed on each of the nine MD 
trajectories, characterizing the phi (ϕ) and psi (Ψ) backbone dihedral torsions of each 
residue to calculate the percentage of coiled-coil residues defined as alpha-helical.  The 
percentage of interhelical hydrogen bonds between i and i+4 residues (specific to alpha-
helices) formed throughout the trajectory was compared to the total number of potential i, 
i+4 hydrogen bonding interactions (total number of residues in each coiled-coil minus 
four). 
 
5.4.7 p53-CCmutE34K-R55E Interaction  
with Endogenous Bcr 
The mammalian two-hybrid assay illustrates the ability of our CCmutE34K-R55E 
compound mutation in limiting the interaction of p53-CCmutE34K-R55E with the CCwt 
domain of endogenous Bcr in cells. To substantiate the mammalian two-hybrid assay 
data, a coimmunoprecipitation assay was performed to determine if exogenously added 
p53-CCmutE34K-R55E has limited interaction with the CCwt domain of endogenous Bcr 
compared to p53-CCwt. Cell lysates transfected with either p53-CCmutE34K-R55E or 
p53-CCwt were immunoprecipitated as we have done before (9). Endogenous Bcr that 
could potentially coimmunoprecipitate was probed using anti-CCwt antibody. Figure 
5.6A shows that endogenous Bcr coimmunoprecipitates (i.e., interacts) with p53-
CCmutE34K-R55E to a lesser extent compared to p53-CCwt. Furthermore, we carried 




Figure 5.6 Interaction of p53-CCmutE34K-R55E and p53-CC with endogenous Bcr was 
investigated in T47D cells via co-IP. A) A representative cropped western blot of protein 
complexes coimmunoprecipitated using anti-GFP antibody is shown. Left lane, 
endogenous Bcr (160 kDa) coimmunoprecipitates with p53-CCmutE34K-R55E (71 kDa) 
to a lesser extent compared to that with p53-CC (71 kDa) in the right lane. B) Semi-
quantitative densitometric analyses was carried out as described before (44) to evaluate 
Bcr interaction with p53-CCmutE34K-R55E and p53-CC. Mean values were analyzed 
using one-way ANOVA with Bonferroni’s post test; *** p < 0.001. Error bars represent 
standard deviations (n=3). 
 
 
Figure 5.6B shows that p53-CCwt hetero-oligomerization with endogenous Bcr is 
two-fold higher than the p53-CCmutE34K-R55E interaction with Bcr. These findings 
indicate that the E34K-R55E compound mutation reduces hetero-oligomerization with 
endogenous Bcr compared to CCwt interaction with Bcr, presumably due to the 
formation of charge-charge repulsions (see Figure 5.3B). It should be noted that 
prominent double secondary bands are detected by this anti-CCwt antibody even in 





5.4.8 p53-CCmutE34K-R55E Induces Apoptosis Regardless  
of the p53 Status or Cancer Cell Type 
To ensure that the ability of p53-CCmutE34K-R55E to induce cell death is neither 
dependent on endogenous p53 status nor cancer cell line specific, its apoptotic activity 
was tested in three different cancer cell lines; SKOV-3.ip1 human ovarian cancer cells 
(p53-null) (47), MCF-7 human breast cancer cells (wild type but mislocalized p53) (48), 
and T47D human breast carcinoma cells (mutant p53) (49). Figure 5.7 A-C demonstrates 
that p53-CCmutE34K-R55E is capable of inducing cell death similarly to p53-CCwt and 
wt-p53, regardless of the endogenous p53 status or cancer cell line. 
 
5.5 Discussion 
Since domain swapping to create p53-CC could result in p53-CC interacting with 
endogenous Bcr, we mutated p53-CC to avoid this. The implications of possible binding 
of endogenous Bcr are unknown, but may be undesired, as Bcr is a ubiquitous protein 
involved in inflammatory pathways and cell proliferation (14).  
Since no other proteins in cells contain the Bcr CCwt motif, the sequence-specific 
interaction with Bcr CCwt is the only one we need be concerned with eliminating. In this 
report, we designed mutations in our alternative oligomerization domain, the coiled-coil, 
to avoid interaction with Bcr. Computationally designed and modeled mutations in the 
CC domain (40) were developed to minimize interactions with native endogenous Bcr. 
Based on initial examination of the CC motif, several possible mutation sites were 




Figure 5.7 7-AAD assay was conducted in three different cell lines with varying p53 
status (A) SKOV 3.ip1, (B) MCF-7, and (C) T47D cells. In all three cases, p53-
CCmutE34K-R55E was capable of inducing cell death in a similar fashion compared to 
p53-CC and wt-p53, regardless of the endogenous p53 status or the cancer cell line used. 
Statistical analysis was performed using one-way ANOVA with Bonferroni’s post test; 
** p < 0.01 and *** p < 0.001. 
 
 
In addition, Figure 5.1 shows helical diagrams representing the CCwt, the 
modified CC domain (CCmut), and the hypothesized changes in electrostatic interactions 
(salt bridges). 
Two different modified coiled-coils with a single point mutation each were 
designed to enhance self-oligomerization.  Residues Ser-41 and Gln-60 are arranged 
opposite of charged residues Glu-48 and Lys-39, such that the mutations S41R and Q60E 
serve to create additional salt bridges in the coiled-coil dimers.  In the first mutant, Ser-41 
was mutated to Arg, creating two new salt bridges via interaction with Glu-48 (Figure 
5.1B).  In the second mutant, Gln-60 was mutated to Glu, creating two new salt bridges 
via interaction with Lys-39 (Figure 5.1C). 
Furthermore, two different modified coiled-coils with two point mutations each 
(compound mutants) were designed to increase binding specificity of the modified 
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coiled-coil for itself by disrupting affinity for  CCwt.  By reversing the charge of existing 
salt bridges (dashed line highlighted in green in Figure 5.1 D and E), a scenario is created 
in which charge repulsion disrupts the binding of the CCwt to the modified coiled-coils.  
In the p53-CCmutE34K-R55E mutant, the salt bridge between Glu-34 and Arg-55 is 
effectively reversed by introducing the mutations E34K and R55E.  Similarly, the p53-
CCmutE46K-R53E mutant features the mutations E46K and R53E to reverse the salt 
bridge between Glu-46 and Arg-53. 
Molecular modeling, MD simulation, and free energy analysis revealed the 
ranking of our different modifications in terms of minimizing CCwt-CCmut hetero-
oligomerization (Table 5.2). On one hand, free binding energy analysis by MM-PBSA 
revealed that CCmutS41R and CCmutQ60E may both have strong homo-oligomer 
binding stability (Table 5.2, ∆∆G= -20.5 kcal/mol and ∆∆G= -17.1 kcal/mol, 
respectively) relative to the wt homo-dimer. However, the same analysis revealed that 
both, CCmutS41R and CCmutQ60E, also have similar or increased relative binding 
affinities  for the CCwt coil (Table 5.2, ∆∆G= 4.7 kcal/mol and ∆∆G= -0.1 kcal/mol, 
respectively). In addition, there is no significant difference in relative binding energies 
between CCmutE46K-R53E homo-dimers and hetero-dimers (Table 5.2, ∆∆G= 1.3 
kcal/mol and ∆∆G= 8.5 kcal/mol, respectively). On the other hand, the free energy 
analyses showed that CCmutE34K-R55E may be a suitable candidate for minimizing 
interactions with CCwt, with CCmutE34K-R55E disfavoring interaction with CCwt. A 
significant difference in binding energies exists between the CCmutE34-R55E homo-
dimer and hetero-dimer with CCwt (Table 5.2, ∆∆G= 7.6 kcal/mol and ∆∆G= 22.0 
kcal/mol, respectively). This result suggests that CCmutE34K-R55E favors homo-
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oligomerization over hetero-oligomerization with CCwt of Bcr. Furthermore, the binding  
of the CCmutE34K-R55E hetero-dimer with CCwt is less favored (Table 5.2, ∆∆G= 22.0 
kcal/mol) compared to that of CCwt homo-oligomer (Table 5.2, ∆∆G= 7.6 kcal/mol). To 
test if our possible mutations led to any abrogation in p53-CC activity, we carried out an 
in vitro cell death assay in which p53-CC has been proven previously to induce cell death 
(in T47D cells) (9). Figure 5.2 showed that all mutants (p53-CCmutS41R, p53-
CCmutQ60E, and p53-CCmutE46K-R53E) have lost the tumor suppressor activity of 
p53-CC except for the compound mutant p53-CCmutE34K-R55E. Thus, p53-
CCmutE34K-R55E was the lead, eliminating the need to test the inactive mutants in the 
remaining experiments.  
Both the mammalian two-hybrid assay (Figure 5.5) and the co-
immunoprecipitation experiment (Figure 5.6) validate the computational modeling and 
strongly indicate that p53-CCmutE34K-R55E minimize interaction with CCwt of 
endogenous Bcr in cells, suggesting that our hypothesized interactions are indeed 
occurring. Finally, we confirmed that the tumor suppressor activity (measured by 
apoptotic activity) of p53-CCmutE34K-R55E remains consistent regardless of 
endogenous p53 status or the type of cancer cell line as shown in Figure 5.7.  
This study showed how in silico modeling can guide experimental design (as we 
have done before) (50) and that further iterations of in vitro design resulted in an 
enhanced version of our chimeric p53 (9).  The resulting rationally designed p53-
CCmutE34K-R55E avoids binding to endogenous Bcr and yet retains potent apoptotic 
activity in a variety of cancer cell lines, regardless of p53 status.  This construct will be 
used for future gene therapy experiments for treatment of cancers characterized by p53 
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dysfunction, which represent over half of all human cancers. 
 
5.5.1 Explanation of the Potential Deviation between 
Results Obtained In Silico and In Vitro 
In silico and in vitro studies correlate in terms of describing overall binding trends 
observed of our mutant candidates and endogenous Bcr. However, the results obtained 
from relative energetic analysis of p53-CC wild type and mutant coiled-coil dimers 
obtained by MM-PBSA may not be representative of the full interactions taking place in 
the cellular environment, which may explain the partial deviation between the two sets of 
data. Although in silico estimations (Table 5.2) of relative free binding energies suggest 
disfavored hetero-oligomerization between our lead candidate p53-CCmutE34K-R55E 
and endogenous Bcr (∆∆Gbinding = 22.0 kcal/mol), actual binding evaluation in vitro 
revealed that introduction of the E34K-R55E reduces potential interaction with 
endogenous Bcr by 2 fold (co-immunoprecipitation, Figure 5.6). Some of the reasons that 
may help explain the deviation between in silico and in vitro estimations of relative 
binding are discussed below:   
I. While the calculations of relative binding energies in silico are based on 
estimations of the dimeric interphase binding of each mutant to itself (homo-
oligomerization) or endogenous Bcr (hetero-oligomerization) relative to the wild 
type coiled-coil dimer,  actual evaluation of binding in vitro via co-
immunoprecipitation accounts for the interaction on a tetrameric scale as well as 
the dimeric interphase. Hence, it is logical to observe differences between in silico 
and in vitro evaluation of mutant coiled-coil binding to endogenous Bcr since 
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interactions in the tetrameric interphase are not accounted for in the relative free 
binding energy estimations. 
II. Another factor that may contribute to the observed difference in disfavoring 
hetero-oligomerization of CCmutE34K-R55E in silico vs. in vitro could be 
attributed to the fact that the conditions used for in silico simulations do not fully 
represent the actual intracellular environment where these interactions actually 










 atoms were added to achieve an approximate ion concentration of 200 
mM, there are other ions (including divalent ions such Ca
++
) that are present in the 
cells that may affect the overall interaction. Furthermore, since the rationale 
behind our modifications on the coiled-coil domain is based on altering the ionic 
salt bridges that form in the dimeric interphase, these divalent ions present in cells 
and not accounted for in the relative free binding energy calculations in silico may 
screen the charged residues responsible for salt bridge formation, leading to a 
decrease in overall binding in vitro compared to in silico estimations. 
III. Although solute entropy is accounted for in the relative free energies calculated 
according to standard formulas in order to obtain more representative 
approximation of relative binding energies, the full entropic contributions to the 
relative free binding energies calculated may be different than what exists in 
reality in cells. This can cause further deviations between in silico estimations and 
in vitro measurements of the reduction in hetero-oligomerization between our lead 
candidate p53-CCmutE34K-R55E and endogenous Bcr. 
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Additionally, the potential reason for lack of activity of the mutant candidates 
p53-CCmutE46K-R53E, p53-CCmutS41R, and p53-CCmutQ60E must be addressed. 
Although estimations of relative free binding energies of p53-CCmutE46K-R53E hetero-
dimers may suggest that introduction of the E46K-R53E mutations may favor homo-
dimerization over hetero-oligomerization with endogenous Bcr, our activity assays 
(Figure 5.2) revealed that introduction of the E46K-R53E resulted in complete 
abolishment of activity. Similarly, introduction of S41R and Q60E also resulted in 
complete loss of activity compared to p53-CCwt. We speculate that introduction of these 
mutations may disrupt the overall conformation and stability of the coiled-coil domain, 
leading to loss of the oligomerization required for transcriptional activation and tumor 
suppressor function. We also postulate that this structural instability may be in the 
context of fully formed tetramers, since the relative free binding energies estimated in 
silico appear to support stable formation of coiled-coil dimers. However, to fully 
investigate the actual significance of these residues (S41, Q60, E46, R53) for proper 
tetramer formation and oligomerization, a better computational model must be utilized 
that has the potential to investigate the tetrameric coiled-coil interphase on full scale 
rather than dimeric interphase only. This is beyond the scope of this dissertation work, 
but is a potential new area for computational exploration. Finally, in silico experiments 
were not designed for one to obtain a single absolute free energy for which to compare 
with a single free energy obtained experimentally. Instead, the in silico experiments were 
viewed as an ensemble, and are relevant only when viewed in this manner. Further, the in 
silico free energy calculations were used in this case to obtain a baseline comparison of 
what might work out experimentally, not to provide absolute free binding energy values. 
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5.6 Supporting Information 
 
Supporting Information 5.1  MM-PBSA energetic analysis at 5 ns snapshots.  At 20 ns 
intervals, an MM-PBSA energetic analysis was performed (over a 5 ns window sampled 
at 25 ps intervals) to uncover the most energetically favorable conformations of each 
system. Because each simulation will sample its most favorable conformation 
independently and at varying time points throughout the simulation, it is beneficial to 
perform the energetic analyses at various time points in order to build a profile of the 
relative binding free energies of each of the different systems as the energies evolve over 
time. Highlighted are the most favorable relative binding free energies of each system as 









Supporting Information 5.2 Atomic positional fluctuations of the E34K-R55E 
compound mutant relative to the wild-type homo-dimer. Atomic fluctuations of Cα 
backbone atoms were recorded to identify changes in coil flexibility among p53-
CCmutE34K-R55E homo-dimer (black) and hetero-dimer (complexed with wild-type) 
(blue) relative to the wild-type coiled-coil homo-dimer (red).  Residues 1-67 correspond 
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 CHAPTER 6 
 
CONCLUSIONS AND FUTURE WORK 
 
6.1 Conclusions 
This dissertation described the design of a novel p53-based gene therapeutic that 
is capable of inducing cell death in several types of cancer, regardless of p53 mutation, 
mislocalization, deletion, or malfunction occurring in these cancer cells. The main theme 
of the work is to overcome the limitations of using wt p53 in cancer gene therapy, and 
creating an enhanced version of the tumor suppressor. Hence, we designed the chimeric 
p53-CC for the purpose of evading interaction with mutant p53 and consequently, 
bypassing transdominant inhibition in cancer cells. These approaches lead to the 
hypothesis that swapping the oligomerization domain of p53 with an alternative 
oligomerization domain will prevent transdominant inhibition by mutant p53 in cancer 
cells. The activity of p53-CC was investigated in vitro for proof-of-concept and to 
validate its tumor suppressor functions. The chimeric p53-CC was then tested in an 
orthotopic breast cancer mouse model to investigate if the activity observed in vitro 
translates in vivo. Aided by computational design, we then investigated possible 





6.1.1 Chimeric p53-CC Maintains Tumor 
Suppressor Function 
Due to the dominant negative effect of mutant p53, there has been limited success 
with wt p53 cancer gene therapy. Therefore, an alternative oligomerization domain for 
p53 was investigated to enhance the utility of p53 for gene therapy. The tetramerization 
domain of p53 was substituted with the CC domain from Bcr. Our chimeric p53-CC 
localized to the nucleus successfully upon expression and in fact showed a similar 
expression profile of p53 target genes relative to wt p53. Our apoptosis assays revealed 
that p53-CC was capable of inducing cell death similar to wt p53 in nondominant 
negative cancer cells, regardless of endogenous p53 status or cancer cell type. 
Additionally, we confirmed via reporter gene assays that p53-CC is indeed 
transcriptionally active. Because p53 transcriptional activity is dependent on tetrameric 
formation of the protein, this in fact suggests that our alternative oligomerization domain 
(CC) is capable of driving tetramerization of p53-CC. Since we hypothesized that 
swapping the TD of p53 with CC will allow for our p53-CC chimera to evade hetero-
oligomerization with mutant p53, we carried out co-immunoprecipitation studies to detect 
any possible interaction with endogenous p53. As expected, p53-CC escaped any hetero-
oligomerization with endogenous p53, while wt p53 showed significant levels of 
interaction with endogenous mutant p53. The biological outcomes of the ability of p53 to 
escape transdominant inhibition was then tested, first with transdominant mutant p53 
overexpression, and second, in MDA-MB-468 cells that harbor a tumor-derived 
endogenous transdominant negative p53 mutant. In both cases, p53-CC appears to not be 
affected by this endogenous transdominant inhibition. Finally, adenoviral delivery of 
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p53-CC was tested in MDA-MB-468 cells as well as a p53-null cell line to determine 
feasibility of in vivo studies. 
 
6.1.2 Validation of p53-CC Tumor Suppressor 
Function In Vivo 
Since we validated that the chimeric superactive p53-CC with an alternative 
oligomerization domain is capable of escaping transdominant inhibition by mutant p53 in 
vitro, we initiated animal studies to examine the activity of p53-CC in vivo. MDA-MB-
468 human breast adenocarcinoma cells represent an aggressive breast cancer cell line 
characterized as triple negative due to the absence of molecular targets including estrogen 
receptor, progesterone receptor, and human epidermal growth factor receptor 2 (1). 
Importantly, MDA-MB-468 cells harbor a dominant negative mutant p53 capable of 
impairing the function of wt-p53 (2-4). We therefore used this cell line to induce 
orthotopic breast tumors in mice to compare the impact of the dominant negative effect of 
mutant p53 on the biological activity of p53-CC and wt p53 in viral-mediated gene 
therapy. As expected, p53-CC treatment group achieved significant reduction in mean 
tumor size compared to wt p53 and control groups. Interestingly, wt p53 treatment 
resulted in stable disease and halted tumor progression. Our findings from the in vivo 
efficacy study revealed that p53-CC could achieve tumor regression of an aggressive 
p53-dominant negative breast cancer model in vivo, while wt p53 is only capable of 
halting tumor progression. This is a critical breakthrough in p53 gene therapy not 
achieved before. Furthermore, we investigated the underlying differential mechanisms of 
activity for p53-CC and wt p53 in the MDA-MB-468 tumor model. We discovered that 
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the difference in outcome of the tumor size reduction was due in part to the ability of 
p53-CC to activate the apoptotic pathway, whereas wt p53 activates cell cycle arrest via 
p21 induction. These findings are supported by immunohistochemistry staining and 
western blot analyses from in vitro as well as in vivo MDA-MB-468 cells and tumor 
tissue samples. Therefore, our compelling in vivo data demonstrates that p53-CC is more 
effective than wt p53 in inducing apoptosis, and may serve as a potent and reliable novel 
anticancer therapeutic.  
 
6.1.3 Altering the Design of the p53-CC Chimera 
to Minimize Interaction with Bcr 
Since domain swapping to create the p53-CC chimera could result in p53-CC 
interacting with endogenous Bcr, modifications on the CC domain are necessary to 
minimize potential interactions with Bcr.  Hence, we hypothesized that certain 
modifications to the CC domain in p53-CC could reduce potential interactions with 
endogenous Bcr in cells. We investigated the possible design of mutations that will form 
opposing charges on residues e to e’ and g to g’ of the coiled-helices (where the ’ denotes 
a residue on the opposing coiled-coil in the dimer). This could lead to an increase in salt 
bridge formation, which has the potential to improve homo-dimerization of CC mutants 
and disfavor hetero-oligomerization with CCwt, with the goal of minimizing potential 
interactions with endogenous Bcr in cells. In silico examination of CCwt revealed that 
introducing S41R (Arg, basic) and Q60E (Glu, acidic) mutations separately, would 
potentially form two extra salt bridges per mutation. These two mutant candidates are 
referred to as CCmutS41R and CCmutQ60E. In addition, examination of the coiled-coil 
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interchain salt bridges indicated that two more potential compound mutants (i.e., more 
than one mutation per candidate) could be made to improve homo-dimerization of CC 
mutants. Mutation of Glu-34 to Lys and Arg-55 to a Glu (CCmutE34K-R55E) will 
preserve all 4 stabilizing salt bridges found in CCwt in the case of CCmut homo-
oligomerization. However, in the case of CCmutE34K-R55E hetero-oligomerization with 
CCwt, only 2 stabilizing salt bridges are maintained while 2 destabilizing charge-charge 
repulsions are formed. Similarly, another mutant can be created by introducing the E46K 
and R53E compound mutation (CCmutE46K-R53E), which results in favoring homo-
oligomerization over hetero-oligomerization with CCwt. Computational and in vitro 
assessment of the 4 designed mutants revealed that p53-CCmutE34K-R55E is the only 
candidate that maintains the tumor suppressor function of p53, and hence was considered 
the lead compound. An in vitro protein binding assay (mammalian two-hybrid) as well as 
coimmunoprecipitation analyses validated that p53-CCmutE34K-R55E succeeds at 
minimizing interactions with endogenous Bcr compared to p53-CC. Therefore, this 
construct will be used for future gene therapy experiments for treatment of cancers 
characterized by p53 dysfunction, which represent over half of human cancers. 
 
6.2 Future Studies 
6.2.1 Exploring the Differential in Target Gene 
Regulation by p53-CC vs. Wt p53 
In Chapter 4, we suggested that p53-CC favors induction of apoptosis, while wt 
p53 favors induction of cell cycle arrest, in the MDA-MB-468 breast cancer animal 
model. Immunohistochemistry staining and western blot analysis from tumor tissues 
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treated with Ad-p53-CC expressed low levels of p21 (reduced cell cycle arrest) but high 
levels of active caspase-3 (increased apoptosis). In contrast, tumor tissues injected with 
Ad-wt-p53 expressed high levels of p21 (increased cell cycle arrest) but low levels of 
caspase-3 (decreased apoptosis). To further explore this differential mechanism of 
activity for p53-CC (or p53-CCmutE34K-R55E) and wt p53 and their abilities to regulate 
transcription of target genes, chromatin immunoprecipitation (chIP) analysis will be 
conducted (5, 6). A chIP will allow for us to further investigate whether the ability of 
p53-CC to induce higher levels of apoptosis in the MDA-MB-468 breast cancer model is 
due to increased binding and transcriptional activation of apoptotic target genes. 
Additionally, this assay may offer insights into how p53-CC and wt-p53 differ in binding 
and activating various p53 target genes. Finally, the data obtained from the chIP assay 
conducted in MDA-MB-468 cells and/or tumor tissues will be compared with data from 
chIP assays carried out in other cell lines. This comparison will allow for identification of 
the difference in target gene activation by p53-CC chimeras and wt p53. In addition, 
efficacy data shown in our studies (Chapters 3, 4, and 5) in multiple cell lines (MCF-7, 
T47D, H1373, HeLa, MDA-MB-468, SKOV-3ip1, MDA-MB-231 and others) isolated 
from different types of cancer (breast cancer, lung cancer, ovarian cancer) suggest that 
the tumor suppressor function of our chimeric p53 is universal, and is independent of the 
endogenous p53 status or the cancer type.  
 
6.2.2 Further Optimizations of Our Chimeric p53 
Since our main goal is to create a chimeric p53 that will be an effective 
therapeutic for TNBC and virtually all other types of cancers, we continue to pursue 
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enhancement and optimization of our p53-CC chimera. One such enhancement is 
achieved by introducing mutations on p53-CC that can result in increased induction of 
apoptosis. This can be highly beneficial since cell death induction is one of the main 
purposes for development of a successful cancer therapeutic. To increase apoptosis, we 
have explored introducing mutations in the DBD of p53 to favor apoptosis over DNA 
repair (7); DNA repair is undesired since it runs counter to cell-killing. The selection of 
these functions depends on sequence-specific recognition of p53 to a target decameric 
sequence of gene promoters. For most apoptotic and cell cycle gene promoters, position 9 
of the target DNA decameric sequence is a cytosine (C9) while for DNA repair gene 
promoters; thymine (T9) is found instead. Therefore, selective binding to the C9 cytosine 
may transcribe apoptotic gene promoters and induce apoptosis and cell cycle arrest. 
Molecular modeling indicated that substitution of a hydrophilic residue, A276S, would 
prefer binding to C9 of the target DNA whereas substitution of a hydrophobic residue 
(A276F) would fail to do so (8). Indeed, A276S-p53 showed higher transcription of 
apoptotic (PUMA, PERP) and cell cycle arrest promoters (p21WAF1/CIP1) containing a 
C9 and lower transcription of a DNA repair promoter (GADD45) containing a T9 
compared to wild-type p53. Apoptotic assays and cell cycle analysis also proved the 
superiority of A276S over wt p53 for inducing apoptosis of cancer cells (7). Therefore, 
we will introduce the A276S mutation on our lead candidate p53-CCmutE34K-R55E 
chimera, and further test this will lead to an increase in apoptotic activity.  
We will also computationally design and model more mutations in the CC domain 
(9) which will be designed to: 1) strengthen dimer/tetramer binding that may lead to an 
increase in activity, and 2) examine the CC domain for other possible mutations that can 
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result in enhanced ‘knobs-into-holes’ packing originally proposed by Crick in 1952 (10). 
So far, we have only introduced mutations to enhance the stability and specificity of the 
dimeric interaction interface of the coiled-coil domain. We hypothesize that further 
examination of the essential residues involved in the interactions responsible for the 
tetramerization of the coiled-coil may offer additional mutation sites that could increase 
the stability, and consequently the activity, of our chimeric p53. Lastly, since our coiled-
coil domain adopts an α-helical secondary structure, we can use nearest-neighbor analysis 
coupled with computational modeling to rationally substitute residues that will lead to 
increased stabilization of our p53 chimeras (11-13). 
 
6.2.3 Test the Activity of the Enhanced 
Version of p53-CC In Vivo 
Further in vitro activity studies are needed to validate the tumor suppressor 
function of our lead mutant candidate p53-CCmutE34K-R55E. The following apoptotic 
and cell proliferation assays will be performed: caspase-3, TUNEL, Annexin-V, 7-AAD, 
and colony forming assay. Once the activity of p53-CcmutE34K-R55E is validated, we 
will compare its activity with that of p53-CC in vivo in the same MDA-MB-468 
orthotopic breast cancer tumor model as we have done before. However, prior to starting 
the animal studies, the p53-CcmutE34K-R55E will be cloned into an adenoviral vector 
(Ad-p53-CcmutE34K-R55E).  
If initial tumor regression studies here are successful, we will use the well-
established HCI-003 patient graft model (14) with mutant p53, and additional mutant p53 
tumor grafts that may become available later. The patient-derived tumor graft models will 
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be used to determine if Ad-p53-CcmutE34K-R55E can prevent tumor recurrence, and 
prevent metastases. Although the HCI-003 patient graft model is not characterized as a 
triple negative breast cancer, it is an aggressive and highly metastatic breast cancer model 
that is clinically relevant. While metastases have been found at 4-5 months for most 
tumors in this bank, the minimum latency required for detectable metastases has not yet 
been determined (14). Furthermore, this tumor graft spontaneously metastasizes to 
clinically relevant sites and is therefore an ideal model in which to test the efficacy of our 
constructs.  
In addition, co-engraftment of the original tumor mesenchymal stem cells will 
maintain natural angiogenesis and hence, phenotypic tumor growth of the primary human 
tumor (14). These types of experiments may require additional adenovirus construct 
dosing and some empirical determination of onset/determination metastases. Finally, the 
effect of p53-CcmutE34K-R55E on mice bearing patient grafts derived from metastatic 
pleural effusions (14) would be tested as well. Toxicity, efficacy, and biodistribution 
studies will be carried out as well to determine the feasibility and safety of using our lead 
therapeutic (p53-CcmutE34K-R55E) in the clinic. Since it has been shown before that 
adenovirus delivery of wt-p53 (Advexin™) has a proven record of safety but marginal 
therapeutical success for cancer gene therapy in humans, adenoviral delivery of p53-
CcmutE34K-R55E will be used in a clinical trial following the in vivo studies. 
Similar to Advexin™, our biological therapeutic Ad-p53-CcmutE34K-R55E can 
be used both as monotherapy and in combination with radiation and/or chemotherapy 
agents (15-17). However, we expect our therapeutic candidate (p53-CcmutE34K-R55E) 
to exceed the efficacy observed with Advexin™ in the Phase III clinical trials due to its 
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ability to evade transdominant inhibition, while maintaining a safe profile in for clinical 
use in cancer patients. In addition, we may consider other viral vectors (e.g., adeno-
associated virus) as well as other nonviral vectors (e.g., WSLP) with better safety profiles 
in the clinic compared to adenoviral vectors for delivery of our therapeutics. 
 
6.2.4 Combinational Gene Therapy with Proteasomal  
Protein Switch and Chimeric p53-CC 
Although the novel design of p53-CC chimera with an alternative oligomerization 
domain allows it to escape transdominant inhibition by mutant p53, certain types of 
mutant p53 exhibit ‘gain of function’ that can promote cancer cell survival (18-20). 
Hence, it is essential to address these oncogenic functions of mutant p53 in cancer cells. 
Our multitarget approach takes advantage of the combination therapy concept that has 
proven effective in cancer treatment. We will deliver a combination therapeutic 
consisting of two gene loads: 1) the chimeric p53-CC gene and 2) a gene encoding for 
proteasomal protein switch that is capable of targeting endogenous mutant p53 to the 
proteasome for degradation. This proteasomal protein switch was previously developed 
in our lab by Rian Davis (21). The starting point for this was our nuclear protein switch 
(PS), which consists of a ligand inducible nuclear import signal and an export signal to 
control the localization to the nucleus (22, 23). The localization is strictly controlled by a 
dexamethasone-specific ligand-binding domain from the glucocorticoid receptor (GR). 
Finally, to allow this protein switch to target the proteasome, the nuclear protein switch 
was fused to full-length p53. Upon ligand addition, the proteasomal protein switch 
translocates to the nucleus (as expected), and the p53 portion of it binds MDM2 found at 
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the nucleus. This p53-MDM2 binding allows the ubiquitination of the p53 segment of the 
proteasomal switch and targets the entire complex for degradation at the proteasome. 
Therefore, we can fuse our proteasomal protein switch (PS-p53) to the tetramerization 
domain of p53 (TD) and create a new version of proteasomal switch (PS-p53-TD). In 
theory, the PS-p53-TD should be able to interact with endogenous mutant p53 via the 
TD, and subsequently target it for proteasomal degradation. Hence, our combination 
therapy approach offers 1) introduction of the superactive tumor suppressor p53-CC 
chimera, and 2) targeting the oncogenic mutant p53 for proteasomal degradation and 
eliminating its ‘gain of function.’  
 
6.2.5 Using Chimeric p53-CC for Treatment of Cancers 
in Patients with Li-Fraumeni Syndrome 
Li-Fraumeni Syndrome (LFS) is a rare disorder that is characterized by genetic 
germline TP53 mutation(s) that lead to inherited predisposition for cancer (24-26). Unlike 
other predisposition syndromes, LFS is not associated with site-specific cancers. Instead, 
LFS is linked with a variety of different tumors and leukemias, occurring over a wide age 
range. However, recent studies revealed that LFS can be correlated to increased 
disposition for acquiring sarcomas, lung, pancreatic, and premenopausal breast 
carcinoma. Therefore, individuals identified to have inherited LFS are recommended to 
undergo organ-targeted surveillance. Once diagnosed, treatment for cancer patients with 
LFS does not differ from those without LFS, except for an increased risk for radiation-
induced cancer for individuals with LFS. Hence, radiation therapy is often avoided for 
individuals diagnosed with LFS. 
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Several reports have shown that tumor cells with dysfunctional p53 are very 
responsive to p53-based therapy aimed to reactivate the p53 pathway (27-29). Since 
patients with LFS carry a dysfunctional copy of the tumor suppressor p53, treatment of 
their cancers using our chimeric p53 should be extremely beneficial. For patients with 
solid tumors, adenoviral delivery of the chimeric p53-CC is feasible (15-17) and should 
lead to remission and/or stabilization of patients’ cancers. To validate this, we would 
obtain LFS patients’ tumor samples and test the efficacy of p53-CC in vitro. Furthermore, 
adenovirus gene therapy with chimeric p53-CC will then be tested in vivo using the 
p53+/-, p53R270H/-, and p53R172H/- well established LFS mouse models (29, 30). If 
this proves safe and effective, we will pursue first-in-man clinical trials of our chimeric 
p53-CC lead therapeutic candidates. Although beneficial mainly for solid tumors due to 
delivery hurtles (e.g., head and neck cancer), the chimeric p53-CC can be used in several 
other carcinomas with poor prognosis. If delivery issues can be overcome, p53-CC 
chimera gene therapy would have great potential for treating pancreatic cancer, ovarian 
cancer, and other incurable cancers. 
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